Everolimus for Advanced Pancreatic Neuroendocrine T

New England Journal of Medicine
364, 514-523
DOI: 10.1056/nejmoa1009290

Citation Report

#	Article	IF	Citations
1	Endocrine and metabolic emergencies: hypoglycaemia. Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 81-93.	1.4	17
2	1. Multiple Endocrine Neoplasia Type 1. Translational Endocrinology & Metabolism, 2011, , 13-44.	0.2	8
4	Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. Gastroenterology, 2011, 141, 1728-1737.	0.6	70
6	Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Digestive and Liver Disease, 2011, 43, 912-916.	0.4	27
7	Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer. Drugs, 2011, 71, 841-852.	4.9	11
8	Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2011, 18, S53-S74.	1.6	17
9	Promising Advances in the Treatment of Malignant Pancreatic Endocrine Tumors. New England Journal of Medicine, 2011, 364, 564-565.	13.9	53
10	Neuroendocrine tumors: A population-based study of incidence and survival in Girona province, 1994â€“2004. Cancer Epidemiology, 2011, 35, e49-e54.	0.8	20
12	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 501-513.	13.9	2,216
13	Role of everolimus in pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy, 2011, 11, 1653-1665.	1.1	10
14	A roadmap for the land of small tumors. Nature Reviews Endocrinology, 2011, 7, 319-321.	4.3	0
15	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2011, 378, 2005-2012.	6.3	938
16	mTOR inhibitor therapy for patients with carcinoid. Lancet, The, 2011, 378, 1978-1980.	6.3	2
17	The Changing Paradigm of Treating Pancreatic Neuroendocrine Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1331-1333.	2.3	3
18	AvancÃ©e prometteuse dans le traitement des tumeurs endocrines malignes du pancrÃ©as. Bulletin Du Cancer, 2011, 98, 353.	0.6	0
19	Neuroendocrine Neoplasms of the Gastrointestinal Tract. Deutsches Ärzteblatt International, 2011, 108, 305-12.	0.6	45
20	Time to mandate data release and independent audits for all clinical trials. Medical Journal of Australia, 2011, 195, 575-577.	0.8	8
21	Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Current Opinion in Oncology, 2011, 23, 578-586.	1.1	43

#	Article	IF	Citations
22	Industry Update: The latest developments in therapeutic delivery. Therapeutic Delivery, 2011, 2, 435-440.	1.2	0
23	Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W.) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	1
24	Everolimus for Advanced Pancreatic Neuroendocrine Tumors. Yearbook of Gastroenterology, 2011, 2011, 138-139.	0.1	0
25	AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. International Journal of Oncology, 2011, 40, 876-88.	1.4	14
27	A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. Cancer Control, 2011, 18, 127-137.	0.7	71
28	Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer. Medical Radiology, 2011, , 773-790.	0.0	0
29	New therapeutic options for metastatic malignant insulinomas. Clinical Endocrinology, 2011, 75, 277-284.	1.2	54
30	PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews Cancer, 2011, 11, 289-301.	12.8	682
31	Cancer lessons from mice to humans. Nature, 2011, 471, 316-317.	13.7	80
32	Targeting autophagy during cancer therapy to improve clinical outcomes. , 2011, 131, 130-141.		208
33	Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecologic Oncology, 2011, 122, 190-198.	0.6	254
34	Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Reviews Drug Discovery, 2011, 10, 868-880.	21.5	830
35	Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy, 2011, 11, 1817-1827.	1.1	7
36	The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbeck's Archives of Surgery, 2011, 396, 1145-1156.	0.8	39
40	Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine, 2011, 40, 181-186.	1.1	13
41	Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumor Biology, 2011, 32, 697-705.	0.8	14
42	Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Targeted Oncology, 2011, 6, 119-124.	1.7	36
43	Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Targeted Oncology, 2011, 6, 69-94.	1.7	38

#	Article	IF	Citations
44	New Treatment Options for Patients with Advanced Neuroendocrine Tumors. Current Treatment Options in Oncology, 2011, 12, 136-148.	1.3	45
45	Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors. Journal of Hematology and Oncology, 2011, 4, 29.	6.9	70
46	Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future Oncology, 2011, 7, 1025-1029.	1.1	8
47	Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?. Current Medicinal Chemistry, 2011, 18, 5528-5544.	1.2	51
48	Pituitary Carcinoma: Difficult Diagnosis and Treatment. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3649-3660.	1.8	173
49	New target therapies for patients with neuroendocrine tumors of the pancreas. Expert Review of Gastroenterology and Hepatology, 2011, 5, 563-566.	1.4	3
51	Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3381-3389.	1.8	78
52	Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opinion on Investigational Drugs, 2011, 20, 1685-1705.	1.9	4
53	Advances in Pancreatic Neuroendocrine Tumor Treatment. New England Journal of Medicine, 2011, 364, 1871-1875.	13.9	16
54	Good news for advanced-stage pancreatic neuroendocrine tumors. Nature Reviews Clinical Oncology, 2011, 8, 258-259.	12.5	2
55	Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3741-3749.	1.8	194
56	Hope for pancreatic neuroendocrine tumors. Nature Reviews Clinical Oncology, 2011, 8, 191-191.	12.5	0
59	A Shining Light in the Darkness for the Treatment of Pancreatic Neuroendocrine Tumors. Cancer Discovery, 2011, 1, 213-221.	7.7	26
60	Progression-Free Survival in Neuroendocrine Tumors: Preferred End Point, But How Should It Be Defined?. Journal of Clinical Oncology, 2011, 29, 2835-2836.	0.8	3
61	Novel Therapeutic Agents for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Hormone and Metabolic Research, 2011, 43, 844-853.	0.7	14
62	Role of sunitinib for the management of pancreatic neuroendocrine tumors. Gastrointestinal Cancer: Targets and Therapy, 2011, , 53.	5.5	0
63	Targeting Somatostatin Receptors: Preclinical Evaluation of Novel ¹⁸F-Fluoroethyltriazole-Tyr³-Octreotate Analogs for PET. Journal of Nuclear Medicine, 2011, 52, 1441-1448.	2.8	41
64	Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review. International Journal of Hepatology, 2011, 2011, 1-11.	0.4	62

#	Article	IF	Citations
65	From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2011, 94, 177-190.	1.2	34
66	Optimism surrounds new targeted therapies for pancreatic neuroendocrine tumors. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 179-179.	8.2	1
67	Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. Endocrine-Related Cancer, 2011, 18, 541-554.	1.6	32
68	Advances in the management and treatment of gastroenteropancreatic neuroendocrine tumors. Clinical Investigation, 2011, 1, 1455-1468.	0.0	0
69	Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?. Acta OncolÃ³gica, 2011, 50, 731-732.	0.8	1
70	Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. Cancers, 2011, 3, 2478-2500.	1.7	44
71	Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocrine-Related Cancer, 2011, 18, 595-602.	1.6	79
73	mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocrine-Related Cancer, 2011, 18, C15-C18.	1.6	20
74	Multimodal Liver-Directed Management of Neuroendocrine Hepatic Metastases. International Journal of Hepatology, 2011, 2011, 1-12.	0.4	22
75	Molecular pathology and genetics of pancreatic endocrine tumours. Journal of Molecular Endocrinology, 2012, 49, R37-R50.	1.1	70
76	A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Annals of Oncology, 2012, 23, 2335-2341.	0.6	53
77	Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. OncoTargets and Therapy, 2012, 5, 409.	1.0	14
78	Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Annals of Oncology, 2012, 23, 2663-2670.	0.6	114
79	Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Cancers, 2012, 4, 504-522.	1.7	15
80	Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 2012, 4, 113-129.	1.7	6
81	Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours?. Endocrine-Related Cancer, 2012, 19, R73-R92.	1.6	11
82	A New Era for the Systemic Therapy of Neuroendocrine Tumors. Oncologist, 2012, 17, 326-338.	1.9	21
83	Ectopic Adrenalcorticotropic Hormone Syndrome Improved by Transarterial Embolization to Hepatic Metastatic Lesions of Pancreatic Neuroendocrine Carcinoma: A Case Report. Journal of Clinical Oncology, 2012, 30, e360-e363.	0.8	6

#	Article	IF	Citations
84	Unusual Complication of a Pancreatic Neuroendocrine Tumor Presenting with Malignant Hypercalcemia. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E627-E631.	1.8	21
85	Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors. Journal of Clinical Oncology, 2012, 30, 2963-2968.	0.8	257
86	Population Pharmacokinetics of Everolimus in Cardiac Recipients. Therapeutic Drug Monitoring, 2012, 34, 686-694.	1.0	30
87	The confusion around neuroendocrine tumors. Current Opinion in Oncology, 2012, 24, 431-432.	1.1	0
89	PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Reviews in Molecular Medicine, 2012, 14, e1.	1.6	354
90	Pathology and Molecular Genetics of Pancreatic Neoplasms. Cancer Journal (Sudbury, Mass), 2012, 18, 492-501.	1.0	114
91	Neuroendocrine tumors of the digestive tract. Current Opinion in Oncology, 2012, 24, 433-440.	1.1	38
92	Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-Oncology, 2012, 14, 819-829.	0.6	117
93	Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocrine-Related Cancer, 2012, 19, 615-623.	1.6	27
94	From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of Rapamycin. Journal of Clinical Oncology, 2012, 30, 85-87.	0.8	5
95	Genomic analysis and selected molecular pathways in rare cancers. Physical Biology, 2012, 9, 065004.	0.8	8
96	PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clinical Cancer Research, 2012, 18, 1777-1789.	3.2	191
97	Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. Journal of Clinical Oncology, 2012, 30, 2718-2724.	0.8	630
100	OC-128â€...The effect of obesity on the radicality of subtotal oesophagectomy for oesophageal adenocarcinoma. Gut, 2012, 61, A55.2-A56.	6.1	0
101	Disrupting the mTOR Signaling Network as a Potential Strategy for the Enhancement of Cancer Radiotherapy. Current Cancer Drug Targets, 2012, 12, 899-924.	0.8	28
102	mTOR Inhibitors in Tuberous Sclerosis Complex. Current Neuropharmacology, 2012, 10, 404-415.	1.4	106
103	Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opinion on Therapeutic Targets, 2012, 16, S91-S102.	1.5	7
104	Assessing causal relationships between treatments and clinical outcomes: always read the fine print. Bone Marrow Transplantation, 2012, 47, 626-632.	1.3	8

#	Article	IF	Citations
105	Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut, 2012, 61, 6-32.	6.1	743
106	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. Journal of Clinical Oncology, 2012, 30, 3444-3447.	0.8	18
107	The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy. Cancer Research, 2012, 72, 5683-5691.	0.4	45
108	ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology, 2012, 95, 157-176.	1.2	774
109	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta OncolÃ³gica, 2012, 51, 873-879.	0.8	66
110	Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2012, 4, 9-18.	1.4	33
111	Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model. Clinical Cancer Research, 2012, 18, 4621-4632.	3.2	34
112	Cohort Study of Somatostatin-Based Radiopeptide Therapy With [⁹⁰Y-DOTA]-TOC Versus [⁹⁰Y-DOTA]-TOC Plus [¹⁷⁷Lu-DOTA]-TOC in Neuroendocrine Cancers. Journal of Clinical Oncology, 2012, 30, 1100-1106.	0.8	182
113	Proliferation Rates of Multiple Endocrine Neoplasia Type 1 (MEN1)-Associated Tumors. Endocrinology, 2012, 153, 5167-5179.	1.4	13
114	Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing. Clinical Cancer Research, 2012, 18, 4257-4265.	3.2	122
115	Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy, 2012, 13, 461-471.	0.9	2
116	Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocrine-Related Cancer, 2012, 19, 423-434.	1.6	29
117	Hazard ratios in cancer clinical trialsâ€"a primer. Nature Reviews Clinical Oncology, 2012, 9, 178-183.	12.5	36
118	Successful Control of Intractable Hypoglycemia Using Radiopharmaceutical Therapy with Strontium-89 in a Case with Malignant Insulinoma and Bone Metastases. Japanese Journal of Clinical Oncology, 2012, 42, 640-645.	0.6	4
119	The Risk for Anemia with Targeted Therapies for Solid Tumors. Oncologist, 2012, 17, 715-724.	1.9	34
120	Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7319.	0.6	18
121	Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7350.	0.6	19
122	Critical appraisal of the role of everolimus in advanced neuroendocrine tumors of pancreatic origin. Gastrointestinal Cancer: Targets and Therapy, 2012, , 29.	5.5	0

#	Article	IF	Citations
123	Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin. International Journal of Hepatology, 2012, 2012, 1-8.	0.4	15
124	A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases. International Journal of Hepatology, 2012, 2012, 1-13.	0.4	31
125	Treatment of Neuroendocrine Tumor Liver Metastases. International Journal of Hepatology, 2012, 2012, 1-12.	0.4	34
126	Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial. Japanese Journal of Clinical Oncology, 2012, 42, 903-911.	0.6	47
127	Randomized Phase II Trial Designs With Biomarkers. Journal of Clinical Oncology, 2012, 30, 3304-3309.	0.8	86
128	Onychopathy Induced by Temsirolimus, a Mammalian Target of Rapamycin Inhibitor. Dermatology, 2012, 224, 204-208.	0.9	26
129	Current Status and Perspectives of Targeted Therapy in Well-Differentiated Neuroendocrine Tumors. Oncology, 2012, 83, 117-127.	0.9	23
130	Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead. Neuroendocrinology, 2012, 96, 261-271.	1.2	51
131	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer, 2012, 1, 247-256.	4.2	65
132	Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor. Case Reports in Oncology, 2012, 5, 622-626.	0.3	21
133	Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6. Clinical Cancer Research, 2012, 18, 4612-4620.	3.2	89
134	Advances in the treatment of pancreatic neuroendocrine tumours. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 819-822.	0.2	1
135	Therapeutic Additions and Possible Deletions in Oncology in 2011. Clinical Pharmacology and Therapeutics, 2012, 91, 15-17.	2.3	8
136	Prolonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis. Case Reports in Gastroenterology, 2012, 6, 205-210.	0.3	6
137	Systemic Therapy for Advanced Carcinoid Tumors: Where Do We Go From Here?. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 785-793.	2.3	18
138	mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma. Current Cancer Drug Targets, 2012, 12, 1045-1061.	0.8	22
139	Neuroendocrine tumors of the pancreas. Current Opinion in Oncology, 2012, 24, 46-55.	1.1	101
140	Everolimus for Advanced Pancreatic Neuroendocrine Tumors. Yearbook of Pediatrics, 2012, 2012, 488-490.	0.2	0

#	Article	IF	Citations
141	Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 777-783.	2.3	11
142	OC-129â€...Metastatic pancreatic neuroendocrine tumours: does aggressive surgical intervention improve outcome?. Gut, 2012, 61, A56.1-A56.	6.1	0
143	Editorial [Hot Topic: Recent Advances in the Prevention and Therapy of Hepatocellular Carcinoma]. Current Cancer Drug Targets, 2012, 12, 1043-1044.	0.8	2
145	Neuroendocrine Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 724-764.	2.3	157
146	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Critical Reviews in Oncogenesis, 2012, 17, 69-95.	0.2	204
150	Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. International Journal of Oncology, 2012, 40, 1659-67.	1.4	18
151	Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1594-1601.	0.5	35
152	Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. Clinical Investigation, 2012, 2, 1123-1131.	0.0	0
153	Coronary and endovascular applications of the Absorbâ„¢ bioresorbable vascular scaffold. Interventional Cardiology, 2012, 4, 621-631.	0.0	1
154	Lymph Nodes and Survival in Pancreatic Neuroendocrine Tumors. Archives of Surgery, 2012, 147, 820.	2.3	108
155	Comparison of Methods for Proliferative Index Analysis for Grading Pancreatic Well-Differentiated Neuroendocrine Tumors. American Journal of Clinical Pathology, 2012, 137, 576-582.	0.4	39
156	mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy. Hematology/Oncology Clinics of North America, 2012, 26, 483-505.	0.9	97
157	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology, 2012, 52, 549-573.	4.2	96
158	Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 727-737.	1.8	79
159	Vertical Pathway Targeting in Cancer Therapy. Advances in Pharmacology, 2012, 65, 1-26.	1.2	15
160	Oncology; Everolimus: A New Treatment Option for Advanced Pancreatic Neuroendocrine Tumors. Annals of Pharmacotherapy, 2012, 46, 1212-1219.	0.9	13
161	Everolimus for the treatment of pancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy, 2012, 13, 2073-2084.	0.9	6
162	Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. Journal of Medical Economics, 2012, 15, 55-64.	1.0	19

#	Article	IF	Citations
163	Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Annals of Oncology, 2012, 23, 1928.	0.6	9
164	New treatment strategies in advanced neuroendocrine tumours. Digestive and Liver Disease, 2012, 44, 95-105.	0.4	43
165	Clinical Outcomes in Kidney Transplant Recipients Receiving Long-Term Therapy With Inhibitors of the Mammalian Target of Rapamycin. American Journal of Transplantation, 2012, 12, 379-387.	2.6	27
166	Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. Journal of Gastroenterology, 2012, 47, 941-960.	2.3	98
167	Current status of DILD in molecular targeted therapies. International Journal of Clinical Oncology, 2012, 17, 534-541.	1.0	37
168	Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 83, 887-894.	0.4	137
169	Pancreatic Neuroendocrine Tumors With Involved Surgical Margins: Prognostic Factors and the Role of Adjuvant Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, e337-e343.	0.4	24
170	ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes. Neuroendocrinology, 2012, 95, 98-119.	1.2	509
171	The Current Management of Pancreatic Neuroendocrine Tumors. Advances in Surgery, 2012, 46, 283-296.	0.6	26
172	Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus. Journal of Vascular Surgery, 2012, 56, 1680-1688.	0.6	21
173	Clinical Management of Pituitary Carcinomas. Neurosurgery Clinics of North America, 2012, 23, 595-606.	0.8	13
174	Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic review. Surgical Oncology, 2012, 21, e131-e141.	0.8	116
175	Management of Pancreatic Neuroendocrine Tumors. Gastroenterology Clinics of North America, 2012, 41, 119-131.	1.0	11
176	Chemoradiation in the Management of Pancreatic Neuroendocrine Tumors (PNET). International Journal of Radiation Oncology Biology Physics, 2012, 84, S319.	0.4	0
177	Phase I-II Study of Radiopeptide¹⁷⁷Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 561-569.	0.7	144
178	Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 525-529.	0.7	3
179	An overview of the mTOR pathway as a target in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 481-489.	1.5	33
180	Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 843-854.	1.0	12

#	Article	IF	Citations
181	Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii124-vii130.	0.6	411
182	La terapia medica dei tumori neuroendocrini. L Endocrinologo, 2012, 13, 158-162.	0.0	0
183	A drug safety evaluation of everolimus in kidney transplantation. Expert Opinion on Drug Safety, 2012, 11, 1013-1022.	1.0	19
184	Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics. Annals of Pharmacotherapy, 2012, 46, 851-862.	0.9	24
185	Immunohistochemical Evidence of Dysregulation of the Mammalian Target of Rapamycin Pathway in Primary and Metastatic Pheochromocytomas. Urology, 2012, 80, 736.e7-736.e12.	0.5	9
186	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. Neuroendocrinology, 2012, 96, 32-40.	1.2	55
187	Quality of Clinical Trials in Gastroenteropancreatic Neuroendocrine Tumours. Neuroendocrinology, 2012, 96, 238-248.	1.2	13
188	New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy. Clinical Cancer Research, 2012, 18, 1830-1836.	3.2	46
189	Human Î²-Cell Proliferation and Intracellular Signaling. Diabetes, 2012, 61, 2205-2213.	0.3	208
190	Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Review of Gastroenterology and Hepatology, 2012, 6, 313-334.	1.4	47
191	Clinical Pathways for Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Cancer, 2012, 43, 532-540.	0.6	6
192	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolboxâ€"Point. Cancer Research, 2012, 72, 5145-5149.	0.4	77
193	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis, 2012, 33, 2391-2397.	1.3	161
194	Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors. American Journal of Surgery, 2012, 203, 628-631.	0.9	49
195	Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. Journal of Vascular Surgery, 2012, 55, 400-405.	0.6	8
196	K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer Letters, 2012, 322, 58-69.	3.2	24
197	From drug discovery to biomarker-driven clinical trials in lymphoma. Nature Reviews Clinical Oncology, 2012, 9, 643-653.	12.5	25
198	eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies. Cancer Research, 2012, 72, 6468-6476.	0.4	140

#	Article	IF	Citations
199	Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995â€“2012) in South China. BMC Endocrine Disorders, 2012, 12, 30.	0.9	49
200	Gastric NeuroendocrineTumours. Digestive Surgery, 2012, 29, 331-348.	0.6	35
202	Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 199-208.	8.2	106
203	Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway. Neuroendocrinology, 2012, 96, 228-237.	1.2	25
204	Treatment options for unresectable neuroendocrine liver metastases. Expert Review of Gastroenterology and Hepatology, 2012, 6, 357-369.	1.4	15
205	Apoptosis-Modulating Drugs for Improved Cancer Therapy. European Surgical Research, 2012, 48, 111-120.	0.6	74
206	Skin cancer in organ transplant recipients. Expert Review of Dermatology, 2012, 7, 37-45.	0.3	1
207	Overview of neuroendocrine liver metastases treatment. European Journal of Cancer, Supplement, 2012, 10, 64-66.	2.2	0
208	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Letters, 2012, 325, 139-146.	3.2	54
209	Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treatment Reviews, 2012, 38, 767-775.	3.4	46
210	Neuroendocrinology in 2011. EndocrinologÃa Y NutriciÃ³n (English Edition), 2012, 59, 311-325.	0.5	2
211	Neuroendocrine tumors: The age of targeted therapies. EndocrinologÃa Y NutriciÃ³n (English Edition), 2012, 59, 438-451.	0.5	2
213	Single-operator cholangioscopy for the extraction of cystic duct stones (with video). Gastrointestinal Endoscopy, 2012, 75, 206-210.	0.5	19
214	US-guided ethanol ablation of insulinomas: a new treatment option. Gastrointestinal Endoscopy, 2012, 75, 200-206.	0.5	115
215	Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling. Surgery, 2012, 152, 998-1007.	1.0	14
216	Neuroendocrine neoplasms of the gut and pancreas: new insights. Nature Reviews Endocrinology, 2012, 8, 54-64.	4.3	168
217	Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Targeted Oncology, 2012, 7, 161-168.	1.7	22
218	Inhibition of mTOR in carcinoid tumors. Targeted Oncology, 2012, 7, 189-195.	1.7	16

#	Article	IF	Citations
219	Profiling mTOR pathway in neuroendocrine tumors. Targeted Oncology, 2012, 7, 183-188.	1.7	33
220	New treatment options with cytotoxic agents in neuroendocrine tumours. Targeted Oncology, 2012, 7, 169-172.	1.7	7
221	Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted Oncology, 2012, 7, 173-181.	1.7	26
222	Targeting neuroendocrine tumor: mixing standard options with novel therapies. Targeted Oncology, 2012, 7, 151-152.	1.7	1
223	Overview of Personalized Medicine in GI Cancers. Journal of Gastrointestinal Surgery, 2012, 16, 1641-1644.	0.9	4
224	Treatment of Liver Metastases in Patients with Digestive Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2012, 16, 1981-1992.	0.9	13
225	Pathology and Genetics of Pancreatic Neoplasms. Surgical Pathology Clinics, 2012, 5, 941-959.	0.7	0
226	Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology, 2012, 30, 4017-4025.	0.8	172
227	Neuroendocrine tumor disease: an evolving landscape. Endocrine-Related Cancer, 2012, 19, R163-R185.	1.6	133
228	Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemotherapy and Pharmacology, 2012, 70, 855-860.	1.1	46
229	Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 251-258.	1.1	43
230	Pancreatic Neuroendocrine Tumors. , 2012, , 193-209.		1
231	ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors. Neuroendocrinology, 2012, 95, 120-134.	1.2	478
232	ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology, 2012, 95, 71-73.	1.2	75
234	Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene, 2012, 31, 1459-1467.	2.6	109
235	Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 283-293.	1.5	26
236	Intervention in gastro-enteropancreatic neuroendocrine tumours. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 855-865.	1.0	16
237	Colonic and rectal NET's. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 775-789.	1.0	47

#	Article	IF	Citations
238	Neuroendocrine Tumors. , 2012, , 761-778.		1
239	Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors. Molecular Diagnosis and Therapy, 2012, 16, 151-161.	1.6	13
240	Liver Transplantation for Symptomatic Liver Metastases of Neuroendocrine Tumours. Current Oncology, 2012, 19, 217-221.	0.9	14
241	Targeting mTOR Pathways in Human Malignancies. Current Pharmaceutical Design, 2012, 18, 2766-2777.	0.9	99
242	Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy. Archives of Surgery, 2012, 147, 98-99.	2.3	1
243	New Perspectives on Diagnostics, Prognosis, and Therapy in Aggressive Endocrine Tumours. Journal of Oncology, 2012, 2012, 1-2.	0.6	0
244	Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics. Journal of Oncology, 2012, 2012, 1-9.	0.6	21
245	Pancreatic Endocrine Tumors. , 2012, , 1292-1297.		0
246	Update on the Management of Neuroendocrine Tumors: Focus on Somatostatin Antitumor Effects. Clinical Journal of Oncology Nursing, 2012, 16, 56-64.	0.3	17
247	The Diagnosis and Management of Neuroendocrine Carcinoma of Unknown Primary. , 0, , .		0
248	A review of clinical trials of chemotherapy for pancreatic cancer. Journal of Cancer Research and Experimental Oncology, 2012, 4, 1-20.	0.1	1
249	Neoplastic lesions of endocrine cells in the gastrointestinal tract: ten evolving principles as a basis for clinical understanding. Gastrointestinal Cancer: Targets and Therapy, 2012, , 1.	5.5	0
250	Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors. Tumori, 2012, 98, 394-394.	0.6	4
251	Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; September 8â€“10, 2011. Current Oncology, 2012, 19, 468-477.	0.9	1
252	Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas. Wspolczesna Onkologia, 2012, 5, 371-381.	0.7	8
253	Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors. Scientific World Journal, The, 2012, 2012, 1-7.	0.8	6
254	Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy--Reply. Archives of Surgery, 2012, 147, 99-99.	2.3	0
255	Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. OncoTargets and Therapy, 2012, 5, 217.	1.0	5

#	Article	IF	Citations
256	Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors. Cancer Management and Research, 2012, 4, 207.	0.9	15
257	Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer and Metastasis Reviews, 2012, 31, 733-751.	2.7	58
258	Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update. Current Treatment Options in Oncology, 2012, 13, 24-34.	1.3	85
259	Pancreatic neuroendocrine tumors: A comprehensive review. International Journal of Cancer, 2012, 131, 1013-1022.	2.3	30
260	Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2990-3011.	1.8	1,127
261	Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of ‹sup›90‹/sup›Yâ€ÐOTAâ€Dâ€Phe1â€Tyr3 octreotide. Cancer, 2012, 118, 2915-2924.	2.0	17
262	Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer, 2012, 118, 6162-6170.	2.0	83
263	Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investigational New Drugs, 2012, 30, 1557-1565.	1.2	22
264	Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted Oncology, 2012, 7, 127-133.	1.7	45
265	Relevance of angiogenesis in neuroendocrine tumors. Targeted Oncology, 2012, 7, 93-98.	1.7	10
266	New targeted agents in gastroenteropancreatic neuroendocrine tumors. Targeted Oncology, 2012, 7, 99-106.	1.7	12
267	Sunitinib in pancreatic neuroendocrine tumors. Targeted Oncology, 2012, 7, 117-125.	1.7	26
268	New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?. Targeted Oncology, 2012, 7, 91-92.	1.7	1
269	A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Irish Journal of Medical Science, 2012, 181, 211-214.	0.8	6
270	Pancreatic Neuroendocrine and Carcinoid Tumors: Whatâ€™s New, Whatâ€™s Old, and Whatâ€™s Different?. Current Oncology Reports, 2012, 14, 249-256.	1.8	26
271	Pancreatic neuroendocrine tumours â€“ new therapeutic concepts. Memo - Magazine of European Medical Oncology, 2012, 5, 63-65.	0.3	0
272	The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options. Clinical Oncology, 2012, 24, 282-293.	0.6	74
273	Radionuclide Therapy in Neuroendocrine Tumours: A Systematic Review. Clinical Oncology, 2012, 24, 294-308.	0.6	63

#	Article	IF	Citations
274	Predictive in vivo animal models and translation to clinical trials. Drug Discovery Today, 2012, 17, 253-260.	3.2	92
275	Metastatic Nonfunctioning Pancreatic Neuroendocrine Carcinoma to Liver: Surgical Treatment and Outcomes. Journal of the American College of Surgeons, 2012, 215, 117-124.	0.2	65
276	Angiogenesis inhibition for the improvement of photodynamic therapy: The revival of a promising idea. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 53-70.	3.3	37
277	Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor. Molecular and Cellular Endocrinology, 2012, 350, 99-106.	1.6	19
278	Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma. Clinical Endocrinology, 2012, 77, 154-155.	1.2	17
279	Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine, 2012, 41, 40-52.	1.1	58
280	Contemporary Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2012, 16, 435-446.	0.9	18
283	New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary, 2012, 15, 37-43.	1.6	87
284	Novel Medical Therapies of Recurrent and Metastatic Gastroenteropancreatic Neuroendocrine Tumors. Digestive Diseases and Sciences, 2012, 57, 9-18.	1.1	22
285	mTOR and regulation of energy homeostasis in humans. Journal of Molecular Medicine, 2013, 91, 1167-1175.	1.7	22
286	Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors. Tumor Biology, 2013, 34, 2881-2889.	0.8	20
287	A pilot study of temsirolimus and body composition. Journal of Cachexia, Sarcopenia and Muscle, 2013, 4, 259-265.	2.9	25
288	Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. Tumor Biology, 2013, 34, 2871-2879.	0.8	31
289	Treatment with the Radiolabelled Somatostatin Analog ¹⁷⁷Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2013, 97, 347-354.	1.2	104
290	Pancreatic neuroendocrine tumors. Indian Journal of Gastroenterology, 2013, 32, 3-17.	0.7	4
291	Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors. Onkologie, 2013, 36, 295-302.	1.1	29
292	Mechanisms of resistance to anti-angiogenesis therapies. Biochimie, 2013, 95, 1110-1119.	1.3	113
293	Foolâ€™s gold, lost treasures, and the randomized clinical trial. BMC Cancer, 2013, 13, 193.	1.1	42

#	Article	IF	Citations
294	Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome. Journal of General Internal Medicine, 2013, 28, 1525-1529.	1.3	21
295	Everolimus therapy for progressive adrenocortical cancer. Endocrine, 2013, 44, 187-192.	1.1	45
296	Characterization of Neuroendocrine Tumors of the Pancreas by Real-Time Quantitative Polymerase Chain Reaction. A Methodological Approach. Endocrine Pathology, 2013, 24, 83-91.	5.2	12
297	mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features. Endocrine Pathology, 2013, 24, 11-19.	5.2	25
298	Management of malignant insulinoma. Clinical and Translational Oncology, 2013, 15, 725-731.	1.2	28
299	Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Supportive Care in Cancer, 2013, 21, 2341-2349.	1.0	44
300	Evolving Treatment Strategies for Management of Carcinoid Tumors. Current Treatment Options in Oncology, 2013, 14, 374-388.	1.3	10
301	Met, IGF1R, and Other New Targets in Upper GI Malignancies. Current Treatment Options in Oncology, 2013, 14, 321-336.	1.3	2
302	The role of <scp>mTOR</scp> inhibitors in the treatment of hepatocellular carcinoma. Liver International, 2013, 33, 1133-1134.	1.9	1
303	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1271-1277.	1.8	66
304	Advancements in pancreatic neuroendocrine tumors. Expert Review of Gastroenterology and Hepatology, 2013, 7, 477-490.	1.4	14
305	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1197-1205.	3.3	50
306	Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 881-888.	3.3	123
307	The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 800-816.	3.3	633
308	Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 1241-1246.	1.1	45
309	Hemodialysis no reason to withhold everolimus. Cancer Chemotherapy and Pharmacology, 2013, 71, 273-274.	1.1	5
310	Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. European Radiology, 2013, 23, 3094-3103.	2.3	28
311	Severe everolimus-induced steatohepatis: a case report. European Journal of Medical Research, 2013, 18, 22.	0.9	12

#	Article	IF	Citations
315	Safety and feasibility of targeted agent combinations in solid tumours. Nature Reviews Clinical Oncology, 2013, 10, 154-168.	12.5	57
316	Targeting Receptor Tyrosine Kinases in Solid Tumors. Surgical Oncology Clinics of North America, 2013, 22, 685-703.	0.6	8
317	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. Journal of Clinical Oncology, 2013, 31, 3935-3943.	0.8	411
318	Risk of hematologic toxicities in patients with solid tumors treated with everolimus: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2013, 88, 30-41.	2.0	10
319	Introduction: Recent Advances in the Genetics, Diagnosis, and Treatment of Neuroendocrine Tumors. Seminars in Oncology, 2013, 40, 1-3.	0.8	4
320	mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Letters, 2013, 340, 1-8.	3.2	128
321	Current Management of the Zollinger-Ellison Syndrome. Advances in Surgery, 2013, 47, 59-79.	0.6	40
322	RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2013, 86, 880-884.	0.4	55
325	Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience. Cancer Research, 2013, 73, 1449-1453.	0.4	75
327	Digestive neuroendocrine tumors (DNET): The era of targeted therapies. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 134-141.	0.7	4
328	Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. European Journal of Cancer, 2013, 49, 3122-3130.	1.3	82
329	Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Experimental Hematology and Oncology, 2013, 2, 32.	2.0	32
330	Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors. Journal of Clinical Oncology, 2013, 31, 3418-3425.	0.8	86
331	PI3K Pathway Inhibitors: Better Not Left Alone. Current Pharmaceutical Design, 2013, 19, 895-906.	0.9	37
332	A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer, 2013, 119, 3212-3218.	2.0	71
333	Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. Therapeutic Advances in Gastroenterology, 2013, 6, 412-419.	1.4	16
334	Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Investigational New Drugs, 2013, 31, 1602-1608.	1.2	39
335	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemotherapy and Pharmacology, 2013, 72, 1089-1096.	1.1	24

#	Article	IF	Citations
337	Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report. BMC Research Notes, 2013, 6, 471.	0.6	11
338	The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation. Cancer and Metastasis Reviews, 2013, 32, 465-477.	2.7	11
339	PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Letters, 2013, 335, 1-8.	3.2	65
340	Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecologic Oncology, 2013, 130, 269-274.	0.6	91
341	Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Investigational New Drugs, 2013, 31, 1505-1513.	1.2	36
342	A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. British Journal of Cancer, 2013, 109, 1482-1487.	2.9	23
343	Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications. Cancer Treatment Reviews, 2013, 39, 784-792.	3.4	25
344	Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treatment Reviews, 2013, 39, 709-719.	3.4	85
345	Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 777-788.	1.5	7
346	Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Expert Opinion on Pharmacotherapy, 2013, 14, 1187-1203.	0.9	16
347	Sequelae and survivorship in patients treated with 131I-MIBG therapy. British Journal of Cancer, 2013, 109, 565-572.	2.9	35
348	Pharmacotherapy of Zollingerâ€“Ellison syndrome. Expert Opinion on Pharmacotherapy, 2013, 14, 307-321.	0.9	53
349	Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investigational New Drugs, 2013, 31, 1265-1274.	1.2	39
350	Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies. Expert Opinion on Pharmacotherapy, 2013, 14, 1649-1658.	0.9	4
351	Emerging Approaches in the Management of Patients with Neuroendocrine Liver Metastasis: Role of Liver-Directed and Systemic Therapies. Journal of the American College of Surgeons, 2013, 216, 123-134.	0.2	66
352	Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study. Oncologist, 2013, 18, 46-53.	1.9	53
353	A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Investigational New Drugs, 2013, 31, 85-91.	1.2	29
354	Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management. Radiology, 2013, 266, 38-61.	3.6	156

#	Article	IF	Citations
355	Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 2013, 10, 143-153.	12.5	694
356	Malignant insulinoma: Recommendations for characterisation and treatment. Annales D'Endocrinologie, 2013, 74, 523-533.	0.6	46
357	Dedifferentiated adenoid cystic carcinoma of the trachea: a case report with respect to the immunohistochemical analyses of mammalian target of rapamycin pathway proteins. Human Pathology, 2013, 44, 1700-1703.	1.1	7
358	Carcinoid syndrome and neuroendocrine tumours. Medicine, 2013, 41, 566-569.	0.2	1
359	A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 479-486.	0.4	54
360	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study. Clinical Therapeutics, 2013, 35, 215-225.	1.1	18
361	Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). European Journal of Cancer, 2013, 49, 3780-3787.	1.3	84
362	Primary renal carcinoid: Treatment and prognosis. Critical Reviews in Oncology/Hematology, 2013, 87, 256-264.	2.0	43
363	Translational Research in Endocrine Surgery. Surgical Oncology Clinics of North America, 2013, 22, 857-884.	0.6	11
364	Second-line therapy in advanced biliary tract cancer: What should be the standard?. Critical Reviews in Oncology/Hematology, 2013, 88, 368-374.	2.0	18
365	Practical Guide to Supportive Care of Patients With Functional Neuroendocrine Tumors. Seminars in Oncology, 2013, 40, 45-55.	0.8	8
366	Management of Well-Differentiated Gastrointestinal Neuroendocrine Tumors Metastatic to the Liver. Seminars in Oncology, 2013, 40, 69-74.	0.8	12
367	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€”Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.2	26
368	Pancreatic neuroendocrine tumors. Current Problems in Surgery, 2013, 50, 509-545.	0.6	49
369	INSL5 may be a unique marker of colorectal endocrine cells and neuroendocrine tumors. Biochemical and Biophysical Research Communications, 2013, 432, 586-592.	1.0	35
370	Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors. Seminars in Oncology, 2013, 40, 75-83.	0.8	10
372	Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2013, 37, 62-73.	1.9	60
373	New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncology, The, 2013, 14, e117-e124.	5.1	81

#	Article	IF	Citations
374	Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemotherapy and Pharmacology, 2013, 71, 663-670.	1.1	221
375	Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches. Clinical Cancer Research, 2013, 19, 2842-2849.	3.2	80
376	Are Neuroendocrine Tumors Going Mainstream?. Journal of Clinical Oncology, 2013, 31, 404-405.	0.8	13
377	Recommendations on the use of everolimus in lung transplantation. Transplantation Reviews, 2013, 27, 9-16.	1.2	31
378	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 381, 817-824.	6.3	712
379	The evolution of the TOR pathway and its role in cancer. Oncogene, 2013, 32, 3923-3932.	2.6	136
380	BRAF, KRAS, and Phosphatidylinositol 3-Kinase in the Management of Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 57-67.	1.0	1
381	Everolimus in colorectal cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 505-513.	0.9	22
382	Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. European Journal of Endocrinology, 2013, 168, 665-674.	1.9	90
383	Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature. Oncology, 2013, 84, 127-134.	0.9	14
384	Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 2013, 13, 451-459.	1.1	4
385	Management of Pancreatic Neuroendocrine Tumors. Surgical Clinics of North America, 2013, 93, 675-691.	0.5	29
386	Pancreatic neuroendocrine tumors. Disease-a-Month, 2013, 59, 5-19.	0.4	25
387	Adverse events associated with mTOR inhibitors. Expert Opinion on Drug Safety, 2013, 12, 177-186.	1.0	172
388	Sunitinib malate for the treatment of pancreas malignancies â€“ where does it fit?. Expert Opinion on Pharmacotherapy, 2013, 14, 783-792.	0.9	10
389	Insights into signalling pathways could individualize therapy. Nature Reviews Endocrinology, 2013, 9, 70-72.	4.3	4
390	Doseâ€finding designs using a novel quasiâ€continuous endpoint for multipleâ€‰toxicities. Statistics in Medicine, 2013, 32, 2728-2746.	0.8	45
391	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. Hpb, 2013, 15, 935-943.	0.1	16

#	Article	IF	Citations
392	Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdominal Imaging, 2013, 38, 342-357.	2.0	17
394	Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2013, 22, 715-722.	1.9	16
395	The Evolving Landscape of Neuroendocrine Tumors. Seminars in Oncology, 2013, 40, 4-22.	0.8	25
396	Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. British Journal of Cancer, 2013, 108, 1771-1777.	2.9	100
397	Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective. Cancer Treatment Reviews, 2013, 39, 3-9.	3.4	9
398	Temozolomide and unusual indications: Review of literature. Cancer Treatment Reviews, 2013, 39, 125-135.	3.4	71
399	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer, 2013, 20, R83-R99.	1.6	272
400	Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate. Endocrine-Related Cancer, 2013, 20, 825-831.	1.6	35
401	Longâ€term maintenance of normoglycaemia using everolimus in a patient with disseminated insulinoma and severe hypoglycaemia. Clinical Endocrinology, 2013, 78, 799-800.	1.2	18
402	Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocrine-Related Cancer, 2013, 20, 659-667.	1.6	53
403	Pancreatic Cancer Genomes: Toward Molecular Subtyping and Novel Approaches to Diagnosis and Therapy. Molecular Diagnosis and Therapy, 2013, 17, 287-297.	1.6	6
404	Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Research and Treatment, 2013, 141, 167-172.	1.1	16
405	Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors. Neuroendocrinology, 2013, 97, 99-112.	1.2	40
406	Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch. Neuroendocrinology, 2013, 97, 57-66.	1.2	17
407	Signalling Pathways Passing Src in Pancreatic Endocrine Tumours: Relevance for Possible Combined Targeted Therapies. Neuroendocrinology, 2013, 97, 67-73.	1.2	10
408	EGFR/TGFÎ± and TGFÎ²/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets. Neuroendocrinology, 2013, 97, 35-44.	1.2	31
409	Long-Term Management of a Patient with Well-Differentiated Pulmonary Neuroendocrine Carcinoma: A Case Report. Case Reports in Oncology, 2013, 6, 209-215.	0.3	5
410	Pancreatic Neuroendocrine Tumors: Signal Pathways and Targeted Therapies. Current Molecular Medicine, 2013, 13, 333-339.	0.6	8

#	Article	IF	Citations
411	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4006-4012.	1.8	102
412	Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy. Neuroendocrinology, 2013, 97, 74-85.	1.2	58
413	Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. Expert Opinion on Investigational Drugs, 2013, 22, 679-685.	1.9	8
414	Neuroendocrine tumours: cracking the epigenetic code. Endocrine-Related Cancer, 2013, 20, R65-R82.	1.6	50
415	Traitement des tumeurs neuroendocrines digestives par les inhibiteurs de mTOR : les prÃ©mices dâ€™un traitement personnalisÃ©. , 2013, , 317-330.		0
416	Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?. Annals of Oncology, 2013, 24, 1415-1416.	0.6	2
418	Extra-appendiceal Neuroendocrine Neoplasms in Children â€“ Data from the GPOH-MET 97 Study. Klinische Padiatrie, 2013, 225, 315-319.	0.2	16
419	Brain carcinoid metastases: outcomes and prognostic factors. Journal of Neurosurgery, 2013, 118, 889-895.	0.9	28
420	Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications. Neuroendocrinology, 2013, 97, 45-56.	1.2	77
421	Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens. Clinical Cancer Research, 2013, 19, 3987-3995.	3.2	57
422	Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors, 2013, 5, 121-125.	0.3	27
423	Blockade of IGF-1Râ€”not effective in neuroendocrine tumours. Nature Reviews Endocrinology, 2013, 9, 389-390.	4.3	3
424	Pancreatic endocrine tumors. , 2013, , 433-437.		0
425	mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocrine-Related Cancer, 2013, 20, 463-475.	1.6	62
426	Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2485-2492.	0.8	213
427	Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. International Journal of Molecular Sciences, 2013, 14, 30-45.	1.8	7
428	A Case of Inoperable Malignant Insulinoma with Resistant Hypoglycemia Who Experienced the Most Significant Clinical Improvement with Everolimus. Case Reports in Endocrinology, 2013, 2013, 1-6.	0.2	9
429	Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer, 2013, 13, 427.	1.1	58

#	Article	IF	Citations
430	mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis. Cancer Research, 2013, 73, 1946-1957.	0.4	36
431	Medical treatment of neuroendocrine tumours. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 27-31.	1.2	14
432	Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors. Pancreas, 2013, 42, 397-404.	0.5	21
433	Zollingerâ€"Ellison syndrome. Current Opinion in Gastroenterology, 2013, 29, 650-661.	1.0	72
434	Assigning Site of Origin in Metastatic Neuroendocrine Neoplasms. Advances in Anatomic Pathology, 2013, 20, 285-314.	2.4	108
435	Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors. Pancreas, 2013, 42, 411-421.	0.5	38
436	Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas, 2013, 42, 557-577.	0.5	494
437	Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anti-Cancer Drugs, 2013, 24, 769-780.	0.7	11
438	From Bevacizumab to Tasquinimod. Cancer Journal (Sudbury, Mass), 2013, 19, 99-106.	1.0	20
439	Current Understanding of the Molecular Biology of Pancreatic Neuroendocrine Tumors. Journal of the National Cancer Institute, 2013, 105, 1005-1017.	3.0	107
440	Nocardia Brain Abscess in a Patient Treated With Everolimus for a Metastatic Insulinoma. Journal of Clinical Oncology, 2013, 31, e73-e75.	0.8	2
441	Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clinical Cancer Research, 2013, 19, 5474-5484.	3.2	72
442	Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Experimental Medicine, 2013, 210, 563-579.	4.2	110
443	Current Phase II clinical data for ridaforolimus in cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1485-1493.	1.9	6
444	Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours. European Journal of Endocrinology, 2013, 168, R77-R83.	1.9	57
445	mTOR Inhibitor RAD001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine Cancer. Cancer Research, 2013, 73, 12-18.	0.4	39
446	Recent advancements in the drug treatment of endocrine diseases. Clinical Medicine, 2013, 13, 170-175.	0.8	0
447	The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Therapeutic Advances in Medical Oncology, 2013, 5, 286-300.	1.4	6

#	Article	IF	Citations
448	Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Annals of Oncology, 2013, 24, 2092-2097.	0.6	31
449	A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2013, 20, 383-390.	1.6	32
450	Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned. Oncologist, 2013, 18, 525-532.	1.9	41
451	Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Therapeutic Advances in Gastroenterology, 2013, 6, 396-411.	1.4	28
452	Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Therapeutic Advances in Gastroenterology, 2013, 6, 474-490.	1.4	23
453	Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. Melanoma Research, 2013, 23, 147-151.	0.6	34
454	Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas. Rare Tumors, 2013, 5, 135-139.	0.3	18
455	Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report. Chemotherapy, 2013, 59, 74-78.	0.8	5
456	Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer, 2013, 119, 4094-4102.	2.0	58
457	Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma â€“ systematic review and metaâ€analysis. Cancer Medicine, 2013, 2, 862-871.	1.3	50
458	Interleukinâ€15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer. Journal of Gene Medicine, 2013, 15, 366-374.	1.4	10
459	Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate. Journal of Nuclear Medicine, 2013, 54, 1689-1696.	2.8	41
460	Animal Models and Cell Lines of Pancreatic Neuroendocrine Tumors. Pancreas, 2013, 42, 912-923.	0.5	22
461	Multiple Endocrine Neoplasia Type 1. , 2013, , 479-504.		0
462	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	7.1	33
463	Recent progress in pancreatic cancer. Ca-A Cancer Journal for Clinicians, 2013, 63, 318-348.	157.7	743
464	<scp>M</scp>ultiple endocrine neoplasia type 1 (<scp>MEN1</scp>). Asia-Pacific Journal of Clinical Oncology, 2013, 9, 297-309.	0.7	18
465	Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. European Journal of Cancer Care, 2013, 22, 714-725.	0.7	38

#	Article	IF	Citations
466	Phospho-mTOR is not upregulated in metastaticSDHBparagangliomas. European Journal of Clinical Investigation, 2013, 43, 970-977.	1.7	10
467	Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Annals of the New York Academy of Sciences, 2013, 1291, 14-32.	1.8	74
468	Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review. Journal of Clinical Oncology, 2013, 31, 3957-3963.	0.8	87
469	Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nature Communications, 2013, 4, 2810.	5.8	137
470	In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours. British Journal of Cancer, 2013, 108, 1298-1305.	2.9	6
471	Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. British Journal of Cancer, 2013, 108, 2478-2484.	2.9	31
472	Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. British Journal of Cancer, 2013, 109, 1414-1419.	2.9	71
473	Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients. Expert Review of Anticancer Therapy, 2013, 13, 17-20.	1.1	3
474	Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. Journal of Clinical Oncology, 2013, 31, 365-372.	0.8	148
475	Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. Endocrine-Related Cancer, 2013, 20, 305-319.	1.6	29
476	Angioedema in a Patient With Renal Cell Cancer Treated With Everolimus in Combination With an Angiotensin-Converting Enzyme Inhibitor. Journal of Clinical Oncology, 2013, 31, e57-e58.	0.8	9
477	Phase <scp>II</scp> study of everolimus in metastatic urothelial cancer. BJU International, 2013, 112, 462-470.	1.3	153
478	Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor. Future Oncology, 2013, 9, 909-913.	1.1	3
479	Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature. Oncology Letters, 2013, 5, 117-122.	0.8	17
480	Expression profiles of mTOR pathway proteins in porocarcinoma: A provisional immunohistochemical study. Biomedical Reports, 2013, 1, 28-30.	0.9	1
482	Antitumor Effect of Everolimus in Preclinical Models of High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas. Neuroendocrinology, 2013, 97, 331-340.	1.2	30
483	Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma. Case Reports in Oncology, 2013, 6, 441-449.	0.3	19
484	Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 5-9.	2.3	25

#	Article	IF	Citations
486	Systemic Treatment of Advanced Lung Carcinoid Tumors. Chest, 2013, 143, 884-886.	0.4	3
488	Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor. Journal of Investigative Medicine High Impact Case Reports, 2013, 1, 232470961247327.	0.3	4
489	Pancreatic Neuroendocrine Tumor Associated With Humoral Hypercalcemia of Malignancy and Carcinoid Tumor. Pancreas, 2013, 42, 549-551.	0.5	7
490	Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	176
491	Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. European Journal of Gastroenterology and Hepatology, 2013, 25, 232-238.	0.8	62
492	Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma). Pancreas, 2013, 42, 348-352.	0.5	31
493	International Practice Patterns and Resource Utilization in the Treatment of Neuroendocrine Tumors. Pancreas, 2013, 42, 339-347.	0.5	11
495	Local Therapies for Hepatic Metastases. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 153-160.	2.3	24
496	Granuloma-forming Interstitial Pneumonia Occurring One Year after the Start of Everolimus Therapy. Internal Medicine, 2013, 52, 263-267.	0.3	8
498	The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic Opportunities. , 0, , .		9
499	Tumores neuroendocrinos del pÃ¡ncreas: Resultados quirÃºrgicos y sobrevida alejada. Revista Chilena De Cirugia, 2013, 65, 228-235.	0.1	0
500	Immunostimulatory activity of lifespan-extending agents. Aging, 2013, 5, 793-801.	1.4	27
501	Pancreatic Neuroendocrine Tumor in a Child with a Tuberous Sclerosis Complex 2 (TSC2) Mutation. Endocrine Practice, 2013, 19, e124-e128.	1.1	16
502	Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chinese Journal of Cancer, 2013, 32, 312-324.	4.9	126
503	First-Line Irinotecan Combined with 5-Fluorouracil and Leucovorin for High-Grade Metastatic Gastrointestinal Neuroendocrine Carcinoma. Tumori, 2013, 99, 57-60.	0.6	10
504	The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study. PLoS ONE, 2013, 8, e62487.	1.1	130
505	Identification and Characterization of Poorly Differentiated Invasive Carcinomas in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. PLoS ONE, 2013, 8, e64472.	1.1	15
506	Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis. PLoS ONE, 2013, 8, e65166.	1.1	29

#	Article	IF	Citations
507	The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. ISRN Hepatology, 2013, 2013, 1-9.	0.9	4
508	Targeting the PI3K-AKT-mTOR signaling network in cancer. Chinese Journal of Cancer, 2013, 32, 253-265.	4.9	173
509	Metastatic Pancreatic Insulinoma with Treatment-limiting Thrombocytopenia. American Surgeon, 2013, 79, 124-126.	0.4	0
511	KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine Tumors. International Journal of Biological Sciences, 2014, 10, 957-965.	2.6	61
512	Neuroendocrine Tumors of the Pancreas. , 2014, , 2284-2292.		1
513	18F-FDG and 18F-FLT-PET Imaging for Monitoring Everolimus Effect on Tumor-Growth in Neuroendocrine Tumors: Studies in Human Tumor Xenografts in Mice. PLoS ONE, 2014, 9, e91387.	1.1	26
515	Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature. Journal of Transplantation, 2014, 2014, 1-13.	0.3	41
516	Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature. OncoTargets and Therapy, 2014, 7, 1919.	1.0	9
517	PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms. Theranostics, 2014, 4, 336-365.	4.6	78
518	Systemic Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): Cuirrent Approaches and Future Options. Endocrine Practice, 2014, 20, 167-175.	1.1	18
519	Malignant Pheochromocytoma Secreting Vasoactive Intestinal Peptide and Response to Sunitinib: A Case Report and Literature Review. Endocrine Practice, 2014, 20, e145-e150.	1.1	15
521	Association between time to disease progression end points and overall survival in patients with neuroendocrine tumors. Gastrointestinal Cancer: Targets and Therapy, 2014, , 103.	5.5	4
522	Angiogenic factors and cancer therapy. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2014, , .	0.1	0
523	Calcitonin-Secreting Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature. Endocrine Practice, 2014, 20, e140-e144.	1.1	12
524	Anticancer effects of metformin on neuroendocrine tumor cells in vitro. Hormones, 2014, 13, 498-508.	0.9	23
525	mTOR and Regulation of Translation. , 2014, , 307-343.		3
526	Targeting translation initiation in breast cancer. Translation, 2014, 2, e28968.	2.9	1
527	Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule. Clinical Journal of Gastroenterology, 2014, 7, 449-454.	0.4	9

#	Article	IF	Citations
528	Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function. BMC Cancer, 2014, 14, 906.	1.1	23
529	Diabetes Secondary to Neuroendocrine Gastroenteropancreatic Tumors. Frontiers in Diabetes, 2014, , 64-76.	0.4	3
530	Gastroenteropancreatic neuroendocrine tumour arising in Meckelâ€™s diverticulum coexisting with colon adenocarcinoma. World Journal of Surgical Oncology, 2014, 12, 358.	0.8	6
531	Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis, Management, and Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3060-3069.	1.8	56
532	The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death and Disease, 2014, 5, e1450-e1450.	2.7	51
533	Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2014, 14, 1529-1536.	1.1	13
534	Neuroendocrine Tumors of the Bronchopulmonary System (Typical and Atypical Carcinoid Tumors): Current Strategies in Diagnosis and Treatment. Conclusions of an Expert Meeting February 2011 in Weimar, Germany. Oncology Research and Treatment, 2014, 37, 266-276.	0.8	44
535	Targeting Î²-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours. Nature Communications, 2014, 5, 5809.	5.8	73
536	Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Review of Clinical Pharmacology, 2014, 7, 847-858.	1.3	17
538	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist, 2014, 19, 966-974.	1.9	84
539	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular and Cellular Oncology, 2014, 1, e963447.	0.3	9
540	Hepatic parenchymal preserving technique in the management of diffuse bilateral neuroendocrine tumour liver metastases: a feasible approach. Canadian Journal of Surgery, 2014, 57, E2-E8.	0.5	4
541	The usefulness of endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of pancreatic neuroendocrine tumors based on the World Health Organization classification. Scandinavian Journal of Gastroenterology, 2014, 49, 1367-1374.	0.6	57
542	Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. Bone Marrow Transplantation, 2014, 49, 1412-1418.	1.3	21
543	Everolimus Dramatically Improves Glycemic Control in Unresectable Metastatic Insulinoma: A Case Report. Japanese Journal of Clinical Oncology, 2014, 44, 186-190.	0.6	14
544	Temsirolimus induces surfactant lipid accumulation and lung inflammation in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L1117-L1128.	1.3	15
545	mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment. BioMed Research International, 2014, 2014, 1-9.	0.9	22
546	Mammalian Target of Rapamycin in Inflammatory Skin Conditions. European Journal of Inflammation, 2014, 12, 341-350.	0.2	18

#	Article	IF	Citations
547	Targeted therapy in gastrointestinal malignancies. Journal of Carcinogenesis, 2014, 13, 4.	2.5	7
548	mTOR Inhibition Promotes TTF1-Dependent Redifferentiation and Restores Iodine Uptake in Thyroid Carcinoma Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1368-E1375.	1.8	32
549	Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 288-295.	1.4	26
550	[¹¹¹In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 179-187.	0.7	23
551	Octreotide longâ€acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A populationâ€based analysis. Cancer, 2014, 120, 2039-2049.	2.0	26
552	CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 2014, 21, 879-890.	1.6	21
553	Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Annals of Oncology, 2014, 25, 763-773.	0.6	67
554	Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. Hpb, 2014, 16, 304-311.	0.1	58
555	Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: Case report and review of the literature. Pancreatology, 2014, 14, 542-545.	0.5	10
556	Mammalian target of rapamycin (<scp>mTOR</scp>) inhibitorâ€associated nonâ€infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU International, 2014, 113, 376-382.	1.3	48
557	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annals of Oncology, 2014, 25, 808-815.	0.6	112
558	Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology, 2014, 16, 292-297.	0.6	96
559	Surgical management of noncolorectal cancer liver metastases. Cancer, 2014, 120, 3111-3121.	2.0	60
560	Switch in Signaling Control of mTORC1 Activity After Oncoprotein Expression in Thyroid Cancer Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1976-E1987.	1.8	22
561	Outcome of surgery for pancreatic neuroendocrine neoplasms. British Journal of Surgery, 2014, 101, 1405-1412.	0.1	104
562	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. JAMA - Journal of the American Medical Association, 2014, 312, 57.	3.8	515
563	Use of mTOR inhibitors in the treatment of malignancies. Expert Opinion on Pharmacotherapy, 2014, 15, 979-990.	0.9	5
564	Phase II study of everolimusâ€“erlotinib in previously treated patients with advanced non-small-cell lung cancer. Annals of Oncology, 2014, 25, 409-415.	0.6	43

#	Article	IF	Citations
565	Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors. Investigational New Drugs, 2014, 32, 1308-1310.	1.2	10
566	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer, 2014, 14, 184.	1.1	76
567	Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 22-27.	1.2	24
568	Metastatic Gastrinoma in a Pediatric Patient With Zollinger-Ellison Syndrome. Journal of Pediatric Hematology/Oncology, 2014, 36, e13-e15.	0.3	6
569	Dual Inhibition of PI3K and mTOR Signaling Pathways Decreases Human Pancreatic Neuroendocrine Tumor Metastatic Progression. Pancreas, 2014, 43, 88-92.	0.5	23
570	Rash to the mTOR Inhibitor Everolimus. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 266-271.	0.6	19
571	Somatostatin Analog Inhibits the Growth of Insulinoma Cells by p27-Mediated G1 Cell Cycle Arrest. Pancreas, 2014, 43, 720-729.	0.5	10
572	Advances in small bowel neuroendocrine neoplasia. Current Opinion in Gastroenterology, 2014, 30, 163-167.	1.0	9
573	Comparison of Transarterial Liver-Directed Therapies for Low-Grade Metastatic Neuroendocrine Tumors in a Single Institution. Pancreas, 2014, 43, 219-225.	0.5	33
574	Current Clinical Trials of Targeted Agents for Well-Differentiated Neuroendocrine Tumors. Pancreas, 2014, 43, 1185-1189.	0.5	6
575	Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer. Anti-Cancer Drugs, 2014, 25, 1095-1101.	0.7	14
576	Advanced Digestive Neuroendocrine Tumors. Pancreas, 2014, 43, 212-218.	0.5	46
577	Use of Sorafenib in a Corticotropin-Secreting Pancreatic Neuroendocrine Carcinoma. Pancreas, 2014, 43, 809-810.	0.5	0
578	RABL6A Promotes G1â€“S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner. Cancer Research, 2014, 74, 6661-6670.	0.4	32
579	Hematological Toxicity of Combined ¹⁷⁷Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up. Neuroendocrinology, 2014, 99, 108-117.	1.2	64
580	Treatmentâ€Related Mortality With Everolimus in Cancer Patients. Oncologist, 2014, 19, 661-668.	1.9	12
581	Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors. Clinical Cancer Research, 2014, 20, 1212-1222.	3.2	51
582	Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment. , 2014, , 167-180.		0

#	Article	IF	Citations
583	Everolimus. Recent Results in Cancer Research, 2014, 201, 373-392.	1.8	54
585	Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocrine-Related Cancer, 2014, 21, R105-R120.	1.6	59
586	Targeting PI3K/Akt/mTOR Signaling in Cancer. Frontiers in Oncology, 2014, 4, 64.	1.3	1,077
587	Targeting PI3K/mTOR Signaling in Cancer. Frontiers in Oncology, 2014, 4, 84.	1.3	450
588	ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism. European Journal of Endocrinology, 2014, 170, R43-R55.	1.9	73
589	Long-Term Everolimus Treatment of Patients with Pancreatic Neuroendocrine Tumors. Chemotherapy, 2014, 60, 143-150.	0.8	9
590	Pancreatic neuroendocrine tumors. European Journal of Gastroenterology and Hepatology, 2014, 26, 826-835.	0.8	9
591	Liver transplantation for metastatic liver malignancies. Current Opinion in Organ Transplantation, 2014, 19, 235-244.	0.8	16
592	Factors Affecting Periprocedural Morbidity and Mortality and Long-term Patient Survival after Arterial Embolization of Hepatic Neuroendocrine Metastases. Journal of Vascular and Interventional Radiology, 2014, 25, 22-30.	0.2	37
593	mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Letters, 2014, 346, 309-317.	3.2	22
594	Capecitabine and streptozocinÂ±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer, 2014, 50, 902-911.	1.3	56
595	A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. Cancer Treatment Reviews, 2014, 40, 376-389.	3.4	46
596	Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discovery Today, 2014, 19, 458-468.	3.2	31
597	Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology. European Journal of Cancer, 2014, 50, 486-495.	1.3	66
598	Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth But Promotes Metastasis. Translational Oncology, 2014, 7, 221-229.	1.7	21
599	Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treatment Reviews, 2014, 40, 190-196.	3.4	67
600	Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey. Journal of Gastroenterology, 2014, 49, 511-516.	2.3	33
601	A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors. Modern Pathology, 2014, 27, 44-54.	2.9	35

#	Article	IF	Citations
602	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology, 2014, 9, 195-204.	1.7	20
603	Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 211-213.	3.3	27
604	Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 214-222.	3.3	69
605	Management of aggressive pituitary adenomas and pituitary carcinomas. Journal of Neuro-Oncology, 2014, 117, 459-468.	1.4	77
607	Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook. BioDrugs, 2014, 28, 373-381.	2.2	14
608	Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 925-933.	3.3	165
609	Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced nonâ€“small cell lung cancer. Investigational New Drugs, 2014, 32, 123-134.	1.2	5
610	Targeted therapies in gastroesophageal cancer. European Journal of Cancer, 2014, 50, 1247-1258.	1.3	45
611	Everolimus in combination with octreotide longâ€acting repeatable in a firstâ€line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer, 2014, 120, 2457-2463.	2.0	62
612	Pancreastatin Predicts Survival in Neuroendocrine Tumors. Annals of Surgical Oncology, 2014, 21, 2971-2980.	0.7	57
613	The role of mammalian target of rapamycin inhibitors in the management of postâ€transplant malignancy. Clinical Transplantation, 2014, 28, 635-648.	0.8	28
614	Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. Current Medical Research and Opinion, 2014, 30, 67-74.	0.9	34
615	Small Molecules in Oncology. Recent Results in Cancer Research, 2014, , .	1.8	4
616	The 2010 WHO Classification of Digestive Neuroendocrine Neoplasms: a Critical Appraisal fourÂyears after Its Introduction. Endocrine Pathology, 2014, 25, 186-192.	5.2	141
617	Detection of Metastatic Insulinoma by Positron Emission Tomography With [68Ga]Exendin-4â€”A Case Report. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1519-1524.	1.8	88
618	Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clinical and Translational Imaging, 2014, 2, 55-66.	1.1	66
619	Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nature Reviews Endocrinology, 2014, 10, 102-114.	4.3	120
620	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, 142, 164-175.		648

#	Article	IF	Citations
621	Inhibition of IL-32 and TSLP production through the attenuation of caspase-1 activation in an animal model of allergic rhinitis by Naju Jjok (Polygonum tinctorium). International Journal of Molecular Medicine, 2014, 33, 142-150.	1.8	15
622	Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology, 2014, 386, 101-120.	1.6	32
623	Neuroendocrine Tumors of the Pancreas: Current Concepts and Controversies. Endocrine Pathology, 2014, 25, 65-79.	5.2	113
624	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Annals of Oncology, 2014, 25, 415-422.	0.6	204
625	Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncology, The, 2014, 15, e8-e21.	5.1	413
626	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta OncolÃ³gica, 2014, 53, 1284-1297.	0.8	99
627	A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. Surgery, 2014, 156, 1359-1366.	1.0	35
628	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. Pediatric Blood and Cancer, 2014, 61, 833-839.	0.8	87
629	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocrine-Related Cancer, 2014, 21, 691-704.	1.6	53
630	The role of targeted therapy for gastrointestinal tumors. Expert Review of Gastroenterology and Hepatology, 2014, 8, 875-885.	1.4	27
631	Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocrine-Related Cancer, 2014, 21, R445-R460.	1.6	44
632	Progesterone Receptor and PTEN Expression Predict Survival in Patients With Low- and Intermediate-Grade Pancreatic Neuroendocrine Tumors. Archives of Pathology and Laboratory Medicine, 2014, 138, 1027-1036.	1.2	39
633	Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors. Endocrine-Related Cancer, 2014, 21, 813-824.	1.6	18
634	Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease. Clinical Transplantation, 2014, 28, 1339-1348.	0.8	29
635	Surgical management of nonâ€colorectal hepatic metastasis. Journal of Surgical Oncology, 2014, 109, 8-13.	0.8	15
636	Everolimus Reduces ⁸⁹Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2014, 55, 1087-1092.	2.8	56
637	Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. Journal of Clinical Oncology, 2014, 32, 260-263.	0.8	19
638	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530.	0.8	36

#	Article	IF	Citations
639	Current Options for the Treatment of Facial Angiofibromas. Actas Dermo-sifiliogrÃ¡ficas, 2014, 105, 558-568.	0.2	8
640	Role of ¹⁸Fâ€<scp>FDOPA PET</scp>/<scp>CT</scp> imaging in endocrinology. Clinical Endocrinology, 2014, 81, 789-798.	1.2	67
641	Progression-free survival as an end-point in solid tumours â€“ Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2303-2308.	1.3	32
642	Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opinion on Investigational Drugs, 2014, 23, 1619-1635.	1.9	33
643	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. Clinical Cancer Research, 2014, 20, 3133-3145.	3.2	29
644	Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics. Seminars in Diagnostic Pathology, 2014, 31, 498-511.	1.0	57
645	Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors. Current Treatment Options in Oncology, 2014, 15, 365-379.	1.3	74
646	Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocrine Disorders, 2014, 14, 54.	0.9	36
647	Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushingâ€™s syndrome: treatment response with chemotherapy. BMC Endocrine Disorders, 2014, 14, 70.	0.9	11
648	Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clinical and Experimental Metastasis, 2014, 31, 935-944.	1.7	28
649	Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. International Journal of Cancer, 2014, 135, 128-137.	2.3	22
650	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clinical and Translational Oncology, 2014, 16, 1025-1034.	1.2	21
651	¹⁸F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation. Journal of Nuclear Medicine, 2014, 55, 367-372.	2.8	51
653	Role of Kiâ€67ÂProliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease. World Journal of Surgery, 2014, 38, 1353-1361.	0.8	78
654	Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Research and Treatment, 2014, 146, 245-258.	1.1	48
655	Pancreatic NETs: where do we stand now?. Cancer and Metastasis Reviews, 2014, 33, 361-366.	2.7	4
656	Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?. Cancer and Metastasis Reviews, 2014, 33, 367-372.	2.7	13
657	Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. Cancer and Metastasis Reviews, 2014, 33, 345-351.	2.7	29

#	Article	IF	Citations
658	Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2014, 371, 224-233.	13.9	1,460
659	Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model. EJNMMI Research, 2014, 4, 21.	1.1	14
660	A historical perspective of pancreatic cancer mouse models. Seminars in Cell and Developmental Biology, 2014, 27, 96-105.	2.3	24
661	Diagnostic challenges of respiratory adverse events during everolimus treatment. Targeted Oncology, 2014, 9, 287-291.	1.7	6
662	High-Grade Poorly Differentiated Neuroendocrine Carcinomas of the Gastroenteropancreatic System: from Morphology to Proliferation and back. Endocrine Pathology, 2014, 25, 193-198.	5.2	29
663	Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. Clinical Journal of Gastroenterology, 2014, 7, 255-259.	0.4	16
664	Prognostic Value of Volume-Based Metabolic Parameters Measured by 18F-FDG PET/CT of Pancreatic Neuroendocrine Tumors. Nuclear Medicine and Molecular Imaging, 2014, 48, 180-186.	0.6	33
665	Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review. BMC Cancer, 2014, 14, 305.	1.1	5
666	Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours. British Journal of Cancer, 2014, 111, 858-865.	2.9	20
667	Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncology, 2014, 10, 1611-1617.	1.1	8
668	Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate. Journal of Nuclear Medicine, 2014, 55, 183-190.	2.8	158
669	Ancillary Studies, Including Immunohistochemistry and Molecular Studies, in Pancreatic Cytology. Surgical Pathology Clinics, 2014, 7, 1-34.	0.7	3
670	Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival of Patients With Pancreatic Neuroendocrine Tumors. Gastroenterology, 2014, 146, 453-460.e5.	0.6	355
671	Opciones terapÃ©uticas actuales para los angiofibromas faciales. Actas Dermo-sifiliogrÃ¡ficas, 2014, 105, 558-568.	0.2	19
672	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 241-250.	0.9	25
673	Insulinoma maligno avanzado. Respuesta y toxicidad con everolimus. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2014, 61, e1-e3.	0.8	2
674	Multiple endocrine neoplasia (MEN) syndromes. Seminars in Pediatric Surgery, 2014, 23, 96-101.	0.5	32
676	Advanced malignant insulinoma. Everolimus response and toxicity. EndocrinologÃa Y NutriciÃ³n (English Edition), 2014, 61, e1-e3.	0.5	1

#	Article	IF	Citations
677	SV40 TAg mouse models of cancer. Seminars in Cell and Developmental Biology, 2014, 27, 61-73.	2.3	21
678	Nonfunctional Pancreatic Neuroendocrine Tumors. Surgical Clinics of North America, 2014, 94, 689-708.	0.5	49
679	Alternative Lengthening of Telomeres Predicts Site of Origin in Neuroendocrine Tumor Liver Metastases. Journal of the American College of Surgeons, 2014, 218, 628-635.	0.2	34
680	Molecular Genetics of Pancreatic Neoplasms and Their Morphologic Correlates. American Journal of Clinical Pathology, 2014, 141, 168-180.	0.4	74
681	PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2404-13.	3.3	85
683	Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptorâ€“Positive Advanced Breast Cancer: Considerations for Oncologists. Clinical Breast Cancer, 2014, 14, 297-308.	1.1	24
685	Advances in Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors. Endocrine Practice, 2014, 20, 1222-1230.	1.1	22
686	Intermittent everolimus administration for malignant insulinoma. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140047.	0.2	12
687	A Case of Metastatic Gastric Neuroendocrine Tumor: Therapeutic Considerations. Case Reports in Oncology, 2014, 7, 266-272.	0.3	4
688	2014 Meet-The-Professor: Endocrine Case Management. , 2014, , .		0
689	New Insights into the Role of Chronic Inflammation and Cytokines in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 2014, 99, 75-84.	1.2	28
691	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	0.9	28
692	Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors. Oncology Reports, 2014, 32, 2753-2759.	1.2	18
694	Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Science, 2014, 105, 1464-1471.	1.7	30
695	Tumor-Associated Macrophages Are a Useful Biomarker to Predict Recurrence After Surgical Resection of Nonfunctional Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2014, 260, 1088-1094.	2.1	52
696	Efficacy of Capecitabine and Temozolomide Combination in Well-Differentiated Neuroendocrine Tumors. Pancreas, 2014, 43, 1303-1305.	0.5	31
697	L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway. Oncology Reports, 2014, 31, 2245-2251.	1.2	23
698	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Therapeutic Advances in Medical Oncology, 2015, 7, 170-180.	1.4	105

#	Article	IF	Citations
699	Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 594-601.	1.4	20
700	The upâ€toâ€date review of epidemiological pancreatic neuroendocrine tumors in Japan. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 574-577.	1.4	32
701	Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 628-633.	1.4	20
702	Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 623-627.	1.4	18
703	Rare Gastrointestinal Malignancies. , 2015, , 589-624.		0
704	Cellular and molecular effects of the mTOR inhibitor everolimus. Clinical Science, 2015, 129, 895-914.	1.8	74
706	Aace/Ace Disease State Clinical Review: Pancreatic Neuroendocrine Incidentalomas. Endocrine Practice, 2015, 21, 546-553.	1.1	15
707	Insulinoma in a Patient with Chronic Renal Failure due to Type 2 Diabetes Mellitus Treated Effectively with Diazoxide. Internal Medicine, 2015, 54, 621-625.	0.3	8
708	Metastatic Insulinoma: Current Molecular and Cytotoxic Therapeutic Approaches for Metastatic Well-Differentiated panNETs. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 139-144.	2.3	5
709	2015 Meet-The-Professor: Endocrine Case Management. , 2015, , .		0
710	Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management, and Controversies. International Surgery, 2015, 100, 1089-1097.	0.0	21
711	Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer. Clinical Journal of Oncology Nursing, 2015, 19, 468-474.	0.3	13
712	Strategy for treatment of a nonfunctioning pancreatic neuroendocrine neoplasm with liver metastases. International Cancer Conference Journal, 2015, 4, 133-137.	0.2	0
715	Multidisciplinary approach in the diagnosis and therapy of patients with endocrine tumors. Medicina ClÃnica (English Edition), 2015, 145, 36-41.	0.1	1
718	Renal failure requiring hemodialysis in two patients with metastatic breast cancer treated with everolimus. Breast Cancer Management, 2015, 4, 129-134.	0.2	1
719	Perspectives on surgical management of neuroendocrine liver metastases. International Journal of Endocrine Oncology, 2015, 2, 67-74.	0.4	0
720	PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell International, 2015, 15, 91.	1.8	21
721	Everolimus treatment in advanced solid tumors: a personal view. Future Science OA, 2015, 1, FSO3.	0.9	1

#	Article	IF	Citations
722	Clinical trial end points relevant to patients and society for rare cancers. Clinical Investigation, 2015, 5, 599-612.	0.0	1
723	Current management of mTOR inhibitor-associated stomatitis. Breast Cancer Management, 2015, 4, 255-264.	0.2	0
724	Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?. Clinical Transplantation, 2015, 29, 654-663.	0.8	10
725	SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors. Clinical Nuclear Medicine, 2015, 40, e271-e277.	0.7	9
726	Liver-directed therapy for neuroendocrine liver metastases. International Journal of Endocrine Oncology, 2015, 2, 75-88.	0.4	0
727	Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?. International Journal of Endocrine Oncology, 2015, 2, 201-215.	0.4	1
728	Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. Journal of Clinical Pharmacology, 2015, 55, 368-376.	1.0	21
729	Towards new response criteria in neuroendocrine tumors: Which changes in MRI parameters are associated with longer progressionâ€free survival after radioembolization of liver metastases?. Journal of Magnetic Resonance Imaging, 2015, 41, 361-368.	1.9	11
730	The expanding role of somatostatin analogues in the treatment of neuroendocrine tumours: the CLARINET study. Clinical Endocrinology, 2015, 83, 759-761.	1.2	10
731	A Comparison Between Appendiceal and Nonappendiceal Neuroendocrine Tumors in Children and Young Adults. Journal of Pediatric Hematology/Oncology, 2015, 37, 438-442.	0.3	7
734	Management of neuroendocrine tumours. , 0, , 528-537.		1
736	Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 123-128.	1.8	39
737	The Spectrum of Neuroendocrine Tumors: Histologic Classification, Unique Features and Areas of Overlap. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 92-103.	1.8	48
738	Insulinoma Manifesting Early Postpartum: Case Report and Review of the Literature. AACE Clinical Case Reports, 2015, 1, e230-e239.	0.4	1
739	Diagnostics and treatment of insulinoma. Neoplasma, 2015, 62, 692-704.	0.7	10
740	Profile of lanreotide autogel and its potential in the treatment of gastroenteropancreatic neuroendocrine tumors. Gastrointestinal Cancer: Targets and Therapy, 2015, , 123.	5.5	0
741	Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading. World Journal of Gastroenterology, 2015, 21, 8118.	1.4	44
742	Unusual endoscopic findings of gastric neuroendocrine tumor. Journal of Medical Investigation, 2015, 62, 251-257.	0.2	0

#	Article	IF	Citations
743	IGF-I Influences Everolimus Activity in Medullary Thyroid Carcinoma. Frontiers in Endocrinology, 2015, 6, 63.	1.5	3
744	Metastatic Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropic Hormone Production. Baylor University Medical Center Proceedings, 2015, 28, 46-49.	0.2	4
745	A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2015, 2, 19.	1.8	6
746	Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells. Oncology Research, 2015, 22, 193-201.	0.6	29
747	Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLoS ONE, 2015, 10, e0143830.	1.1	16
748	Diagnosis and management of insulinoma: current best practice and ongoing developments. Research and Reports in Endocrine Disorders, 0, , 125.	0.4	6
749	Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor. Case Reports in Endocrinology, 2015, 2015, 1-3.	0.2	12
750	Pasireotide for malignant insulinoma. Hormones, 2015, 15, 271-276.	0.9	29
751	Spinal cord compression after radiolabeled metaiodobenzylguanidine analogue therapy in advanced malignant insulinoma. Archives of Endocrinology and Metabolism, 2015, 59, 186-189.	0.3	2
754	Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncology, The, 2015, 16, 695-703.	5.1	111
755	The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. Cancer Treatment Reviews, 2015, 41, 423-430.	3.4	22
756	The Multiple Endocrine Neoplasia Syndromes. , 2015, , 317-352.		0
757	Targeting Unselective Autophagy of Cellular Aggregates. , 2015, , 95-133.		0
758	Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma. Journal of the American College of Surgeons, 2015, 221, 26-36.	0.2	18
759	GEP-NETS UPDATE: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. European Journal of Endocrinology, 2015, 172, R151-R166.	1.9	109
760	Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer. Journal of Oncology Pharmacy Practice, 2015, 21, 433-442.	0.5	7
761	Pancreatic neuroendocrine tumors: a review. Future Oncology, 2015, 11, 853-864.	1.1	33
762	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer, 2015, 15, 395.	1.1	96

#	Article	IF	Citations
763	Pazopanib: a new drug for pancreatic neuroendocrine tumours. Lancet Oncology, The, 2015, 16, 606-607.	5.1	4
764	Neuroendocrine Tumours. , 2015, , .		6
765	Targeted Therapies. , 2015, , 551-561.		0
767	Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. Expert Review of Anticancer Therapy, 2015, 15, 477-486.	1.1	3
768	Recent insights into the pathophysiology of mTOR pathway dysregulation. Research and Reports in Biology, 2015, , 1.	0.2	0
769	Combined Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor Pathway Inhibition in Pancreatic Neuroendocrine Tumors: More Than the Sum of Its Parts?. Journal of Clinical Oncology, 2015, 33, 1523-1526.	0.8	4
770	Treatment options for advanced pancreatic neuroendocrine tumors: what is on the horizon?. International Journal of Endocrine Oncology, 2015, 2, 39-55.	0.4	0
771	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer and Metastasis Reviews, 2015, 34, 823-842.	2.7	39
772	Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open, 2015, 5, e008248-e008248.	0.8	29
773	Prognostic Value of ⁶⁸Ga-DOTANOC PET/CT SUV_{max} in Patients with Neuroendocrine Tumors of the Pancreas. Journal of Nuclear Medicine, 2015, 56, 1843-1848.	2.8	78
774	Pancreatic Neuroendocrine Tumors: an Update. Indian Journal of Surgery, 2015, 77, 395-402.	0.2	15
775	An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Rare Cancers and Therapy, 2015, 3, 13-33.	0.2	4
777	Genetics and Epigenetics of Pancreatic Neuroendocrine Tumors and Pulmonary Carcinoids. Frontiers of Hormone Research, 2015, 44, 115-138.	1.0	5
778	Management of pancreatic neuroendocrine tumors. International Journal of Endocrine Oncology, 2015, 2, 57-65.	0.4	0
779	Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. Neuroendocrinology, 2015, 101, 274-288.	1.2	72
780	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncology, The, 2015, 16, 98-107.	5.1	270
781	Everolimus-Induced Hematologic Changes in Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2015, 15, 48-53.	1.1	12
782	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Molecular Oncology, 2015, 9, 749-757.	2.1	146

#	Article	IF	Citations
783	Pathological and Molecular Evaluation of Pancreatic Neoplasms. Seminars in Oncology, 2015, 42, 28-39.	0.8	64
784	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 1859-1868.	3.2	22
785	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology, 2015, 26, 1604-1620.	0.6	514
786	Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirusâ€“positive and Merkel cell polyomavirusâ€“negative carcinomas. Human Pathology, 2015, 46, 210-216.	1.1	28
787	PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine, 2015, 48, 363-370.	1.1	94
788	A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic Neuroendocrine Tumors. Annual Review of Medicine, 2015, 66, 1-16.	5.0	27
789	Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. Journal of Molecular Endocrinology, 2015, 54, 137-147.	1.1	83
790	Current treatment strategies for inhibiting mTOR in cancer. Trends in Pharmacological Sciences, 2015, 36, 124-135.	4.0	234
791	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology, 2015, 17, 1261-1269.	0.6	126
792	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Annals of Oncology, 2015, 26, 58-64.	0.6	111
793	Angiogenesis in primary hyperparathyroidism. Annals of Diagnostic Pathology, 2015, 19, 91-98.	0.6	6
794	Early phase clinical trials to identify optimal dosing and safety. Molecular Oncology, 2015, 9, 997-1007.	2.1	81
795	The genetic classification of pancreatic neoplasia. Journal of Gastroenterology, 2015, 50, 520-532.	2.3	6
796	Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocrine-Related Cancer, 2015, 22, 1-9.	1.6	76
797	Targeting the translation machinery in cancer. Nature Reviews Drug Discovery, 2015, 14, 261-278.	21.5	628
798	AERIO news in brief. Oncologie, 2015, 17, 57-60.	0.2	0
799	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Internal and Emergency Medicine, 2015, 10, 219-246.	1.0	11
800	Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 176-185.	3.3	91

#	Article	IF	Citations
801	Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan. Journal of Gastroenterology, 2015, 50, 769-775.	2.3	32
802	SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Molecular Imaging and Biology, 2015, 17, 313-318.	1.3	172
803	Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1144-1155.	3.3	29
804	Renal effects of targeted anticancer therapies. Nature Reviews Nephrology, 2015, 11, 354-370.	4.1	95
805	Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. Journal of the National Cancer Institute, 2015, 107, djv123.	3.0	38
806	Liver Metastases of Neuroendocrine Tumors and CCC. , 2015, , 73-88.		0
807	Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality. Scientific Reports, 2015, 4, 5927.	1.6	2
808	Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. International Journal of Surgery, 2015, 21, S10-S14.	1.1	21
810	A Phase I Study of Everolimus and Docetaxel inÂPatients With Castration-Resistant ProstateÂCancer. Clinical Genitourinary Cancer, 2015, 13, 113-123.	0.9	33
811	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of Oncology, 2015, 26, 1987-1993.	0.6	112
812	Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model. Clinical Cancer Research, 2015, 21, 4856-4867.	3.2	25
813	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2015, 95, 251-263.	2.0	8
814	Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex. Journal of Surgical Research, 2015, 194, 388-393.	0.8	10
815	Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2015, 41, 754-760.	3.4	19
816	Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2015, 22, 431-441.	1.6	26
817	Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. Future Oncology, 2015, 11, 1809-1828.	1.1	19
818	Comparison of the Utility of Cocaine- and Amphetamine-Regulated Transcript (CART), Chromogranin A, and Chromogranin B in Neuroendocrine Tumor Diagnosis and Assessment of Disease Progression. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1520-1528.	1.8	15
819	Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes and Endocrinology,the, 2015, 3, 895-905.	5.5	81

#	Article	IF	Citations
820	Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica, 2015, 100, 541-547.	1.7	34
821	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. Future Oncology, 2015, 11, 1947-1959.	1.1	9
822	Clinical Translation of Nanomedicine. Chemical Reviews, 2015, 115, 11147-11190.	23.0	619
823	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2015, 15, 847-858.	1.1	15
824	Immunotherapy of Pancreatic Cancer. , 2015, , 237-248.		1
826	Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. Cancer Genetics, 2015, 208, 374-381.	0.2	63
827	Carcinoid and Neuroendocrine Tumors: Building on Success. Journal of Clinical Oncology, 2015, 33, 1855-1863.	0.8	123
828	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs, 2015, 33, 700-709.	1.2	12
829	Targeted Therapy in Advanced Bladder Cancer. Urologic Clinics of North America, 2015, 42, 253-262.	0.8	14
830	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. Journal of Clinical Oncology, 2015, 33, 1551-1556.	0.8	110
831	Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 1099-1114.	1.1	13
832	Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 1135-1141.	1.1	56
833	Treatment-related fatigue with everolimus and temsirolimus in patients with cancerâ€"a meta-analysis of clinical trials. Tumor Biology, 2015, 36, 643-654.	0.8	8
834	Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data. Tumor Biology, 2015, 36, 467-478.	0.8	14
835	Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature. Future Oncology, 2015, 11, 1275-1290.	1.1	21
836	Site-specific bioalkylation of rapamycin by the RapM 16-O-methyltransferase. Chemical Science, 2015, 6, 2885-2892.	3.7	47
837	The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs, 2015, 75, 847-858.	4.9	42
838	Higher Risk of Infections with PI3Kâ€"AKTâ€"mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clinical Cancer Research, 2015, 21, 1869-1876.	3.2	33

#	Article	IF	Citations
839	Incidence and risk of xerosis with targeted anticancer therapies. Journal of the American Academy of Dermatology, 2015, 72, 656-667.	0.6	39
840	Apoptosis and Autophagy. , 2015, , 161-181.		1
841	Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. European Journal of Cancer, 2015, 51, 1253-1262.	1.3	95
843	Sequencing and Combining Systemic Therapies for Pancreatic Neuroendocrine Tumors. Journal of Clinical Oncology, 2015, 33, 1534-1538.	0.8	11
844	Inhibition of Heat Shock Protein 90 with AUY922 Represses Tumor Growth in a Transgenic Mouse Model of Islet Cell Neoplasms. Neuroendocrinology, 2015, 100, 300-309.	1.2	8
845	GEPâ€“NETs UPDATE: Radionuclide therapy in neuroendocrine tumors. European Journal of Endocrinology, 2015, 172, R1-R8.	1.9	107
846	Autophagy in endocrine tumors. Endocrine-Related Cancer, 2015, 22, R205-R218.	1.6	31
848	Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology, 2015, 102, 18-25.	1.2	32
849	Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors. Pancreas, 2015, 44, 190-197.	0.5	46
850	Inhibidores de la vÃa mTOR y de receptores tirosina cinasas en el tratamiento de los tumores neuroendocrinos. , 2015, , 241-249.		0
851	Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 131-153.	2.3	29
852	Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas, 2015, 44, 181-189.	0.5	43
853	Pancreatic neuroendocrine tumors. Current Opinion in Oncology, 2015, 27, 38-43.	1.1	9
854	Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients. Cancer Investigation, 2015, 33, 70-77.	0.6	27
855	Neuroendocrine gastro-enteropancreatic tumors â€“ from eminence based to evidence-based medicine â€“ A Scandinavian view. Scandinavian Journal of Gastroenterology, 2015, 50, 727-739.	0.6	11
856	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research, 2015, 21, 3412-3419.	3.2	101
857	Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1407-1419.	1.4	43
858	Symptomatic Control of Neuroendocrine Tumours with Everolimus. Hormones and Cancer, 2015, 6, 254-259.	4.9	29

#	Article	IF	Citations
860	Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study. Breast, 2015, 24, 718-722.	0.9	8
861	mTOR inhibitors and diabetes. Diabetes Research and Clinical Practice, 2015, 110, 101-108.	1.1	86
862	Octreotide Long-Acting Repeatable among Elderly Patients with Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1656-1665.	1.1	11
863	Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer, 2015, 15, 495.	1.1	25
864	Overcoming Resistance to Targeted Therapies in Cancer. Seminars in Oncology, 2015, 42, 896-908.	0.8	36
866	Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy?. Seminars in Diagnostic Pathology, 2015, 32, 456-468.	1.0	22
867	Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. BMC Cancer, 2015, 15, 241.	1.1	16
868	Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents. Leukemia and Lymphoma, 2015, 56, 2518-2523.	0.6	1
869	NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 261-269.	0.7	80
872	Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors?. International Journal of Endocrine Oncology, 2015, 2, 13-20.	0.4	1
873	Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1949-1954.	3.3	15
874	Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. Japanese Journal of Clinical Oncology, 2015, 45, hyv143.	0.6	24
875	Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 286-294.	0.9	5
876	Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbeck's Archives of Surgery, 2015, 400, 715-723.	0.8	50
877	Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer and Metastasis Reviews, 2015, 34, 381-400.	2.7	49
878	Application and Dosimetric Requirements for Gallium-68â€“labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, 2015, 10, 477-486.	1.5	14
879	Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro-Oncology, 2015, 17, 1550-1559.	0.6	123
880	Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it. International Journal of Surgery, 2015, 21, S89-S94.	1.1	17

#	Article	IF	Citations
881	Nonfunctioning Pancreatic Neuroendocrine Tumors. , 2015, , 275-298.		0
882	Microbe-associated immunomodulatory metabolites: Influence on T cell fate and function. Molecular Immunology, 2015, 68, 575-584.	1.0	23
883	Multiple Endocrine Neoplasia. Surgical Oncology Clinics of North America, 2015, 24, 795-832.	0.6	73
884	Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncology, 2015, 11, 1687-1699.	1.1	46
885	Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate. Journal of Nuclear Medicine, 2015, 56, 1647-1653.	2.8	97
886	Unexpected Cardiac Masses. JAMA Oncology, 2015, 1, 1343.	3.4	3
887	bULKing up mTOR inhibition. Nature Chemical Biology, 2015, 11, 758-760.	3.9	1
888	Simple structure, complex function. Nature Chemical Biology, 2015, 11, 760-761.	3.9	8
889	Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer. Annals of Oncology, 2015, 26, 1838-1845.	0.6	15
890	Systemic therapy for pulmonary carcinoids. Lung Cancer, 2015, 90, 139-147.	0.9	16
891	Complications of hyperglycaemia with PI3Kâ€“AKTâ€“mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. British Journal of Cancer, 2015, 113, 1541-1547.	2.9	30
892	Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center. Oncologist, 2015, 20, 1011-1018.	1.9	81
894	Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors. Cancer Genetics, 2015, 208, 564-570.	0.2	25
895	Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. Future Oncology, 2015, 11, 79-90.	1.1	15
896	Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate. Clinical Journal of Gastroenterology, 2015, 8, 414-420.	0.4	9
898	Familial and Hereditary Forms of Primary Hyperparathyroidism. , 2015, , 341-363.		7
899	A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline Gastroenterology, 2015, 6, 264-269.	0.9	14
900	Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Annals of Surgical Oncology, 2015, 22, 2685-2699.	0.7	76

#	Article	IF	Citations
901	Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. Journal of Gastroenterology, 2015, 50, 58-64.	2.3	325
902	A successful case of pancreaticoduodenectomy with resection of the hepatic arteries preserving a single aberrant hepatic artery for a pancreatic neuroendocrine tumor: report of a case. Surgery Today, 2015, 45, 363-368.	0.7	8
904	Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. Journal of Cancer Research and Clinical Oncology, 2015, 141, 295-305.	1.2	30
905	Therapeutic strategies for neuroendocrine liver metastases. Cancer, 2015, 121, 1172-1186.	2.0	158
906	Targeting PI3 kinase in cancer. , 2015, 146, 53-60.		129
907	Incidence and risk of rash to mTOR inhibitors in cancer patients â€“ a meta-analysis of randomized controlled trials. Acta OncolÃ³gica, 2015, 54, 124-132.	0.8	9
908	Pancreatic Neuroendocrine Tumors. , 2015, , 1375-1406.		0
909	Genomic Applications in Pathology. , 2015, , .		1
910	Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2016, 68, 169.	0.2	0
911	Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy. Journal of Cancer Science & Therapy, 2016, 08, 20-29.	1.7	18
912	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget, 2016, 7, 10547-10556.	0.8	52
913	New advances in targeted gastric cancer treatment. World Journal of Gastroenterology, 2016, 22, 6776.	1.4	74
914	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. Journal of Cancer, 2016, 7, 1044-1048.	1.2	17
915	New Developments in the Treatment of Neuroendocrine Tumours â€“ RADIANT-4, NETTER-1 and Telotristat Etiprate. European Endocrinology, 2016, 12, 44.	0.8	1
916	Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?. Journal of Gastrointestinal Oncology, 2016, 7, 804-818.	0.6	9
917	A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). Oncotarget, 2016, 7, 24950-24961.	0.8	19
918	Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. Journal of Transplantation, 2016, 2016, 1-11.	0.3	43
919	Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma. Journal of Immunology Research, 2016, 2016, 1-9.	0.9	10

#	Article	IF	Citations
920	Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. International Journal of Biological Sciences, 2016, 12, 1523-1532.	2.6	31
921	Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. OncoTargets and Therapy, 2016, 9, 699.	1.0	20
922	The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Frontiers in Endocrinology, 2015, 6, 188.	1.5	104
923	Notch Signaling in Neuroendocrine Tumors. Frontiers in Oncology, 2016, 6, 94.	1.3	59
924	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS ONE, 2016, 11, e0158140.	1.1	22
925	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489.	1.2	106
926	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Frontiers in Pharmacology, 2016, 7, 395.	1.6	131
928	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget, 2016, 7, 18865-18875.	0.8	26
929	Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. Translational Oncogenomics, 2016, Suppl. 1, 33-49.	1.7	25
930	The Role of Autophagy in Cancer and Chemotherapy. , 2016, , 253-265.		1
931	Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. Hormones, 2016, 15, 118-121.	0.9	4
932	Molecular-targeted Therapies in Gastrointestinal Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1051-1060.	0.0	0
933	The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution. Medicine (United States), 2016, 95, e3534.	0.4	13
934	Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabineâ€“temozolamide. Nuclear Medicine Communications, 2016, 37, 669-671.	0.5	12
935	Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. Pancreas, 2016, 45, 528-532.	0.5	2
936	Expression of Sex Determining Region Y-Box 2 and Pancreatic and Duodenal Homeobox 1 in Pancreatic Neuroendocrine Tumors. Pancreas, 2016, 45, 522-527.	0.5	9
937	Homeobox-Only Protein Expression Is a Critical Prognostic Indicator of Pancreatic Neuroendocrine Tumor and Is Regulated by Promoter DNA Hypermethylation. Pancreas, 2016, 45, 1255-1262.	0.5	18
938	Oxaliplatinâ€“Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors. Pancreas, 2016, 45, 1394-1400.	0.5	53

#	Article	IF	Citations
939	Diagnosis, treatment, and prognosis of bronchopulmonary carcinoid. Anti-Cancer Drugs, 2016, 27, 54-59.	0.7	4
940	Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Current Opinion in Oncology, 2016, 28, 359-366.	1.1	28
941	Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. Journal of Surgical Oncology, 2016, 114, 440-445.	0.8	47
942	Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors. Pancreas, 2016, 45, 941-946.	0.5	38
943	C8-T1 Radiculopathy Due to an Intradural Extramedullary Metastasis of a Pancreatic Neuroendocrine Tumor. Pancreas, 2016, 45, 772-779.	0.5	5
944	Uncommon Thoracic Tumors. , 2016, , 865-894.e8.		0
945	<scp>mTOR</scp> inhibitorâ€induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. International Journal of Cancer, 2016, 138, 2312-2321.	2.3	76
946	The mTOR Complexes in Cancer Cell Metabolism. Cancer Drug Discovery and Development, 2016, , 29-63.	0.2	2
947	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. American Journal of Transplantation, 2016, 16, 2892-2902.	2.6	151
948	Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors. Pancreas, 2016, 45, 1032-1035.	0.5	10
949	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19â€¯784 Diverse Solid Tumors. JAMA Oncology, 2016, 2, 1565.	3.4	195
950	Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor. Clinical Nuclear Medicine, 2016, 41, 561-563.	0.7	1
951	Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease. Internal Medicine, 2016, 55, 629-634.	0.3	9
952	Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study. Oncology and Therapy, 2016, 4, 275-286.	1.0	1
953	Sporadic Pancreatic Endocrine Tumors. , 2016, , 1-23.		0
955	Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data. Critical Reviews in Oncology/Hematology, 2016, 108, 1-12.	2.0	18
956	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
957	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. Clinical Pharmacokinetics, 2016, 55, 1447-1456.	1.6	17

#	Article	IF	Citations
958	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multiâ€institution observational study in Taiwan. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 396-402.	0.7	12
959	Evaluation and management of pancreatic lesions in patients with von Hippelâ€“Lindau disease. Nature Reviews Clinical Oncology, 2016, 13, 537-549.	12.5	72
960	Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4464-4469.	3.3	70
961	New Indications of mTOR Inhibitors in Rare Tumors. , 2016, , 113-137.		0
962	Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells. Clinical Immunology, 2016, 168, 47-54.	1.4	21
963	mTOR inhibitors in urinary bladder cancer. Tumor Biology, 2016, 37, 11541-11551.	0.8	23
964	Therapeutic innovations in endocrine diseases â€“ partÂ3Â: temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. Presse Medicale, 2016, 45, e211-e216.	0.8	9
965	Therapeutic Benefit of Selective Inhibition of p110Î± PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	3.2	35
966	Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors. Investigational New Drugs, 2016, 34, 654-662.	1.2	20
967	Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Reports, 2016, 15, 1144-1160.	2.9	175
968	DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treatment Reviews, 2016, 44, 1-9.	3.4	14
969	Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?. Endocrine, 2016, 53, 58-62.	1.1	18
970	Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials. Future Oncology, 2016, 12, 1529-1539.	1.1	7
971	New horizons for targeted treatment of neuroendocrine tumors. Future Oncology, 2016, 12, 1059-1065.	1.1	4
972	Diagnosis and Management of Hereditary Carcinoids. Recent Results in Cancer Research, 2016, 205, 149-168.	1.8	6
973	Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. Endocrine-Related Cancer, 2016, 23, R173-R183.	1.6	28
974	Surgical Oncology Manual. , 2016, , .		1
975	A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. Cancer Investigation, 2016, 34, 213-219.	0.6	13

#	Article	IF	Citations
976	Digestive neuroendocrine neoplasms: A 2016 overview. Digestive and Liver Disease, 2016, 48, 829-835.	0.4	14
978	Predictive Biomarkers of Response to mTOR Inhibitors. , 2016, , 217-228.		1
980	Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice. Hormone and Metabolic Research, 2016, 48, 575-580.	0.7	10
981	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Future Oncology, 2016, 12, 1251-1260.	1.1	29
982	Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. Acta OncolÃ³gica, 2016, 55, 1196-1203.	0.8	18
983	Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemporary Clinical Trials, 2016, 50, 143-149.	0.8	25
984	BEZ235: When Promising Science Meets Clinical Reality. Oncologist, 2016, 21, 1033-1034.	1.9	33
985	Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology, 2016, 16, 882-887.	0.5	34
986	Progress in Endocrine Neoplasia. Clinical Cancer Research, 2016, 22, 4981-4988.	3.2	8
987	Prognostic Factors in Resected Pancreatic Neuroendocrine Tumours: Experience in 95 Patients. CirugÃa EspaÃ±ola (English Edition), 2016, 94, 473-480.	0.1	4
988	Factores pronÃ³sticos de los tumores neuroendocrinos de pÃ¡ncreas resecados. Experiencia en 95 pacientes. CirugÃa EspaÃ±ola, 2016, 94, 473-480.	0.1	5
989	mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2016, 23, 883-891.	1.6	28
990	Molecular Genetics of Pancreatic Neoplasms. Surgical Pathology Clinics, 2016, 9, 685-703.	0.7	12
991	Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocrine-Related Cancer, 2016, 23, R551-R566.	1.6	80
992	Role of Immunohistochemistry and Molecular Genetics in Neuroendocrine Tumors. , 2016, , 43-56.		0
993	Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. British Journal of Cancer, 2016, 115, 564-570.	2.9	88
994	Carbidopa-assisted 18F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. Annals of Nuclear Medicine, 2016, 30, 659-668.	1.2	15
995	Glucagonoma syndrome: a review and update on treatment. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 2016-2022.	1.3	65

#	Article	IF	Citations
996	Everolimus in ileum neuroendocrine tumours. Lancet, The, 2016, 388, 236.	6.3	2
997	Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and longâ€term outcomes. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 61-69.	0.7	37
998	Smart Materials for Controlled Drug Release. , 2016, , 98-135.		0
999	Single institutional series of neuroendocrine tumors managed in the <scp>A</scp>ustralian <scp>C</scp>apital <scp>T</scp>erritory. Asia-Pacific Journal of Clinical Oncology, 2016, 12, e133-40.	0.7	8
1000	Management of pancreatic neuroendocrine tumors. International Journal of Endocrine Oncology, 2016, 3, 267-277.	0.4	0
1001	Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab. Orthopaedic Surgery, 2016, 8, 234-240.	0.7	7
1002	Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. , 2016, , .		6
1003	Neuroendocrine Tumors of the Pancreas. , 2016, , 131-151.		0
1004	The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Medicine, 2016, 5, 2953-2964.	1.3	15
1005	Molecular profiles in foregut oncology. Cancer Genetics, 2016, 209, 537-553.	0.2	0
1006	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2525.	1.8	55
1007	Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. Oncologist, 2016, 21, 1326-1336.	1.9	49
1009	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Journal of Clinical Oncology, 2016, 34, 3906-3913.	0.8	206
1010	Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opinion on Pharmacotherapy, 2016, 17, 2191-2205.	0.9	68
1011	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	0.8	83
1012	Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for â€˜Off-Target' Effects Not Mediated by c-Met Inhibition. Neuroendocrinology, 2016, 103, 383-401.	1.2	21
1013	Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. Neuroendocrinology, 2016, 103, 495-499.	1.2	19
1014	WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. Endocrine-Related Cancer, 2016, 23, T135-T154.	1.6	17

#	Article	IF	Citations
1015	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. British Journal of Cancer, 2016, 114, 889-896.	2.9	46
1016	Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeriaâ€related disorders. British Journal of Clinical Pharmacology, 2016, 82, 1229-1244.	1.1	47
1017	Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocrine-Related Cancer, 2016, 23, 563-570.	1.6	24
1018	Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Future Oncology, 2016, 12, 2561-2578.	1.1	3
1019	Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist, 2016, 21, 1191-1199.	1.9	123
1020	Histological features of mixed neuroendocrine carcinoma and hepatocellular carcinoma in the liver: a case report and literature review. Clinical Journal of Gastroenterology, 2016, 9, 272-279.	0.4	29
1021	Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. Cancer Biology and Therapy, 2016, 17, 883-888.	1.5	6
1022	Cancer Drug Discovery. , 2016, , .		6
1023	In vitro models of cancer stem cells and clinical applications. BMC Cancer, 2016, 16, 738.	1.1	65
1024	Management of neuroendocrine tumors. American Journal of Health-System Pharmacy, 2016, 73, 1729-1744.	0.5	11
1025	Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus. Targeted Oncology, 2016, 11, 667-675.	1.7	28
1026	Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3. Nature Communications, 2016, 7, 11776.	5.8	37
1027	Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer. Cancer Investigation, 2016, 34, 521-530.	0.6	24
1028	Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2487-2498.	0.9	27
1029	Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5022-5029.	3.2	20
1030	Neuroendocrine Tumors. , 2016, , 473-501.		0
1031	Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. Cancer Biology and Therapy, 2016, 17, 1274-1281.	1.5	11
1032	Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology, 2016, 27, 2172-2183.	0.6	58

#	Article	IF	Citations
1033	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Medicine, 2016, 8, 116.	3.6	15
1034	Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: Case Report. Oncology Research and Treatment, 2016, 39, 643-645.	0.8	11
1035	Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. Breast Cancer: Basic and Clinical Research, 2016, 10, BCBCR.S12443.	0.6	8
1036	Daunting but Worthy Goal. Transplantation, 2016, 100, 2569-2583.	0.5	16
1037	Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. BMC Cancer, 2016, 16, 858.	1.1	6
1038	Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors. Molecular Cancer, 2016, 15, 78.	7.9	54
1039	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. Cancer Research, 2016, 76, 4100-4112.	0.4	42
1040	Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nature Reviews Clinical Oncology, 2016, 13, 691-705.	12.5	47
1041	Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocrine Disorders, 2016, 16, 8.	0.9	10
1042	Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin. Endocrine Pathology, 2016, 27, 179-187.	5.2	9
1043	Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Review of Endocrinology and Metabolism, 2016, 11, 1-17.	1.2	1
1044	Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocrine-Related Cancer, 2016, 23, R229-R247.	1.6	32
1045	Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells. Neuroendocrinology, 2016, 103, 724-737.	1.2	21
1046	Surgical and molecular pathology of pancreatic neoplasms. Diagnostic Pathology, 2016, 11, 47.	0.9	100
1047	Everolimus pharmacokinetics and its exposureâ€“toxicity relationship in patients with thyroid cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 63-71.	1.1	34
1048	Clinicalâ€“Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2016, 128, 277-286.	1.0	1
1049	Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptorâ€“Positive, HER2-Negative Early Breast Cancer. Translational Oncology, 2016, 9, 114-123.	1.7	27
1050	Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. Oncologist, 2016, 21, 855-860.	1.9	48

#	Article	IF	Citations
1051	A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist, 2016, 21, 785-786g.	1.9	34
1052	A case of pancreatic neuroendocrine tumors. International Cancer Conference Journal, 2016, 5, 1-4.	0.2	1
1053	A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. Cancer Chemotherapy and Pharmacology, 2016, 78, 101-109.	1.1	23
1056	Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1â€“Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. Endocrinology, 2016, 157, 1789-1798.	1.4	26
1057	EphA4-mediated signaling regulates the aggressive phenotype of irradiation survivor colorectal cancer cells. Tumor Biology, 2016, 37, 12411-12422.	0.8	26
1058	Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 2016, 16, 391-401.	1.1	2
1059	CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells. International Journal of Oncology, 2016, 48, 657-669.	1.4	37
1060	Pancreatic neuroendocrine tumors: Nosography, management and treatment. International Journal of Surgery, 2016, 28, S156-S162.	1.1	42
1061	Safety and Efficacy of ⁶⁸Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Journal of Nuclear Medicine, 2016, 57, 708-714.	2.8	183
1063	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategyâ€”A literature review. Critical Reviews in Oncology/Hematology, 2016, 98, 264-274.	2.0	26
1064	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. European Radiology, 2016, 26, 3094-3101.	2.3	19
1065	Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 103-114.	2.2	54
1066	Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. British Journal of Cancer, 2016, 114, 650-658.	2.9	69
1067	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clinical Oncology, 2016, 28, 283-291.	0.6	3
1068	[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncology, 2016, 12, 313-321.	1.1	3
1069	Islet Cell Tumors of the Pancreas. Gastroenterology Clinics of North America, 2016, 45, 83-100.	1.0	19
1071	Antiangiogenic therapy in oncology: current status and future directions. Lancet, The, 2016, 388, 518-529.	6.3	663
1072	Universal everolimus for malignant neuroendocrine tumours?. Lancet, The, 2016, 387, 924-926.	6.3	2

#	Article	IF	Citations
1073	ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology, 2016, 103, 172-185.	1.2	844
1074	Tuberous sclerosisâ€"A model for tumour growth. Seminars in Cell and Developmental Biology, 2016, 52, 3-11.	2.3	18
1075	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. Cancer Treatment Reviews, 2016, 44, 26-41.	3.4	45
1076	Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. Critical Reviews in Oncology/Hematology, 2016, 101, 193-206.	2.0	21
1077	Incidentalomas of the Pancreas. , 2016, , 111-120.		0
1078	Medical Management of Pancreatic Neuroendocrine Tumors. Surgical Oncology Clinics of North America, 2016, 25, 423-437.	0.6	12
1079	Gastroenteropancreatic neuroendocrine tumours: an overview. British Journal of Nursing, 2016, 25, S12-S15.	0.3	11
1080	Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. Neuroendocrinology, 2016, 103, 806-814.	1.2	61
1081	ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. Journal of the American College of Radiology, 2016, 13, 265-273.	0.9	9
1082	Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Annals of Oncology, 2016, 27, 519-525.	0.6	68
1083	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. Critical Reviews in Oncology/Hematology, 2016, 98, 122-136.	2.0	24
1085	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2016, 387, 968-977.	6.3	962
1086	Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. European Journal of Cancer, 2016, 53, 163-170.	1.3	45
1087	Advances in Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine, 2016, 46, 40-46.	2.5	34
1088	Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocrine-Related Cancer, 2016, 23, 191-199.	1.6	193
1089	Targeting mTOR: A Little Bit of History and a Large Future. , 2016, , 1-17.		0
1090	Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. Oncologist, 2016, 21, 28-32.	1.9	92
1091	Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. Pancreatology, 2016, 16, 99-105.	0.5	25

#	Article	IF	Citations
1092	C-Reactive Protein as a New Prognostic Factor for Survival in Patients With Pancreatic Neuroendocrine Neoplasia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 937-944.	1.8	23
1093	mTOR Inhibition for Cancer Therapy: Past, Present and Future. , 2016, , .		3
1095	Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 63-82.	0.9	8
1096	Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 179-191.	0.9	106
1097	Clinical Trial Design in Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 209-217.	0.9	4
1098	The role of hypoxia in pancreatic cancer: a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 301-316.	1.4	114
1099	Pancreatic Masses. , 2016, , .		0
1100	Animal models of spontaneous pancreatic neuroendocrine tumors. Molecular and Cellular Endocrinology, 2016, 421, 60-67.	1.6	12
1101	Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scandinavian Journal of Gastroenterology, 2016, 51, 245-252.	0.6	80
1102	Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors. Scandinavian Journal of Gastroenterology, 2016, 51, 55-59.	0.6	11
1103	Surgical Management of Pancreatic Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 103-118.	0.9	32
1104	Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 119-133.	0.9	27
1105	Pathologic Classification of Neuroendocrine Neoplasms. Hematology/Oncology Clinics of North America, 2016, 30, 1-19.	0.9	49
1106	Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. Neuroendocrinology, 2016, 103, 345-353.	1.2	79
1107	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. Clinical Cancer Research, 2016, 22, 79-85.	3.2	65
1108	Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination ¹⁷⁷Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy. Neuroendocrinology, 2016, 103, 432-439.	1.2	87
1109	Neuroendocrine Tumor Syndromes. , 2016, , 2606-2614.e4.		2
1110	Multiple Endocrine Neoplasia Type 1. , 2016, , 2566-2593.e9.		5

#	Article	IF	Citations
1111	Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2016, 23, 197-205.	0.7	39
1112	Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia. Neuroendocrinology, 2017, 104, 11-25.	1.2	86
1113	Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. Neuroendocrinology, 2017, 104, 209-222.	1.2	13
1114	Principles of Kinase Inhibitor Therapy for Solid Tumors. Annals of Surgery, 2017, 265, 311-319.	2.1	10
1115	Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer Treatment Reviews, 2017, 54, 24-33.	3.4	76
1116	The Evolving Role of Pathology in New Developments, Classification, Terminology, and Diagnosis of Pancreatobiliary Neoplasms. Archives of Pathology and Laboratory Medicine, 2017, 141, 366-380.	1.2	22
1117	Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight. BMC Medicine, 2017, 15, 1.	2.3	242
1118	Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma. Scientific Reports, 2017, 7, 39597.	1.6	10
1120	IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis. Cancer Research, 2017, 77, 320-329.	0.4	29
1121	Radionuclide Imaging of Gastrointestinal Neuroendocrine Tumors. , 2017, , 321-349.		0
1122	Molecular Genetics of MEN1-Related Neuroendocrine Tumors. , 2017, , 47-64.		1
1123	Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumours. , 2017, , 127-140.		0
1124	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Supportive Care in Cancer, 2017, 25, 1713-1739.	1.0	125
1125	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. Journal of Clinical Oncology, 2017, 35, 1487-1488.	0.8	3
1126	BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. Cancer Biology and Therapy, 2017, 18, 229-236.	1.5	8
1127	Refractory carcinoid syndrome: a review of treatment options. Therapeutic Advances in Medical Oncology, 2017, 9, 127-137.	1.4	50
1128	Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Molecular and Clinical Oncology, 2017, 6, 44-48.	0.4	22
1129	Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. Molecular Cancer Research, 2017, 15, 744-752.	1.5	35

#	Article	IF	Citations
1130	Underlying Mechanisms for Distant Metastasis - Molecular Biology. Visceral Medicine, 2017, 33, 11-20.	0.5	100
1131	Design, synthesis, and biological evaluation of imidazo[1,2- b]pyridazine derivatives as mTOR inhibitors. European Journal of Medicinal Chemistry, 2017, 129, 135-150.	2.6	24
1132	Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. Oncologist, 2017, 22, 165-172.	1.9	24
1133	Asbestos and Mesothelioma. Current Cancer Research, 2017, , .	0.2	5
1134	Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Medical Oncology, 2017, 34, 88.	1.2	6
1135	Molecular subtypes in cancers of the gastrointestinal tract. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 333-342.	8.2	99
1136	Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 2017, 24, R203-R221.	1.6	36
1138	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1209-1224.	1.2	14
1139	Marital status is an independent prognostic factor for pancreatic neuroendocrine tumors patients: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 476-486.	0.7	51
1140	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clinical Cancer Research, 2017, 23, 4617-4624.	3.2	399
1141	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues. Neuroendocrinology, 2017, 105, 295-309.	1.2	229
1142	ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology, 2017, 105, 310-319.	1.2	97
1143	Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 2017, 57, 28-35.	3.4	15
1144	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer, 2017, 17, 211.	1.1	24
1145	Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncology Letters, 2017, 13, 1165-1174.	0.8	52
1146	Recent progress towards clinically relevant ATP-competitive Akt inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2838-2848.	1.0	34
1147	Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors. Oncology, 2017, 92, 353-359.	0.9	11
1148	Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Annals of Oncology, 2017, 28, 1569-1575.	0.6	88

#	Article	IF	Citations
1149	Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials. Oncology, 2017, 92, 243-254.	0.9	4
1150	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncology, 2017, 3, 1335.	3.4	2,289
1151	Diabetic Ketoacidosis and Acute Pancreatitis: Serious Adverse Effects ofÂEverolimus. Annals of Emergency Medicine, 2017, 69, 666-667.	0.3	6
1152	Do patient access schemes for high-cost cancer drugs deliver value to society?â€"lessons from the NHS Cancer Drugs Fund. Annals of Oncology, 2017, 28, 1738-1750.	0.6	102
1153	Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. Clinical Cancer Research, 2017, 23, 4625-4632.	3.2	150
1154	Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators. Annals of Surgical Oncology, 2017, 24, 1399-1405.	0.7	21
1155	A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. Oncologist, 2017, 22, 784-e74.	1.9	1
1156	Atypical Colorectal Neoplasms. Surgical Clinics of North America, 2017, 97, 641-656.	0.5	6
1157	Cancer and mTOR Inhibitors in Transplant Recipients. Transplantation, 2017, 101, 45-55.	0.5	104
1158	Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Targeted Oncology, 2017, 12, 611-622.	1.7	20
1159	Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. European Journal of Cancer, 2017, 81, 9-16.	1.3	13
1160	Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival. Annals of Surgical Oncology, 2017, 24, 2206-2212.	0.7	46
1161	Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET. Nuclear Medicine Communications, 2017, 38, 593-600.	0.5	15
1162	Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. Expert Opinion on Orphan Drugs, 2017, 5, 525-536.	0.5	0
1163	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Medicine, 2017, 6, 1493-1499.	1.3	11
1164	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (United States), 2017, 96, e6931.	0.4	3
1165	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Pancreas, 2017, 46, 302-305.	0.5	53
1166	Ketamine Causing Apnea?. Annals of Emergency Medicine, 2017, 69, 667-668.	0.3	0

#	Article	IF	Citations
1167	Pathophysiology of Gastric NETs: Role of Gastrin and Menin. Current Gastroenterology Reports, 2017, 19, 32.	1.1	13
1168	Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas, 2017, 46, 751-757.	0.5	6
1169	O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas, 2017, 46, 758-763.	0.5	28
1170	Gastro-entero-pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: a therapy update. International Journal of Endocrine Oncology, 2017, 4, 43-58.	0.4	1
1171	Prognostic and predictive biomarkers in neuroendocrine tumours. Critical Reviews in Oncology/Hematology, 2017, 113, 268-282.	2.0	42
1172	May we challenge the ENETS guidelines in pancreatic neuroendocrine neoplasms? A quiz for French experts. Digestive and Liver Disease, 2017, 49, 809-819.	0.4	0
1173	Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors. International Journal of Clinical Oncology, 2017, 22, 734-739.	1.0	20
1174	Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Annals of Nuclear Medicine, 2017, 31, 347-356.	1.2	47
1175	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 2017, 28, 1309-1315.	0.6	82
1176	Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Therapeutic Advances in Medical Oncology, 2017, 9, 189-199.	1.4	38
1177	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Therapeutic Advances in Medical Oncology, 2017, 9, 183-188.	1.4	20
1178	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology, 2017, 105, 266-280.	1.2	122
1179	A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Targeted Oncology, 2017, 12, 323-332.	1.7	84
1180	Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice. Medecine Nucleaire, 2017, 41, 42-54.	0.2	1
1181	Everolimus in the management of metastatic neuroendocrine tumours. Therapeutic Advances in Gastroenterology, 2017, 10, 132-141.	1.4	33
1182	Principles of diagnosis and management of neuroendocrine tumours. Cmaj, 2017, 189, E398-E404.	0.9	66
1183	Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Current Treatment Options in Oncology, 2017, 18, 14.	1.3	52
1184	The role of liquid biopsies to manage and predict PRRT for NETs. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 331-332.	8.2	14

#	Article	IF	Citations
1185	Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Annals of Surgical Oncology, 2017, 24, 2319-2325.	0.7	98
1186	Defining rules for increasingly personalized treatments. Nature Reviews Clinical Oncology, 2017, 14, 80-82.	12.5	6
1187	Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. Clinical Science, 2017, 131, 27-36.	1.8	22
1188	Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. Journal of Hepato-Biliary-Pancreatic Sciences, 2017, 24, 95-102.	1.4	11
1189	Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. , 2017, , .		2
1190	Principles and Application of Molecular Imaging for Personalized Medicine and Guiding Interventions in Neuroendocrine Tumors. , 2017, , 219-238.		2
1191	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
1192	Effect of everolimus on the pharmacokinetics of octreotide longâ€acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANTâ€2 trial. Clinical Pharmacology and Therapeutics, 2017, 101, 462-468.	2.3	11
1193	Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines. Endocrine-Related Cancer, 2017, 24, 71-81.	1.6	16
1194	Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemotherapy and Pharmacology, 2017, 79, 139-146.	1.1	28
1195	Regression of advanced neuroendocrine tumors among patients receiving placebo. Endocrine-Related Cancer, 2017, 24, L13-L16.	1.6	5
1196	Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opinion on Pharmacotherapy, 2017, 18, 1679-1689.	0.9	21
1197	Glucagonoma syndrome with serous oligocystic adenoma. Medicine (United States), 2017, 96, e8448.	0.4	2
1198	Clinically relevant radioresistant cell line: a simple model to understand cancer radioresistance. Medical Molecular Morphology, 2017, 50, 195-204.	0.4	38
1199	Cell Cycle Protein Expression in Neuroendocrine Tumors. Pancreas, 2017, 46, 1347-1353.	0.5	17
1200	Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor. Pancreas, 2017, 46, 1381-1385.	0.5	4
1201	Towards personalised medicine in lung and thymus neuroendocrine tumours. Lancet Oncology, The, 2017, 18, 1563-1565.	5.1	1
1202	Maintaining quality of life for patients with neuroendocrine tumours. Lancet Oncology, The, 2017, 18, 1299-1300.	5.1	4

#	Article	IF	Citations
1203	Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma. Neuroendocrinology, 2017, 105, 426-434.	1.2	41
1204	Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Current Oncology Reports, 2017, 19, 72.	1.8	13
1205	Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea. Cancer Chemotherapy and Pharmacology, 2017, 80, 799-805.	1.1	12
1206	Radionuclides in oncology clinical practice â€“ review of the literature. Dalton Transactions, 2017, 46, 14475-14487.	1.6	4
1207	Differences between Grades G1 and G2 Hypovascular Pancreatic Neuroendocrine Tumors and Pancreatic Neuroendocrine Carcinoma. Radiology, 2017, 285, 331-332.	3.6	1
1208	mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment. Molecular Cancer Therapeutics, 2017, 16, 2432-2441.	1.9	13
1209	Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology, 2017, 105, 412-425.	1.2	119
1210	Somatostatin Receptor 2â€“Targeting Compounds. Journal of Nuclear Medicine, 2017, 58, 54S-60S.	2.8	38
1211	Cyto-histology in NET: what is necessary today and what is the future?. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 381-391.	2.6	18
1212	Management of pulmonary neuroendocrine tumors. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 433-442.	2.6	32
1213	Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors. Clinical Nuclear Medicine, 2017, 42, e457-e466.	0.7	56
1214	Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation. Annals of Oncology, 2017, 28, 904-905.	0.6	8
1215	Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism. Molecular Cancer Therapeutics, 2017, 16, 2502-2515.	1.9	52
1216	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine, 2017, 57, 366-375.	1.1	33
1217	The safety of available treatments options for neuroendocrine tumors. Expert Opinion on Drug Safety, 2017, 16, 1149-1161.	1.0	29
1218	Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 776-779.	0.7	2
1219	Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Seminars in Oncology, 2017, 44, 141-156.	0.8	22
1220	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open, 2017, 2, e000166.	2.0	4

#	Article	IF	Citations
1221	A vicious partnership between <scp>AKT</scp> and <scp>PHLDA</scp>3 to facilitate neuroendocrine tumors. Cancer Science, 2017, 108, 1101-1108.	1.7	20
1222	Probing the phosphatidylinositol 3â€kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult lowâ€grade gliomas. Cancer, 2017, 123, 4631-4639.	2.0	43
1223	Carcinoid syndrome and neuroendocrine tumours. Medicine, 2017, 45, 543-546.	0.2	1
1224	Four <scp>PTEN</scp>â€targeting coâ€expressed mi<scp>RNA</scp>s and <scp>ACTN</scp>4â€targeting mi<scp>R</scp>â€548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue. International Journal of Cancer, 2017, 141, 2318-2328.	2.3	20
1225	The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors. Clinical Nuclear Medicine, 2017, 42, e135-e141.	0.7	13
1226	Randomized Controlled Trials in Neuroendocrine Tumors. Surgical Oncology Clinics of North America, 2017, 26, 751-765.	0.6	2
1227	Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. Cancer Investigation, 2017, 35, 552-561.	0.6	5
1228	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. Clinical Cancer Research, 2017, 23, 6958-6968.	3.2	74
1229	PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours. Oncology Letters, 2017, 14, 1373-1378.	0.8	13
1231	Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review. Clinical Therapeutics, 2017, 39, 2146-2157.	1.1	19
1232	A Case of Cervical Carcinoid and Review of the Literature. Case Reports in Oncology, 2017, 10, 737-742.	0.3	11
1233	The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors. Digestion, 2017, 96, 67-75.	1.2	27
1234	The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Targeted Oncology, 2017, 12, 757-774.	1.7	1
1235	Update in the Therapy of Advanced Neuroendocrine Tumors. Current Treatment Options in Oncology, 2017, 18, 72.	1.3	18
1236	Inherited and acquired clinical phenotypes associated with neuroendocrine tumors. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 431-442.	1.1	6
1237	Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia, 2017, 19, 991-1002.	2.3	474
1238	Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Pancreas, 2017, 46, 891-897.	0.5	2
1239	Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12). Metabolomics, 2017, 13, 98.	1.4	12

#	Article	IF	Citations
1240	Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms. Endocrine-Related Cancer, 2017, 24, 475-483.	1.6	17
1242	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. Journal of Vascular and Interventional Radiology, 2017, 28, 1210-1223.e3.	0.2	103
1243	Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study. Neuroendocrinology, 2017, 105, 26-34.	1.2	11
1244	Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?. Radiology, 2017, 283, 883-894.	3.6	38
1245	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0
1246	Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. CardioVascular and Interventional Radiology, 2017, 40, 69-80.	0.9	81
1247	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. Future Oncology, 2017, 13, 615-624.	1.1	32
1248	Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. Neuroendocrinology, 2017, 105, 90-104.	1.2	20
1249	An overview of rapamycin: from discovery to future perspectives. Journal of Industrial Microbiology and Biotechnology, 2017, 44, 537-553.	1.4	79
1250	Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience. Annals of Surgical Oncology, 2017, 24, 450-459.	0.7	23
1251	Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 925-931.	1.4	23
1252	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 476-489.	3.3	42
1253	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. Journal of Endocrinological Investigation, 2017, 40, 9-20.	1.8	38
1254	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2017, 21, 155-163.	0.9	34
1255	Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene, 2017, 36, 1899-1907.	2.6	26
1256	The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 473-483.	2.6	26
1257	A case of long-survival insulinoma with multiple neuroendocline tumour type 1 controlled by multimodal therapy. Journal of Surgical Case Reports, 2017, 2017, rjx244.	0.2	1
1258	Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. Neuroendocrinology, 2017, 105, 394-402.	1.2	27

#	Article	IF	Citations
1259	Twins in spirit part IV â€“ [177Lu] high affinity DOTATATE. Nuklearmedizin - NuclearMedicine, 2017, 56, 1-8.	0.3	6
1260	Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?. World Journal of Gastroenterology, 2017, 23, 2640.	1.4	21
1261	Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World Journal of Gastroenterology, 2017, 23, 516.	1.4	32
1262	Emerging use of everolimus in the treatment of neuroendocrine tumors. Cancer Management and Research, 2017, Volume 9, 215-224.	0.9	14
1263	Pancreatic neuroendocrine tumors. , 2017, , 997-1006.e3.		0
1264	Systemic Therapy in Incurable Gastroenteropancreatic Neuroendocrine Tumours: A Clinical Practice Guideline. Current Oncology, 2017, 24, 249-255.	0.9	5
1265	Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. International Journal of Molecular Sciences, 2017, 18, 143.	1.8	49
1266	Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Frontiers in Endocrinology, 2017, 8, 341.	1.5	12
1267	Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Archives of Medical Science, 2017, 2, 271-282.	0.4	8
1268	Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. Gastroenterology Research and Practice, 2017, 2017, 1-9.	0.7	7
1269	Neuroendocrine tumors. , 2017, , 399-437.		1
1270	Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. International Journal of Surgical Oncology, 2017, 2017, 1-14.	0.3	8
1271	The evolving landscape of systemic therapy for well-differentiated neuroendocrine tumors of the lung. International Journal of Endocrine Oncology, 2017, 4, 63-65.	0.4	0
1272	Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. BioMed Research International, 2017, 2017, 1-12.	0.9	25
1273	Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	65
1274	Reply to the letter to the editor â€˜Integrating communication as a core skill in the global curriculum for medical oncologyâ€™ by Horlait et al.. Annals of Oncology, 2017, 28, 905-906.	0.6	1
1275	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE, 2017, 12, e0180192.	1.1	27
1276	Recent advances in the management of endocrine malignancies associated with hereditary hyperparathyroidism syndromes. International Journal of Endocrine Oncology, 2017, 4, 85-102.	0.4	0

#	Article	IF	Citations
1277	A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor. Surgical Case Reports, 2017, 3, 82.	0.2	8
1278	Multimodal Therapy for Pancreatic Neuroendocrine Tumors with Multiple Liver Metastases - Two Case Reports. Journal of Clinical Gastroenterology and Hepatology, 2017, 01, .	0.2	0
1279	Functional pancreatic neuroendocrine tumour causing Cushingâ€™s syndrome: the effect of chemotherapy on clinical symptoms. Ecancermedicalscience, 2017, 11, 773.	0.6	4
1280	The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review. Oncotarget, 2017, 8, 95023-95029.	0.8	8
1281	Alterations in Cancer-related Genes Associated with Grading of Well Differentiated Pancreatic Neuroendocrine Neoplasms. Pancreatic Disorders & Therapy, 2017, 07, .	0.3	0
1282	Multimodal Treatment of Vasoactive Intestinal Polypeptide-producing Pancreatic Neuroendocrine Tumors with Liver Metastases. Internal Medicine, 2017, 56, 517-522.	0.3	6
1283	Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. OncoTargets and Therapy, 2017, Volume 10, 1465-1474.	1.0	29
1284	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. OncoTargets and Therapy, 2017, Volume 10, 5013-5030.	1.0	8
1285	Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. Cancers, 2017, 9, 152.	1.7	41
1286	Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite. OncoTargets and Therapy, 2017, Volume 10, 5077-5087.	1.0	1
1287	Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience, 2017, 11, 716.	0.6	16
1288	Glycemic control in patients with insulinoma. Hormones, 2017, 15, 489-499.	0.9	27
1289	Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. Journal of Clinical Oncology, 2017, 35, 1695-1703.	0.8	122
1290	Reply to V. Amoroso et al. Journal of Clinical Oncology, 2017, 35, 1488-1489.	0.8	1
1291	Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series. World Journal of Clinical Oncology, 2017, 8, 293.	0.9	1
1292	Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. Journal of Global Oncology, 2017, 3, 43-53.	0.5	105
1293	Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 210-215.	1.8	25
1294	Biologics in gastrointestinal and pancreatic neuroendocrine tumors. Journal of Gastrointestinal Oncology, 2017, 8, 457-465.	0.6	17

#	Article	IF	Citations
1295	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer, 2018, 124, 1992-2000.	2.0	17
1296	Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 471-480.	1.6	1
1297	Targeting the PI3K pathway in cancer: are we making headway?. Nature Reviews Clinical Oncology, 2018, 15, 273-291.	12.5	762
1298	Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. Pancreatology, 2018, 18, 313-317.	0.5	13
1299	Hepatobiliary and Pancreatic Cancer. Cancer Dissemination Pathways, 2018, , .	0.0	2
1300	Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors. Journal of the National Cancer Institute, 2018, 110, 1019-1029.	3.0	18
1301	Drug discovery targeting the mTOR pathway. Clinical Science, 2018, 132, 543-568.	1.8	65
1302	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation, 2018, 102, 727-743.	0.5	178
1303	Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	39
1304	Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. Oncologist, 2018, 23, 660-669.	1.9	16
1305	Peptide receptor radionuclide therapy for neuroendocrine tumours. Clinical and Translational Imaging, 2018, 6, 101-111.	1.1	3
1306	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling) Tj ETQq1 1 0.784314 rgBT /Ove	2.8	81
1307	Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics, 2018, 36, 1005-1013.	1.7	11
1308	(â˜)-Guaiol regulates autophagic cell death depending on mTOR signaling in NSCLC. Cancer Biology and Therapy, 2018, 19, 706-714.	1.5	17
1309	Current and emerging therapies for PNETs in patients with or without MEN1. Nature Reviews Endocrinology, 2018, 14, 216-227.	4.3	46
1310	Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival. Cellular Physiology and Biochemistry, 2018, 45, 389-396.	1.1	41
1313	Biofilm reduction, cell proliferation, anthelmintic and cytotoxicity effect of green synthesised silver nanoparticle usingArtemisia vulgarisextract. IET Nanobiotechnology, 2018, 12, 71-77.	1.9	10
1314	Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up. , 2018, , 203-222.		0

#	Article	IF	Citations
1315	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
1322	Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors. Pancreas, 2018, 47, 326-331.	0.5	15
1323	Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncology, 2018, 14, 1155-1164.	1.1	8
1324	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro-Oncology, 2018, 20, 666-673.	0.6	108
1325	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. Hpb, 2018, 20, 197-203.	0.1	29
1326	Metastatic primary neuroendocrine carcinoma of the breast (NECB). Journal of Cancer Research and Practice, 2018, 5, 38-42.	0.2	5
1327	Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits. Pancreatology, 2018, 18, 304-312.	0.5	4
1328	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery, 2018, 163, 761-767.	1.0	65
1329	Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology, 2018, 154, 998-1008.e1.	0.6	62
1330	The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology, 2018, 106, 357-365.	1.2	57
1331	Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. Molecular Cancer Research, 2018, 16, 496-507.	1.5	55
1332	Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer. European Journal of Clinical Pharmacology, 2018, 74, 465-471.	0.8	20
1333	A Lymph Node Ratioâ€“Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 187-195.	1.8	18
1334	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes and Endocrinology,the, 2018, 6, 404-415.	5.5	56
1335	Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Annals of Oncology, 2018, 29, 707-714.	0.6	46
1336	Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open, 2018, 3, e000291.	2.0	37
1337	Sporadic Pancreatic Endocrine Tumors. , 2018, , 241-263.		0
1338	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology, 2018, 155, 479-489.e7.	0.6	54

#	Article	IF	Citations
1339	Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocrine-Related Cancer, 2018, 25, 619-631.	1.6	14
1340	Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clinical Pathology, 2018, 18, 3.	1.8	23
1341	Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. British Journal of Cancer, 2018, 118, 966-971.	2.9	35
1342	Oral stomatitis and <scp>mTOR</scp> inhibitors: A review of current evidence in 20,915 patients. Oral Diseases, 2018, 24, 144-171.	1.5	18
1343	Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 547-560.	1.6	9
1344	Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 169-175.	0.6	18
1345	Developing advanced clinical practice skills in gastrointestinal consequences of cancer treatment. British Journal of Nursing, 2018, 27, 237-247.	0.3	6
1347	IFN-Î± in advanced well-differentiated neuroendocrine tumors: the neglected drug?. Future Oncology, 2018, 14, 897-899.	1.1	1
1348	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 607-618.	1.6	18
1349	The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. Endocrine, 2018, 62, 46-56.	1.1	16
1350	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
1351	From Initial Description by Wermer to Presentâ€Day MEN1: What have We Learned?. World Journal of Surgery, 2018, 42, 1031-1035.	0.8	9
1352	Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 326-331.	0.6	1
1353	The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53^{wild type} Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology, 2018, 106, 1-19.	1.2	25
1354	Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index â‰¥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE). Neuroendocrinology, 2018, 106, 38-46.	1.2	15
1355	The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. Neuroendocrinology, 2018, 106, 58-73.	1.2	18
1356	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2018, 267, 1148-1154.	2.1	101
1357	Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology, 2018, 106, 211-220.	1.2	35

#	Article	IF	Citations
1358	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 114-116.	0.7	4
1359	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
1360	GSK3Î±/Î²: A Novel Therapeutic Target for Neuroendocrine Tumors. Neuroendocrinology, 2018, 106, 335-351.	1.2	10
1361	Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells. Molecular Cancer Therapeutics, 2018, 17, 60-72.	1.9	8
1362	Drug-Induced Lung Injury. Respiratory Disease Series, 2018, , .	0.1	2
1363	Development and validation of an analytical method using UPLCâ€“MS/MS to quantify everolimus in dried blood spots in the oncology setting. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 106-113.	1.4	23
1364	Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer, 2018, 25, R11-R29.	1.6	112
1365	Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. Neuroendocrinology, 2018, 106, 307-311.	1.2	17
1366	Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. Toxicology in Vitro, 2018, 46, 229-236.	1.1	13
1367	The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?. Endocrine, 2018, 60, 15-27.	1.1	22
1368	Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. Neuroendocrinology, 2018, 106, 318-323.	1.2	7
1369	Molecular Targeted Therapy for Gastroenteropancreatic Neuroendocrine Tumors. Current Human Cell Research and Applications, 2018, , 145-156.	0.1	0
1370	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. British Journal of Cancer, 2018, 118, 181-188.	2.9	23
1371	Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Endocrine Connections, 2018, 7, R1-R25.	0.8	22
1373	Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates. Histopathology, 2018, 72, 153-167.	1.6	38
1374	Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-NaÃ¯ve Advanced Pancreatic Neuroendocrine Tumors. Oncologist, 2018, 23, 766-e90.	1.9	59
1375	Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine, 2018, 59, 426-437.	1.1	31
1376	Multidisciplinary management of refractory insulinomas. Clinical Endocrinology, 2018, 88, 615-624.	1.2	32

#	Article	IF	Citations
1377	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002329.	0.5	30
1378	Hereditary Syndromes and Abdominal Neuroendocrine Tumors. Updates in Surgery Series, 2018, , 33-52.	0.0	0
1379	Carcinoid-syndrome: recent advances, current status and controversies. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 22-35.	1.2	83
1380	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine, 2018, 60, 490-498.	1.1	59
1381	Synthesis and biological evaluation of rapamycin-derived, next generation small molecules. MedChemComm, 2018, 9, 27-43.	3.5	12
1382	Prognostic and predictive role of the PI3Kâ€“AKTâ€“mTOR pathway in neuroendocrine neoplasms. Clinical and Translational Oncology, 2018, 20, 561-569.	1.2	10
1383	Everolimus in advanced, progressive, wellâ€differentiated, nonâ€functional neuroendocrine tumors: <scp>RADIANT</scp>â€4 lung subgroup analysis. Cancer Science, 2018, 109, 174-181.	1.7	72
1384	Pancreatic Neuroendocrine Tumours. , 2018, , 173-179.		0
1385	Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. Clinical Pharmacokinetics, 2018, 57, 637-644.	1.6	21
1386	A Case of Everolimus-Induced Eyelid Edema. Ophthalmic Plastic and Reconstructive Surgery, 2018, 34, e21-e22.	0.4	4
1387	Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors. Medicine (United States), 2018, 97, e12750.	0.4	7
1388	Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO Precision Oncology, 2018, 2018, 1-18.	1.5	39
1389	Well differentiated neuroendocrine tumors, a single center experience. Journal of Oncological Science, 2018, 4, 119-124.	0.1	0
1390	Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 292-299.	1.8	9
1391	Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors. Journal of Oncology Practice, 2018, 14, 487-489.	2.5	0
1392	Developing advanced clinical practice skills in gastrointestinal consequences of cancer treatment. Gastrointestinal Nursing, 2018, 16, 27-36.	0.0	0
1393	Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. Annals of Gastroenterology, 2018, 31, 140-150.	0.4	5
1394	Primary hepatic neuroendocrine neoplasm. Medicine (United States), 2018, 97, e11764.	0.4	22

#	Article	IF	Citations
1395	Gastrointestinal Neuroendocrine Tumor Syndromes (GI NETS). , 2018, , 597-616.		0
1396	Gastrinomas. , 2018, , 617-625.		0
1397	Response to Mammalian Target of Rapamycinâ€“Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation. JCO Precision Oncology, 2018, 2, 1-6.	1.5	2
1398	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. Journal of Clinical Oncology, 2018, 36, 342-349.	0.8	120
1399	Management of functional neuroendocrine tumors of the pancreas. Gland Surgery, 2018, 7, 20-27.	0.5	56
1400	Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology. Gland Surgery, 2018, 7, 42-46.	0.5	27
1401	Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 494-502.	0.5	2
1402	Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms. Medicine (United States), 2018, 97, e12784.	0.4	39
1404	Il-ÂLes tumeurs neuroendocrines pancrÃ©atiques sporadiquesÂ: quelle chirurgie pour la tumeur primitiveÂ?. Journal De Chirurgie ViscÃ©rale, 2018, 155, 497-507.	0.0	0
1405	Pancreatic Islet Cell Tumors. , 2018, , 626-634.		0
1406	8 Carcinoid Tumor (Neuroendocrine Tumors of the Gastrointestinal Tract). , 2018, , .		0
1407	Sporadic pancreatic neuroendocrine tumor: Surgery of the primary tumor. Journal of Visceral Surgery, 2018, 155, 483-492.	0.4	2
1408	The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring. Internal Medicine, 2018, 57, 2527-2531.	0.3	1
1409	Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors. Journal of Cancer, 2018, 9, 4783-4790.	1.2	5
1410	My burning issues in neuroendocrine tumours (NET). Memo - Magazine of European Medical Oncology, 2018, 11, 313-316.	0.3	0
1411	177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours. Nuclear Medicine Communications, 2018, 39, 789-796.	0.5	53
1412	Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Journal of Oncology, 2018, 2018, 1-10.	0.6	13
1413	17 Management of Liver Metastases. , 2018, , .		0

#	Article	IF	Citations
1414	Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms. Cancer Cytopathology, 2018, 126, 980-991.	1.4	10
1415	Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. World Journal of Gastroenterology, 2018, 24, 2152-2162.	1.4	20
1416	Pancreatic Neuroendocrine Tumours. , 2018, , 467-476.		0
1417	Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 2018, 118, 416-421.	0.8	18
1418	Resection Versus Chemotherapy for Metastatic Neuroendocrine Tumors of the Pancreas. Difficult Decisions in Surgery: an Evidence-based Approach, 2018, , 441-457.	0.0	0
1419	Gastroenteropancreatic Neuroendocrine Tumors. Ca-A Cancer Journal for Clinicians, 2018, 68, 471-487.	157.7	378
1420	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Molecular Cancer Therapeutics, 2018, 17, 2702-2709.	1.9	30
1421	The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nationâ€wide cancer registryâ€based study from Taiwan. Cancer Medicine, 2018, 7, 5775-5788.	1.3	27
1422	Neuroendocrine tumors with hepatic metastases: A review of evolving treatment options. Liver Research, 2018, 2, 92-99.	0.5	6
1423	Bone marrow edema associated with everolimus. American Journal of Health-System Pharmacy, 2018, 75, e23-e27.	0.5	4
1424	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open, 2018, 8, e017240.	0.8	20
1425	Systemic Therapy for the Management of Neuroendocrine Tumor Liver Metastases. , 2018, , 267-277.		0
1426	Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration. Cell Communication and Signaling, 2018, 16, 64.	2.7	13
1427	New Insights into the Role of Exercise in Inhibiting mTOR Signaling in Triple-Negative Breast Cancer. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-19.	1.9	33
1428	Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Seminars in Oncology, 2018, 45, 249-258.	0.8	56
1430	Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Seminars in Oncology, 2018, 45, 232-235.	0.8	22
1431	Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. Cancer Treatment Reviews, 2018, 71, 39-46.	3.4	14
1432	Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas, 2018, 47, 1123-1129.	0.5	63

#	Article	IF	Citations
1433	Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 2018, 7, 947-958.	0.6	5
1434	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. International Journal of Cancer, 2018, 143, 3008-3018.	2.3	16
1435	Hypercalcemia in Glucagon Cell Hyperplasia and Neoplasia (Mahvash Syndrome): A New Association. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3119-3123.	1.8	27
1436	Liver Resection for Neuroendocrine Metastases and the Obligation to Individualize Care. Annals of Surgical Oncology, 2018, 25, 3787-3789.	0.7	1
1437	The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas. Annals of Diagnostic Pathology, 2018, 37, 30-34.	0.6	20
1438	Management of Liver Neuroendocrine Tumors in 2018. JAMA Oncology, 2018, 4, 1605.	3.4	13
1439	Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review. OncoTargets and Therapy, 2018, Volume 11, 1813-1819.	1.0	10
1440	Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocrine-Related Cancer, 2018, 25, R453-R466.	1.6	39
1441	An update on the management of pancreatic neuroendocrine tumors. Anti-Cancer Drugs, 2018, 29, 597-612.	0.7	8
1442	Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opinion on Pharmacotherapy, 2018, 19, 909-928.	0.9	53
1443	2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clinical and Translational Oncology, 2018, 20, 1361-1372.	1.2	35
1444	Results of treatment for thymic neuroendocrine tumours: multicentre clinicopathological studyâ€. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 18-24.	0.5	18
1445	Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology, 2018, 2018, 1-12.	0.6	49
1446	Cost-Effectiveness of Everolimus for the Treatment of Advanced Neuroendocrine Tumours of Gastrointestinal or Lung Origin in Canada. Current Oncology, 2018, 25, 32-40.	0.9	5
1447	Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition. Journal of the Endocrine Society, 2018, 2, 589-596.	0.1	9
1448	Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-18.	1.9	154
1449	mTOR and Tumor Cachexia. International Journal of Molecular Sciences, 2018, 19, 2225.	1.8	24
1450	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine, 2018, 62, 663-680.	1.1	9

#	Article	IF	Citations
1451	Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Medical Oncology, 2018, 35, 123.	1.2	10
1452	Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Frontiers in Physiology, 2018, 9, 335.	1.3	66
1453	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. Cancers, 2018, 10, 23.	1.7	108
1454	Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy. Cancer Chemotherapy and Pharmacology, 2018, 82, 661-668.	1.1	25
1455	Treatment options for PNET liver metastases: a systematic review. World Journal of Surgical Oncology, 2018, 16, 142.	0.8	44
1456	Everolimus. Recent Results in Cancer Research, 2018, 211, 101-123.	1.8	68
1457	Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells. Genes, 2018, 9, 337.	1.0	9
1458	Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Review of Anticancer Therapy, 2018, 18, 837-860.	1.1	63
1459	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. International Journal of Molecular Sciences, 2018, 19, 747.	1.8	42
1460	Targeting mTOR as a Therapeutic Approach in Medulloblastoma. International Journal of Molecular Sciences, 2018, 19, 1838.	1.8	13
1461	Reduced expression of the RNAâ€binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27^{Kip1} levels and poor prognosis. Journal of Pathology, 2018, 246, 231-243.	2.1	21
1462	Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clinical Diabetes and Endocrinology, 2018, 4, 16.	1.3	51
1463	The recent European approval of lutetium (¹⁷⁷Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors. International Journal of Endocrine Oncology, 2018, 5, IJE09.	0.4	8
1464	When and How to Use Somatostatin Analogues. Endocrinology and Metabolism Clinics of North America, 2018, 47, 549-555.	1.2	10
1465	New Treatments for the Carcinoid Syndrome. Endocrinology and Metabolism Clinics of North America, 2018, 47, 557-576.	1.2	8
1466	The IGF pathway is activated in insulinomas but downregulated in metastatic disease. Endocrine-Related Cancer, 2018, 25, 1005-1018.	1.6	5
1467	Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. Npj Genomic Medicine, 2018, 3, 18.	1.7	37
1468	In vitro Studies on Cytotoxic, DNA Protecting, Antibiofilm and Antibacterial Effects of Biogenic Silver Nanoparticles Prepared with Bergenia ciliata Rhizome Extract. Current Pharmaceutical Biotechnology, 2018, 19, 68-78.	0.9	17

#	Article	IF	Citations
1470	Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer, 2018, 18, 194.	1.1	18
1471	Pancreatic Neuroendocrine Tumors (pNETs). , 2018, , 129-157.		0
1472	Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?. Cancer Treatment Reviews, 2018, 67, 1-9.	3.4	30
1473	Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics. Theranostics, 2018, 8, 533-548.	4.6	188
1474	Neuroendokrine Tumoren des Pankreas. Evidenzbasierte Chirurgie, 2018, , 189-202.	0.0	0
1475	Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. British Journal of Radiology, 2018, 91, 20180108.	1.0	27
1476	The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 185-197.	3.3	40
1477	Expert opinion on the metabolic complications of mTOR inhibitors. Annales D'Endocrinologie, 2018, 79, 583-590.	0.6	8
1478	Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2018, 47, 525-548.	1.2	17
1479	The Genesis of the Neuroendocrine Tumors Concept. Endocrinology and Metabolism Clinics of North America, 2018, 47, 711-731.	1.2	17
1480	Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review. Hellenic Journal of Cardiology, 2018, 59, 196-200.	0.4	11
1481	An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease. Internal Medicine, 2018, 57, 2007-2011.	0.3	0
1482	The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocrine-Related Cancer, 2018, 25, 893-908.	1.6	24
1485	Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. PLoS ONE, 2018, 13, e0192464.	1.1	51
1486	E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist, 2018, 23, 1006-e104.	1.9	5
1487	Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. Journal of Endocrinological Investigation, 2019, 42, 249-260.	1.8	26
1488	Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. Oncologist, 2019, 24, 38-46.	1.9	23
1489	mTOR signalling: jack-of-all-trades. Biochemistry and Cell Biology, 2019, 97, 58-67.	0.9	19

#	Article	IF	Citations
1490	Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database. Journal of Gastrointestinal Cancer, 2019, 50, 816-823.	0.6	7
1491	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. International Review of Cell and Molecular Biology, 2019, 343, 219-297.	1.6	16
1492	Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 2019, 26, 1-12.	1.6	24
1493	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. Health Information and Libraries Journal, 2019, 36, 318-340.	1.3	3
1494	Everolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway. Journal of Investigative Medicine, 2019, 67, 39-47.	0.7	10
1495	Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 74.	1.3	17
1496	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Journal of Clinical Oncology, 2019, 37, 2571-2580.	0.8	49
1497	The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. Journal of Gastrointestinal Oncology, 2019, 10, 645-651.	0.6	15
1498	mTOR: Role in cancer, metastasis and drug resistance. Seminars in Cancer Biology, 2019, 59, 92-111.	4.3	299
1499	Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. International Journal of Endocrinology, 2019, 2019, 1-10.	0.6	4
1500	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced Î²-TrCP degradation. Oncogene, 2019, 38, 6270-6282.	2.6	53
1501	The Differences Between Pancreatic Neuroendocrine Tumors Grade 2 and Grade 3â€"Letter. Clinical Cancer Research, 2019, 25, 4580-4580.	3.2	1
1502	Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. Targeted Oncology, 2019, 14, 441-451.	1.7	11
1503	Invasive fungal infections in the immunocompromised host: Mechanistic insights in an era of changing immunotherapeutics. Medical Mycology, 2019, 57, S307-S317.	0.3	23
1504	Targeting mTOR for cancer therapy. Journal of Hematology and Oncology, 2019, 12, 71.	6.9	542
1505	Carcinoid Syndrome: Updates and Review of Current Therapy. Current Treatment Options in Oncology, 2019, 20, 70.	1.3	16
1506	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 72.	1.3	7
1507	Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma. Anticancer Research, 2019, 39, 3937-3944.	0.5	0

#	Article	IF	Citations
1508	¹⁷⁷Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1023-1031.	1.4	60
1509	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. Pancreatology, 2019, 19, 1067-1073.	0.5	15
1510	Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. International Journal of Molecular Sciences, 2019, 20, 4949.	1.8	15
1511	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. Frontiers in Oncology, 2019, 9, 902.	1.3	8
1512	Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes . Cancer Management and Research, 2019, Volume 11, 7537-7556.	0.9	3
1514	Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. European Journal of Cancer, 2019, 123, 92-100.	1.3	3
1516	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Current Oncology, 2019, 26, 665-681.	0.9	2
1517	A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences, 2019, 20, 5658.	1.8	5
1518	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	1.4	24
1519	Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. Scandinavian Journal of Gastroenterology, 2019, 54, 1111-1117.	0.6	1
1520	Treatment strategies for neuroendocrine liver metastases: an update. Expert Opinion on Orphan Drugs, 2019, 7, 327-335.	0.5	4
1521	EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Cancer Genomics and Proteomics, 2019, 16, 309-318.	1.0	4
1522	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). British Journal of Cancer, 2019, 121, 537-544.	2.9	18
1523	Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. Annals of Pancreatic Cancer, 2019, 2, 12-12.	1.2	14
1524	Therapy of Patients with Neuroendocrine Neoplasiaâ€"Evidence-Based Approaches and New Horizons. Journal of Clinical Medicine, 2019, 8, 1474.	1.0	8
1525	A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE, 2019, 14, e0221994.	1.1	23
1526	Deep Learning and Convolutional Neural Networks for Medical Imaging and Clinical Informatics. Advances in Computer Vision and Pattern Recognition, 2019, , .	0.9	51
1527	Pancreas and Biliary Tract Cytohistology. Essentials in Cytopathology Series, 2019, , .	0.1	1

#	Article	IF	Citations
1528	Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome. Journal of Clinical Medicine, 2019, 8, 1479.	1.0	9
1529	Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). Neuroendocrinology, 2019, 108, 317-327.	1.2	16
1530	An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocrine Pathology, 2019, 30, 118-127.	5.2	43
1531	Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncology, 2019, 15, 1219-1230.	1.1	17
1532	The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncology and Therapy, 2019, 7, 1-32.	1.0	19
1533	Clinical remission of an inoperable malignant insulinoma by the combination treatment with octreotide and everolimus. Journal of General and Family Medicine, 2019, 20, 107-110.	0.3	4
1534	Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surgical Clinics of North America, 2019, 99, 793-814.	0.5	69
1535	Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers, 2019, 11, 828.	1.7	55
1536	Zebrafish model of KRAS-initiated pancreatic endocrine tumor. Animal Cells and Systems, 2019, 23, 209-218.	0.8	8
1537	Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS ONE, 2019, 14, e0218953.	1.1	10
1538	Revisiting mTOR inhibitors as anticancer agents. Drug Discovery Today, 2019, 24, 2086-2095.	3.2	18
1539	Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor. Journal of Physical Education and Sports Management, 2019, 5, a003814.	0.5	17
1540	Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. , 2019, , 43-64.		0
1541	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Medicine, 2019, 45, 988-997.	3.9	18
1542	Treatments for patients with advanced neuroendocrine tumors: a network meta-analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985367.	1.4	7
1543	A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types. International Journal of Clinical Oncology, 2019, 24, 1320-1327.	1.0	1
1544	Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 2019, 109, 333-345.	1.2	52
1545	Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer. International Journal of Biological Sciences, 2019, 15, 929-941.	2.6	21

#	Article	IF	Citations
1546	Nuclear Medicine Therapy. , 2019, , .		5
1547	Surgery for Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases. Digestive Disease Interventions, 2019, 03, 030-037.	0.3	0
1548	mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro. Cells, 2019, 8, 431.	1.8	19
1549	Corticotropin secreting pancreatic neuroendocrine tumour, a therapeutic management challenge. A presentation of 2 cases. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2019, 66, 204-206.	0.1	0
1551	Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors. Endocrine, 2019, 65, 460-467.	1.1	7
1552	A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib. International Cancer Conference Journal, 2019, 8, 24-28.	0.2	1
1553	Does a workload influence the performance of bank employees?. Management Science Letters, 2019, , 639-650.	0.8	9
1554	Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review. Oncology, 2019, 96, 273-289.	0.9	13
1555	Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 73, 124.	0.2	2
1556	Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study . OncoTargets and Therapy, 2019, Volume 12, 1717-1728.	1.0	13
1557	In Silico Drug Design Methods for Drug Repurposing. , 2019, , 47-84.		10
1558	Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1336-1344.	1.8	95
1559	In Silico Modeling of FDA-Approved Drugs for Discovery of Anti-Cancer Agents: A Drug-Repurposing Approach. , 2019, , 577-608.		6
1560	Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881982821.	1.4	8
1561	Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. Clinical Cancer Research, 2019, 25, 3486-3494.	3.2	56
1562	Neuroendocrine Tumours. , 2019, , 1229-1257.		0
1563	Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 403.	1.0	23
1564	Oncogene Panel Sequencing Analysis Identifies Candidate Actionable Genes in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Endocrine Practice, 2019, 25, 580-588.	1.1	9

#	Article	IF	Citations
1565	Multiple Endocrine Neoplasia. , 2019, , 1259-1278.		1
1566	Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report. Journal of Medical Case Reports, 2019, 13, 82.	0.4	8
1567	Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes. Endocrine Journal, 2019, 66, 571-574.	0.7	10
1568	Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis, 2019, 8, 16.	2.1	27
1569	Systemic treatment of pancreatic neuroendocrine tumors. Surgical Practice, 2019, 23, 48-58.	0.1	0
1570	Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances. Journal of Nuclear Medicine, 2019, 60, 721-727.	2.8	15
1571	Systemic Therapy for Neuroendocrine Neoplasms. Digestive Disease Interventions, 2019, 03, 063-070.	0.3	0
1573	Therapeutic Options for Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 480.	3.4	67
1575	Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. Oncologist, 2019, 24, 47-53.	1.9	4
1576	Metaâ€Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist, 2019, 24, e1315-e1320.	1.9	8
1577	Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist, 2019, 24, 463-474.	1.9	11
1578	Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors. Journal of Clinical Medicine, 2019, 8, 1980.	1.0	23
1579	Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas. Surgical Pathology Clinics, 2019, 12, 1021-1044.	0.7	20
1580	7. Maligne Erkrankungen Des Gastrointestinaltrakts. , 2019, , 145-192.		0
1581	Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Review of Anticancer Therapy, 2019, 19, 1029-1050.	1.1	53
1582	Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials. Oncology Reviews, 2019, 13, 455.	0.8	12
1584	Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients . OncoTargets and Therapy, 2019, Volume 12, 9669-9683.	1.0	7
1585	Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 87.	1.3	2

#	Article	IF	Citations
1586	Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives. Therapeutic Drug Monitoring, 2019, 41, 568-574.	1.0	13
1587	177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors. Nuclear Medicine Communications, 2019, 40, 1195-1203.	0.5	28
1588	Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors. Pancreas, 2019, 48, 510-513.	0.5	9
1589	Parallel Signaling through IRE1Î± and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Research, 2019, 79, 6190-6203.	0.4	25
1590	Pancreatic neuroendocrine tumors. Current Opinion in Gastroenterology, 2019, 35, 468-477.	1.0	29
1591	Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. Journal of Pancreatology, 2019, 2, 91-99.	0.3	4
1592	A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas, 2019, 48, 381-386.	0.5	8
1593	Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. Cells, 2019, 8, 1584.	1.8	149
1594	Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. Neuroendocrinology, 2019, 108, 18-25.	1.2	9
1595	Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. Neuro-Oncology, 2019, 21, 252-263.	0.6	21
1596	Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. Abdominal Radiology, 2019, 44, 576-585.	1.0	49
1597	The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist, 2019, 24, 54-61.	1.9	6
1598	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs, 2019, 79, 21-42.	4.9	54
1599	Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. Investigational New Drugs, 2019, 37, 763-770.	1.2	10
1601	Genomic Applications in Pancreatic and Gastric Tumors. , 2019, , 401-418.		0
1602	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 2019, 68, 742-758.	6.1	68
1603	Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. Investigational New Drugs, 2019, 37, 331-337.	1.2	18
1604	Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 319-329.	2.0	11

#	Article	IF	Citations
1605	Management of NETs in the Precision Medicine Era. , 2019, , 575-589.		0
1606	Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study. Cancer Chemotherapy and Pharmacology, 2019, 83, 201-207.	1.1	7
1607	The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Review of Clinical Pharmacology, 2019, 12, 101-108.	1.3	12
1608	The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors. Pancreas, 2019, 48, 9-21.	0.5	17
1610	Accuracy of grading pancreatic neuroendocrine neoplasms with Kiâ€67 index in fineâ€needle aspiration cellblock material. Cytopathology, 2019, 30, 187-193.	0.4	16
1611	Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemotherapy and Pharmacology, 2019, 83, 43-52.	1.1	12
1612	Liver Cancers. , 2019, , .		2
1613	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clinical and Translational Oncology, 2019, 21, 55-63.	1.2	17
1614	ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67. Annals of Surgical Oncology, 2019, 26, 531-532.	0.7	10
1615	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). International Journal of Cancer, 2019, 144, 1704-1712.	2.3	20
1616	Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 57-73.	1.8	38
1617	Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1104, 234-239.	1.2	33
1618	Recent advances in the diagnosis and management of pancreatic neuroendocrine tumours. Frontline Gastroenterology, 2019, 10, 269-274.	0.9	8
1619	Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 704-717.	3.3	90
1620	Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. Pathology and Oncology Research, 2019, 25, 149-156.	0.9	4
1621	Recurrence of Metastatic Pro-insulinoma Nearly 50ÂYears After Subtotal Pancreatectomy. Journal of Gastrointestinal Cancer, 2019, 50, 345-348.	0.6	1
1622	Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours. European Journal of Surgical Oncology, 2019, 45, 52-59.	0.5	18
1623	An Inter-disciplinary Approach to Evaluate Human Health Risks Due to Long-Term Exposure to Contaminated Groundwater Near a Chemical Complex. Exposure and Health, 2020, 12, 199-214.	2.8	42

#	Article	IF	Citations
1624	Two well-differentiated pancreatic neuroendocrine tumor mouse models. Cell Death and Differentiation, 2020, 27, 269-283.	5.0	40
1625	Ancillary Techniques in Cytologic Specimens Obtained from Solid Lesions of the Pancreas: A Review. Acta Cytologica, 2020, 64, 103-123.	0.7	5
1626	Intracellular Signaling. , 2020, , 24-46.e12.		0
1627	Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Annals of Surgery, 2020, 271, 566-573.	2.1	64
1628	Spatio-Temporal Convolutional LSTMs for Tumor Growth Prediction by Learning 4D Longitudinal Patient Data. IEEE Transactions on Medical Imaging, 2020, 39, 1114-1126.	5.4	39
1629	Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocrine Reviews, 2020, 41, 371-403.	8.9	116
1630	Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of Neuroendocrine Tumor Liver Metastasis to Transcatheter Arterial Bland Embolization. Neuroendocrinology, 2020, 110, 697-704.	1.2	7
1631	ALPPS in neuroendocrine liver metastases not amenable for conventional resection â€“ lessons learned from an interim analysis of the International ALPPS Registry. Hpb, 2020, 22, 537-544.	0.1	43
1632	The functioning side of the pancreas: a review on insulinomas. Journal of Endocrinological Investigation, 2020, 43, 139-148.	1.8	32
1633	Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelialâ€mesenchymal transition in Pancâ€1 and MiaPaCaâ€2 pancreatic cancer cells. Journal of Cellular Biochemistry, 2020, 121, 508-523.	1.2	16
1634	A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 377-383.	1.2	15
1635	Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 907-921.	3.3	21
1636	Tumor angiogenesis: causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences, 2020, 77, 1745-1770.	2.4	927
1637	Conversion surgery after extensive chemotherapy for stage IV mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: clinical implications from the patterns of response and recurrence. Clinical Journal of Gastroenterology, 2020, 13, 240-246.	0.4	7
1638	Cancer of the Endocrine System. , 2020, , 1074-1107.e11.		5
1639	Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site. Neuroendocrinology, 2020, 110, 563-573.	1.2	20
1640	Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis. Anticancer Research, 2020, 40, 121-132.	0.5	13
1641	Advances in the Diagnosis and Management of Nonfunctional Pancreatic Neuroendocrine Tumors. , 2020, , 221-232.		0

#	Article	IF	Citations
1642	Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?. Journal of the National Cancer Institute, 2020, 112, 773-778.	3.0	6
1643	The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, 1-33.	0.5	226
1644	Impact of initial imaging with galliumâ€68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. Journal of Surgical Oncology, 2020, 121, 480-485.	0.8	40
1645	Multiple endocrine neoplasia type 1. , 2020, , 1293-1306.		5
1646	Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. Journal of Cancer Research and Clinical Oncology, 2020, 146, 793-799.	1.2	9
1647	Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology, 2020, 145, 102835.	2.0	35
1648	New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy, 2020, 21, 183-191.	0.9	9
1649	Renal Neuroendocrine Neoplasms: A Single-center Experience. Clinical Genitourinary Cancer, 2020, 18, e343-e349.	0.9	14
1650	Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?. Human Pathology, 2020, 96, 8-33.	1.1	114
1651	Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends in Endocrinology and Metabolism, 2020, 31, 239-255.	3.1	8
1652	Advances in the Diagnosis and Management of Insulinoma. , 2020, , 199-206.		0
1653	Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. Diagnostics, 2020, 10, 732.	1.3	7
1654	Research progress of mTOR inhibitors. European Journal of Medicinal Chemistry, 2020, 208, 112820.	2.6	116
1655	Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Translational Oncology, 2020, 13, 100847.	1.7	20
1656	New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdominal Radiology, 2022, 47, 3078-3100.	1.0	18
1657	Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinicianâ€™s Guide to a Complex Illness. JCO Oncology Practice, 2020, 16, 720-728.	1.4	9
1658	Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2020, 21, 96.	1.3	2
1659	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Expert Opinion on Pharmacotherapy, 2020, 21, 2317-2324.	0.9	0

#	Article	IF	Citations
1660	Surgical treatment of non-functioning pancreatic neuroendocrine tumors: current controversies and challenges. Journal of Pancreatology, 2020, 3, 51-58.	0.3	1
1661	Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51. Biochemistry and Biophysics Reports, 2020, 23, 100778.	0.7	5
1662	Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. Journal of Gastrointestinal Oncology, 2020, 11, 601-608.	0.6	17
1663	Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. Journal of Gastrointestinal Oncology, 2020, 11, 567-577.	0.6	14
1664	An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts. Archives of Medical Research, 2020, 51, 765-776.	1.5	9
1665	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, 863-881.	0.5	88
1666	A Ki-67 Index to Predict Treatment Response to the Capecitabine Temozolomide (CAPTEM) Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study. Neuroendocrinology, 2020, 111, 752-763.	1.2	16
1667	Sequence of Therapy and Survival in Patients with Advanced Pancreatic Neuroendocrine Tumours. Current Oncology, 2020, 27, 215-219.	0.9	0
1668	Elevated Serum Amino Acids Induce a Subpopulation of Alpha Cells to Initiate Pancreatic Neuroendocrine Tumor Formation. Cell Reports Medicine, 2020, 1, 100058.	3.3	9
1669	Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Journal of Clinical Medicine, 2020, 9, 3655.	1.0	23
1670	Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomideâ€induced high tumor mutational burden. Cancer Communications, 2020, 40, 746-751.	3.7	16
1671	Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus. Antioxidants, 2020, 9, 1104.	2.2	2
1672	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers, 2020, 12, 1988.	1.7	12
1673	Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surgery and Nutrition, 2020, 9, 440-451.	0.7	37
1674	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. Frontiers in Immunology, 2020, 11, 1423.	2.2	5
1675	Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions. Cancers, 2020, 12, 2005.	1.7	18
1676	Image-Guided Interventions in Oncology. , 2020, , .		1
1678	Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature . Lung Cancer: Targets and Therapy, 2020, Volume 11, 41-52.	1.3	4

#	Article	IF	Citations
1679	Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. Cancers, 2020, 12, 2143.	1.7	13
1680	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. Journal of Clinical Medicine, 2020, 9, 2468.	1.0	11
1681	Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology, 2020, 20, 1183-1188.	0.5	6
1683	Interplay Between Diabetes and Pancreatic Ductal Adenocarcinoma and Insulinoma: The Role of Aging, Genetic Factors, and Obesity. Frontiers in Endocrinology, 2020, 11, 563267.	1.5	10
1684	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Translational Lung Cancer Research, 2020, 9, 1258-1267.	1.3	47
1686	An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm. Medicine (United States), 2020, 99, e21682.	0.4	1
1687	Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients. Neuroendocrinology, 2020, 111, 863-875.	1.2	3
1688	Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 1489-1499.	5.1	94
1689	Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer. Cancers, 2020, 12, 2586.	1.7	9
1690	Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs. Acta Radiologica, 2021, 62, 1006-1015.	0.5	3
1691	How I treat neuroendocrine tumours. ESMO Open, 2020, 5, e000811.	2.0	14
1692	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092727.	1.4	8
1693	High Molecular Weight ACTH-Precursor Presence in a Metastatic Pancreatic Neuroendocrine Tumor Causing Severe Ectopic Cushing's Syndrome: A Case Report. Frontiers in Endocrinology, 2020, 11, 557.	1.5	1
1694	Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 647-663.	2.6	3
1695	mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Frontiers in Endocrinology, 2020, 11, 562505.	1.5	25
1696	Successful Long-Term Medical Management of Unresectable Insulinomas. Case Reports in Oncology, 2020, 13, 948-954.	0.3	2
1698	Metformin and everolimus in neuroendocrine tumours: A synergic effect?. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 954-960.	0.7	5
1699	Small Bowel Neuroendocrine Tumors. Current Problems in Surgery, 2020, 57, 100823.	0.6	12

#	Article	IF	Citations
1700	Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years. Pancreatology, 2020, 20, 709-715.	0.5	10
1701	Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights . OncoTargets and Therapy, 2020, Volume 13, 3545-3555.	1.0	27
1702	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Letters, 2020, 485, 1-13.	3.2	10
1703	Sorafenib and everolimus in patients with advanced solid tumors and KRASâ€mutated NSCLC: A phase I trial with early pharmacodynamic FDGâ€PET assessment. Cancer Medicine, 2020, 9, 4991-5007.	1.3	14
1704	A Neuroendocrine Tumor Specialty Center in New Orleansâ€™ (NOLANETS) Response to Patient Care During the COVID â€19 Pandemic. Oncologist, 2020, 25, 548-551.	1.9	4
1705	The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas. Oncologist, 2020, 25, e1318-e1329.	1.9	19
1706	mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus. Cancers, 2020, 12, 1201.	1.7	6
1707	Opportunistic and Serious Infections in Patients with Neuroendocrine Tumors Treated with Everolimus: A Multicenter Study of Real-World Patients. Neuroendocrinology, 2021, 111, 631-638.	1.2	6
1708	The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor. Frontiers in Oncology, 2020, 10, 546.	1.3	2
1709	UHPLCâ€“MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study. Bioanalysis, 2020, 12, 367-378.	0.6	1
1710	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research, 2020, 26, 4454-4459.	3.2	110
1711	p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis. International Journal of Molecular Sciences, 2020, 21, 4098.	1.8	18
1712	Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer, 2020, 126, 3689-3697.	2.0	11
1713	Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology, 2020, 20, 944-950.	0.5	14
1714	Prognosis of Resected Neuroendocrine Metastases: A Complex Puzzle Can Only be Solved One Small Piece at a Time. Annals of Surgical Oncology, 2020, 27, 3579-3580.	0.7	1
1715	Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. Journal of Clinical Medicine, 2020, 9, 1677.	1.0	23
1716	Should everolimus be stopped after radiological progression in metastatic insulinoma? A â€œconsâ€•point of view. Endocrine, 2020, 69, 481-484.	1.1	5
1717	Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors. Clinical Pharmacology in Drug Development, 2020, 9, 876-888.	0.8	7

#	Article	IF	Citations
1718	Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2020, 9, 1860.	1.0	10
1719	Targeted Î±-Emitter Therapy of Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2020, 50, 171-176.	2.5	30
1720	Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review. Neuroendocrinology, 2021, 111, 354-369.	1.2	17
1721	Scientometric analysis of mTOR signaling pathway in liver disease. Annals of Translational Medicine, 2020, 8, 93-93.	0.7	18
1722	Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. Biology, 2020, 9, 51.	1.3	2
1723	Pancreatic Neuroendocrine Tumors. , 2020, , 1-19.		0
1724	Manifestations of Glucagonoma Syndrome. AACE Clinical Case Reports, 2020, 6, e46-e49.	0.4	2
1725	Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide. Pancreas, 2020, 49, e19-e20.	0.5	5
1726	Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine. Frontiers in Oncology, 2020, 10, 174.	1.3	5
1727	Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature Reviews Clinical Oncology, 2020, 17, 360-371.	12.5	263
1728	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. Cancer Research, 2020, 80, 2190-2203.	0.4	4
1729	Advances in the Diagnosis and Management of Gastrinoma. , 2020, , 207-219.		0
1730	Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center. Oncologist, 2020, 25, e644-e650.	1.9	9
1731	Surgical Management of Pancreatic Neuroendocrine Tumors. Surgical Oncology Clinics of North America, 2020, 29, 243-252.	0.6	16
1732	Management of Other Gastric and Duodenal Neuroendocrine Tumors. Surgical Oncology Clinics of North America, 2020, 29, 253-266.	0.6	5
1733	4. Supportivtherapie. , 2020, , 127-216.		0
1734	Surgical management of pancreatic neuroendocrine liver metastases. Journal of Gastrointestinal Oncology, 2020, 11, 590-600.	0.6	19
1735	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Translational Cancer Research, 2020, 9, 3222-3230.	0.4	3

#	Article	IF	Citations
1736	Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surgical Oncology Clinics of North America, 2020, 29, 293-316.	0.6	5
1737	North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas, 2020, 49, 723-728.	0.5	6
1738	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. Neuroendocrinology, 2021, 111, 217-236.	1.2	17
1739	MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells. Neuroendocrinology, 2021, 111, 739-751.	1.2	7
1740	Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors. Cancer Gene Therapy, 2020, 27, 898-909.	2.2	2
1741	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸F) positronâ€emission tomography positive intermediate grade pancreatic neuroendocrine tumors. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 150-157.	0.7	2
1742	Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of ¹⁷⁷Lu-DOTATATE PRRT. Acta OncolÃ³gica, 2020, 59, 644-651.	0.8	7
1743	Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clinical Cancer Research, 2020, 26, 2337-2345.	3.2	66
1744	¹⁷⁷Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. Neuroendocrinology, 2021, 111, 330-343.	1.2	31
1746	Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms. Pancreas, 2020, 49, 255-260.	0.5	11
1747	Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms. Hormone and Metabolic Research, 2020, 52, 614-620.	0.7	7
1748	A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial). Neuroendocrinology, 2020, 110, 988-993.	1.2	18
1749	RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma. Acta Pharmaceutica Sinica B, 2020, 10, 1004-1019.	5.7	19
1750	miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor. American Journal of Pathology, 2020, 190, 689-701.	1.9	14
1751	Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 922-933.	3.3	31
1752	Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. Scandinavian Journal of Surgery, 2020, 109, 42-52.	1.3	23
1753	Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2020, 26, 2011-2021.	3.2	40
1754	PIK3CA gene aberrancy and role in targeted therapy of solid malignancies. Cancer Gene Therapy, 2020, 27, 634-644.	2.2	22

#	Article	IF	Citations
1755	Pharmacological cancer treatment and venous thromboembolism risk. European Heart Journal Supplements, 2020, 22, C2-C14.	0.0	11
1756	Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 844-860.	0.6	571
1758	Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD,) Tj ETQq0 0 0 rgBT /Overlock	0.4	38
1759	Pancreatic Neuroendocrine Neoplasms: Landscape and Horizon. Archives of Pathology and Laboratory Medicine, 2020, 144, 816-828.	1.2	11
1760	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 2825.	1.8	11
1761	Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188367.	3.3	14
1762	Pembrolizumab for the treatment of programmed deathâ€“ligand 1â€'positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTEâ€028 study. Cancer, 2020, 126, 3021-3030.	2.0	97
1763	The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 1788-1792.	0.7	15
1764	Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Scientific Reports, 2020, 10, 6367.	1.6	45
1765	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer, 2020, 20, 326.	1.1	38
1766	Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014. BMC Endocrine Disorders, 2020, 20, 44.	0.9	14
1767	The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. Cancer, 2020, 126, 2561-2565.	2.0	2
1768	Examining Perioperative Risk Associated with Simultaneous Resection of Primary Neuroendocrine Tumors and Synchronous Hepatic Metastases. World Journal of Surgery, 2021, 45, 531-542.	0.8	5
1769	[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. Journal of Endocrinological Investigation, 2021, 44, 811-818.	1.8	2
1770	Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer. Annals of Surgical Oncology, 2021, 28, 685-694.	0.7	9
1771	Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex. International Journal of Clinical Oncology, 2021, 26, 163-168.	1.0	8
1772	Update on gastroenteropancreatic neuroendocrine tumors. Digestive and Liver Disease, 2021, 53, 171-182.	0.4	45
1773	Targeting translation regulators improves cancer therapy. Genomics, 2021, 113, 1247-1256.	1.3	12

#	Article	IF	Citations
1774	Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. Oncologist, 2021, 26, 115-119.	1.9	15
1775	Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies. Cancer, 2021, 127, 345-353.	2.0	14
1776	Eficacia y seguridad de la radioembolizaciÃ³n con 90Y en el tratamiento de metÃ¡stasis hepÃ¡ticas de tumores neuroendocrinos. Seguimiento a largo plazo y repercusiÃ³n en la supervivencia. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 82-90.	0.0	2
1777	Radiopharmaceuticals for Neuroendocrine Tumors. Seminars in Radiation Oncology, 2021, 31, 60-70.	1.0	10
1778	Surgical Management of Neuroendocrine Tumor Liver Metastases. Surgical Oncology Clinics of North America, 2021, 30, 39-55.	0.6	20
1779	Comparison of long-term survival outcome after curative hepatectomy between selected patients with non-colorectal and colorectal liver metastasis: A propensity score matching analysis. Asian Journal of Surgery, 2021, 44, 459-464.	0.2	7
1780	Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response. Oncology Research and Treatment, 2021, 44, 276-280.	0.8	2
1781	Pancreatic Neuroendocrine Tumors. , 2021, , 938-948.e4.		0
1782	Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Frontiers in Endocrinology, 2020, 11, 575620.	1.5	8
1783	Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	1.4	21
1784	Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2022, 112, 34-42.	1.2	9
1785	Pancreatic Neuroendocrine Tumors. , 2021, , 1933-1951.		0
1786	Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. In Vivo, 2021, 35, 2425-2432.	0.6	6
1787	Intra-arterial Radiopeptide InfusionsÂwith High Activity of 111In-Octreotide: From â€œAretaieion Protocolâ€•to the Temporal Intra-arterial Port Installation. , 2021, , 85-105.		0
1788	Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxelâ€sensitive and docetaxelâ€resistant castrationâ€resistant prostate cancer cells. Journal of Cellular and Molecular Medicine, 2021, 25, 2436-2449.	1.6	17
1789	Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors. Cancer Control, 2021, 28, 107327482098682.	0.7	3
1790	Jejunoileal Neuroendocrine Tumors. , 2021, , 157-177.		0
1791	Carcinoid Heart Disease. , 2021, , 139-151.		0

#	Article	IF	Citations
1792	Treatment of Pancreatic Neuroendocrine Tumors. , 2021, , 191-199.		0
1793	Pharmacodynamic Drugâ€“Drug Interaction on Human Peripheral Blood Mononuclear Cells Between Everolimus and Tacrolimus at the Therapeutic Concentration Range in Renal Transplantation. Annals of Transplantation, 2021, 26, e928817.	0.5	0
1795	Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor. The Korean Journal of Pancreas and Biliary Tract, 2021, 26, 24-32.	0.0	0
1796	Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 169-191.	5.2	26
1797	A literature-based treatment algorithm for low-grade neuroendocrine liver metastases. Hpb, 2021, 23, 63-70.	0.1	0
1798	Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. Oncologist, 2021, 26, e632-e638.	1.9	9
1799	Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine. International Journal of Molecular Sciences, 2021, 22, 1631.	1.8	23
1801	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. Journal of Nuclear Medicine, 2021, 62, 1278-1284.	2.8	25
1802	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	1.3	12
1803	Microscopic Invasion of Nerve Is Associated With Aggressive Behaviors in Pancreatic Neuroendocrine Tumors. Frontiers in Oncology, 2021, 11, 630316.	1.3	4
1804	mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms. Frontiers in Oncology, 2020, 10, 578380.	1.3	3
1805	Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Modern Pathology, 2021, 34, 1062-1073.	2.9	17
1806	Markers of Systemic Inflammation in Neuroendocrine Tumors. Pancreas, 2021, 50, 130-137.	0.5	6
1807	The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 1086-1098.	1.2	5
1808	The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Journal of Pancreatology, 2021, 4, 1-17.	0.3	4
1809	Liver-Directed Therapies for Neuroendocrine Neoplasms. Current Oncology Reports, 2021, 23, 44.	1.8	8
1810	Eficacia de lutecio-177 DOTATATE/TOC en pacientes con tumores neuroendocrinos bien diferenciados en estado avanzado. Ensayo clÃnico fase II. Revista Colombiana De CancerologÃa, 2021, 25, .	0.0	2
1811	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research, 2021, 27, 3845-3853.	3.2	25

#	Article	IF	Citations
1812	Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma. Frontiers in Oncology, 2021, 11, 640314.	1.3	10
1814	Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study. Investigational New Drugs, 2021, 39, 1298-1305.	1.2	18
1815	Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. Gut, 2021, 70, 1768-1781.	6.1	28
1816	Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 82-90.	0.1	0
1817	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers, 2021, 13, 1052.	1.7	5
1818	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	1.3	120
1819	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 94, 102168.	3.4	6
1820	Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms. Annals of Gastroenterological Surgery, 2021, 5, 692-700.	1.2	5
1821	Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors. Frontiers in Endocrinology, 2021, 12, 676973.	1.5	1
1822	Tribbles Pseudokinase 3 Regulation and Contribution to Cancer. Cancers, 2021, 13, 1822.	1.7	19
1823	Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Internal Medicine, 2021, 60, 977-983.	0.3	3
1825	Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Seminars in Cancer Biology, 2022, 79, 141-162.	4.3	18
1826	Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers, 2021, 13, 1936.	1.7	18
1827	Targeted Cancer Therapy: Whatâ€™s New in the Field of Neuroendocrine Neoplasms?. Cancers, 2021, 13, 1701.	1.7	19
1828	Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Research and Treatment, 2021, 53, 291-300.	1.3	8
1829	An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Scientific Reports, 2021, 11, 7881.	1.6	23
1830	Treating neuroendocrine neoplasms in the setting of HIV infection. Translational Science of Rare Diseases, 2021, 5, 143-159.	1.6	1
1831	Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. Endocrine-Related Cancer, 2021, 28, 237-246.	1.6	2

#	Article	IF	Citations
1832	Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20ÂYears (2000â€“2019): A Bibliometric Study. Frontiers in Pharmacology, 2021, 12, 624534.	1.6	24
1833	Chemotherapy in NEN: still has a role?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 595-614.	2.6	13
1834	Liver metastases. Nature Reviews Disease Primers, 2021, 7, 27.	18.1	190
1835	Cytotoxicity, Anti-diabetic, and hepato-protective potential of Ajuga bracteosa-conjugated silver nanoparticles in Balb/c mice. Current Pharmaceutical Biotechnology, 2021, 22, .	0.9	4
1836	Better Management for Neuroendocrine Neoplasms: A Complex Task Ahead. Journal of Clinical Medicine, 2021, 10, 1859.	1.0	0
1837	Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. Cancers, 2021, 13, 1873.	1.7	17
1838	Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors. Anticancer Research, 2021, 41, 2071-2078.	0.5	6
1839	Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers. Frontiers in Pharmacology, 2021, 12, 631135.	1.6	2
1840	Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Cancers, 2021, 13, 2159.	1.7	4
1841	Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANTâ€3 and RADIANTâ€4 trials. Cancer, 2021, 127, 2674-2682.	2.0	4
1842	Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?. Current Oncology Reports, 2021, 23, 80.	1.8	1
1843	Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas, 2021, 50, 719-726.	0.5	5
1844	Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance. Cancers, 2021, 13, 2634.	1.7	9
1845	The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance. Current Cancer Drug Targets, 2021, 21, 326-352.	0.8	23
1846	Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Japanese Journal of Clinical Oncology, 2021, 51, 1185-1196.	0.6	8
1847	Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers, 2021, 13, 2448.	1.7	13
1848	State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Current Opinion in Oncology, 2021, 33, 378-385.	1.1	3
1849	Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer, 2021, 21, 597.	1.1	6

#	Article	IF	Citations
1850	PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors. Cells, 2021, 10, 1261.	1.8	13
1851	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2021, 14, 476.	1.7	16
1852	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta OncolÃ³gica, 2021, 60, 931-941.	0.8	32
1853	Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. Investigational New Drugs, 2021, 39, 1707-1715.	1.2	4
1854	Pancreatic neuroendocrine carcinoma in a pregnant woman: A case report and review of the literature. World Journal of Clinical Cases, 2021, 9, 4327-4335.	0.3	0
1855	Functioning and nonfunctioning pNENs. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 284-290.	0.6	3
1856	Personalized Management of Pheochromocytoma and Paraganglioma. Endocrine Reviews, 2022, 43, 199-239.	8.9	127
1857	The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Frontiers in Endocrinology, 2021, 12, 654975.	1.5	16
1858	Metastatic well-differentiated pancreatic neuroendocrine tumors to the liver: a narrative review of systemic and surgical management. Journal of Pancreatology, 2021, 4, 82-89.	0.3	2
1859	RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo. Biomedicines, 2021, 9, 633.	1.4	4
1860	Medical treatment of neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 139-144.	0.6	0
1861	A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia. Current Problems in Cancer, 2022, 46, 100776.	1.0	7
1862	Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality. Journal of Clinical Medicine, 2021, 10, 3023.	1.0	9
1863	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). Journal of Clinical Oncology, 2021, 39, 2304-2312.	0.8	49
1864	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Molecular Cancer Therapeutics, 2021, 20, 1836-1845.	1.9	14
1865	Updated Trends inÂImaging Practices for Pancreatic Neuroendocrine Tumors (PNETs): A Systematic Review and Meta-Analysis to Pave the Way for Standardization in the New Era of Big Data and Artificial Intelligence. Frontiers in Oncology, 2021, 11, 628408.	1.3	4
1866	Neuroendocrine Carcinomas of the Digestive Tract: What Is New?. Cancers, 2021, 13, 3766.	1.7	10
1867	Alpelisib in combination with everolimusÂÂ±Âexemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European Journal of Cancer, 2021, 151, 49-62.	1.3	19

#	Article	IF	Citations
1868	The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials. Journal of Neuroendocrinology, 2021, 33, e13015.	1.2	0
1869	Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours. Neuroendocrinology, 2022, 112, 595-605.	1.2	3
1870	Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 54-63.	3.3	35
1871	Neuroendocrine neoplasms: Evolving and future treatments. Current Opinion in Endocrine and Metabolic Research, 2021, 19, 15-21.	0.6	4
1872	Liver transplantation in malignant disease. World Journal of Clinical Oncology, 2021, 12, 623-645.	0.9	7
1873	Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. Journal of Experimental and Clinical Cancer Research, 2021, 40, 262.	3.5	2
1874	High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer. Cancer Letters, 2021, 514, 79-89.	3.2	14
1875	Longâ€term effect of everolimus in recurrent thymic neuroendocrine neoplasia. Clinical Endocrinology, 2021, 95, 744-751.	1.2	5
1876	Carcinoid syndrome and neuroendocrine tumours. Medicine, 2021, 49, 544-547.	0.2	1
1877	Intrahepatic Cholangiocarcinoma Coexisting With Multiple Bile Duct Adenoma Treated as Liver Metastasis from a Pancreatic Neuroendocrine Tumor. Anticancer Research, 2021, 41, 5249-5254.	0.5	1
1878	Mutation and Expression of Gene YY1 in Pancreatic Neuroendocrine Tumors and Its Clinical Significance. Endocrine Practice, 2021, 27, 874-880.	1.1	2
1879	Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Annals of Nuclear Medicine, 2021, 35, 1332-1341.	1.2	8
1880	Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101572.	0.7	2
1881	Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms. Endocrine-Related Cancer, 2021, 28, 631-644.	1.6	8
1882	Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Scientific Reports, 2021, 11, 19490.	1.6	2
1883	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World Journal of Gastroenterology, 2021, 27, 5890-5907.	1.4	26
1884	Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine, 2022, 75, 293-302.	1.1	8
1885	Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835.	2.7	41

#	Article	IF	Citations
1886	JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. Journal of Gastroenterology, 2021, 56, 1033-1044.	2.3	58
1887	Inappropriate censoring in Kaplan-Meier analyses. Lancet Oncology, The, 2021, 22, 1358-1360.	5.1	8
1888	Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. European Journal of Cancer, 2021, 157, 403-414.	1.3	33
1889	Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. Endocrines, 2021, 2, 28-36.	0.4	2
1890	Apoptosis modulating nanochemotherapeutics in the treatment of cancer: Recent progress and advances. , 2021, , 153-207.		1
1891	Tumeurs neuroendocrines pancrÃ©atiques. , 2021, , 191-218.e2.		0
1894	Treatment of NETs from Rare Origin. , 2021, , 211-229.		0
1895	Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. Cancers, 2021, 13, 358.	1.7	11
1896	The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Annals of Surgical Oncology, 2021, 28, 2741-2751.	0.7	16
1897	Sporadischer organischer Hyperinsulinismus (Insulinom). Springer Reference Medizin, 2021, , 1-11.	0.0	0
1899	Streptozocin-Based Chemotherapy: Still a Standard of Care for Neuroendocrine Tumours?. , 2014, , 65-75.		1
1900	Management of Neuroendocrine Tumors. , 2016, , 13-18.		1
1901	Title is missing!. , 2017, , .		10
1902	Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. Current Cancer Research, 2017, , 313-345.	0.2	1
1903	Sunitinib in the Treatment of Advanced Solid Tumors. Recent Results in Cancer Research, 2014, 201, 165-184.	1.8	31
1904	Pancreatic Neuroendocrine Tumors. , 2014, , 1-29.		1
1905	Multiple Endocrine Neoplasia. , 2016, , 1723-1761.e3.		2
1906	Multiple Endocrine Neoplasia. , 2011, , 1728-1767.		6

#	Article	IF	Citations
1907	Cancer of the Endocrine System. , 2014, , 1112-1142.e7.		2
1908	Diseases of the Pleura and Mediastinum. , 2014, , 1193-1206.e4.		1
1909	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clinical Colorectal Cancer, 2020, 19, 156-164.	1.0	16
1910	Mechanisms of resistance to mTOR inhibitors. Critical Reviews in Oncology/Hematology, 2020, 147, 102886.	2.0	27
1911	The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Pagetâ€™s disease. Cell Research, 2020, 30, 854-872.	5.7	17
1912	Introduction: Biomarkers in Translational and Personalized Medicine. RSC Drug Discovery Series, 2013, , 3-39.	0.2	1
1913	Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors. Seminars in Interventional Radiology, 2017, 34, 101-108.	0.3	4
1915	Convolutional Invasion and Expansion Networks for Tumor Growth Prediction. IEEE Transactions on Medical Imaging, 2018, 37, 638-648.	5.4	64
1916	Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis. BMJ Case Reports, 2016, 2016, bcr2015214206.	0.2	3
1917	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clinical Cancer Research, 2020, 26, 2124-2130.	3.2	132
1918	Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases. Case Reports in Oncology, 2016, 9, 76-82.	0.3	7
1919	RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. Journal of Clinical Investigation, 2019, 129, 1641-1653.	3.9	25
1920	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2013, 123, 2551-2563.	3.9	108
1921	Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. Tumori, 2014, 100, e2-e3.	0.6	7
1922	Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats. EJNMMI Research, 2020, 10, 41.	1.1	6
1923	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e395-e401.	1.8	67
1924	Marital Status and Survival of Patients with Chondrosarcoma: A Population-Based Analysis. Medical Science Monitor, 2018, 24, 6638-6648.	0.5	34
1925	Prognostic Factors and Treatment Options for Patients with High-Grade Chondrosarcoma. Medical Science Monitor, 2019, 25, 8952-8967.	0.5	17

#	Article	IF	Citations
1926	Disseminated Pancreatic Neuroendocrine Neoplasm (NEN) with an Uncommon Localisation in the Central Nervous System. A Case Report. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2017, 82, 120-125.	1.0	2
1927	Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. F1000Research, 2017, 6, 663.	0.8	7
1928	Refractory Metastatic Insulinoma Treated with Everolimus, Complicated by Cryptogenic Organizing Pneumonia. American Journal of Medical Case Reports, 2019, 7, 125-132.	0.1	2
1929	Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World Journal of Clinical Cases, 2020, 8, 4793-4806.	0.3	3
1930	Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease. PLoS ONE, 2011, 6, e23379.	1.1	177
1931	Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene. PLoS ONE, 2012, 7, e34456.	1.1	28
1932	Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials. PLoS ONE, 2012, 7, e52638.	1.1	4
1933	Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma. PLoS ONE, 2013, 8, e55096.	1.1	131
1934	Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo. PLoS ONE, 2014, 9, e105280.	1.1	34
1935	Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms â€“ Predictive and Prognostic Markers for Treatment Stratification. PLoS ONE, 2015, 10, e0143822.	1.1	70
1936	The selective PI3KÎ± inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLoS ONE, 2017, 12, e0182852.	1.1	23
1937	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e395-e401.	1.8	51
1938	Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocrine Connections, 2019, 8, 641-653.	0.8	11
1939	The role of mTOR pathway as target for treatment in adrenocortical cancer. Endocrine Connections, 2019, 8, R144-R156.	0.8	12
1940	Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140097.	0.2	9
1941	Role of the tumor microenvironment in digestive neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, R519-R544.	1.6	13
1942	Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 2019, 26, 391-403.	1.6	32
1943	Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, R109-R130.	1.6	24

#	Article	IF	Citations
1944	Management of carcinoid syndrome: a systematic review and meta-analysis. Endocrine-Related Cancer, 2019, 26, R145-R156.	1.6	59
1945	UCHL1 loss alters the cell cycle in metastatic pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 411-423.	1.6	17
1946	Novel cancer therapies and their association with diabetes. Journal of Molecular Endocrinology, 2019, 62, R187-R199.	1.1	20
1947	First-line irinotecan combined with 5-fluorouracil and leucovorin for high-grade metastatic gastrointestinal neuroendocrine carcinoma. Tumori, 2013, 99, 57-60.	0.6	6
1948	Optimising Therapeutic Options for Patients with Advanced Pancreatic Neuroendocrine Tumours. European Oncology and Haematology, 2012, 08, 217.	0.0	17
1949	Mirk kinase inhibition targets ovarian cancer ascites. Genes and Cancer, 2014, 5, 201-211.	0.6	15
1950	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	0.8	44
1951	Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group. Oncotarget, 2016, 7, 85306-85317.	0.8	22
1952	Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget, 2017, 8, 2936-2948.	0.8	20
1953	Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget, 2017, 8, 42076-42086.	0.8	35
1954	mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines. Oncotarget, 2017, 8, 20974-20987.	0.8	11
1955	Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. Oncotarget, 2017, 8, 55582-55592.	0.8	9
1956	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. Oncotarget, 2017, 8, 41044-41063.	0.8	24
1957	DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget, 2017, 8, 49796-49806.	0.8	59
1958	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354.	0.8	54
1959	The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors. Oncotarget, 2017, 8, 98068-98083.	0.8	13
1960	Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget, 2014, 5, 5381-5391.	0.8	41
1961	Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. Oncotarget, 2017, 8, 103613-103625.	0.8	17

#	Article	IF	Citations
1962	Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget, 2017, 8, 104046-104056.	0.8	35
1963	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget, 2014, 5, 8161-8172.	0.8	31
1964	Dynamic changes during the treatment of pancreatic cancer. Oncotarget, 2018, 9, 14764-14790.	0.8	21
1965	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget, 2018, 9, 36894-36905.	0.8	9
1966	Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. Oncotarget, 2019, 10, 6260-6268.	0.8	6
1967	Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. Oncotarget, 2015, 6, 11264-11280.	0.8	64
1968	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget, 2015, 6, 39538-39549.	0.8	27
1969	Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. Oncotarget, 2016, 7, 323-341.	0.8	33
1970	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget, 2016, 7, 9718-9731.	0.8	19
1971	Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget, 2016, 7, 23454-23467.	0.8	33
1972	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget, 2016, 7, 44841-44847.	0.8	15
1973	Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget, 2016, 7, 30585-30596.	0.8	10
1974	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. Oncotarget, 2016, 7, 40073-40084.	0.8	15
1975	Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. , 2019, 2, 1069-1085.		11
1976	" Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors". Annals of Gastroenterology, 2017, 30, 622-628.	0.4	22
1977	Genomic dissection of gastrointestinal and lung neuroendocrine neoplasm. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 918-929.	0.7	9
1978	Clinical and Translational Research Challenges in Neuroendocrine Tumours. Current Medicinal Chemistry, 2020, 27, 4823-4839.	1.2	5
1979	Therapeutic Targeting of Cancers with Loss of PTEN Function. Current Drug Targets, 2014, 15, 65-79.	1.0	194

#	Article	IF	Citations
1980	mTOR Inhibitors in Tuberous Sclerosis Complex. Current Neuropharmacology, 2012, 10, 404-415.	1.4	64
1981	Management of Gastro-intestinal Neuroendocrine Tumors with Liver Metastases: A Comprehensive Review. Open Colorectal Cancer Journal, 2012, 5, 28-37.	0.5	1
1982	Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment. Anticancer Research, 2017, 37, 1305-1312.	0.5	10
1983	Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors. Anticancer Research, 2017, 37, 2491-2500.	0.5	16
1984	1Î±,25(OH)2D3 Analog, MART-10, Inhibits Neuroendocrine Tumor Cell Metastasis After VEGF-A Stimulation. Anticancer Research, 2017, 37, 6215-6221.	0.5	4
1985	Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 2020, 30, 863-867.	0.2	2
1986	A case of neuroendocrine carcinoma originating from the pancreas with multiple liver metastasis resected after chemotherapy with etoposide and cisplatin. Suizo, 2011, 26, 563-568.	0.1	1
1987	New drugs in the therapy of neuroendocrine tumors. Journal of Endocrinological Investigation, 2012, 35, 930-6.	1.8	9
1988	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-326.	1.3	21
1989	Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Current Oncology, 2021, 28, 115-127.	0.9	14
1990	United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World Journal of Gastroenterology, 2013, 19, 2348.	1.4	22
1991	Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. World Journal of Gastroenterology, 2014, 20, 10038.	1.4	13
1992	Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World Journal of Gastroenterology, 2014, 20, 14348.	1.4	30
1993	Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors. World Journal of Gastroenterology, 2014, 20, 15920.	1.4	2
1994	Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World Journal of Gastroenterology, 2015, 21, 9512.	1.4	99
1995	Neuroendocrine differentiation: The mysterious fellow of colorectal cancer. World Journal of Gastroenterology, 2015, 21, 11740.	1.4	29
1996	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World Journal of Gastroenterology, 2015, 21, 11793.	1.4	29
1997	Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World Journal of Gastroenterology, 2015, 21, 2450.	1.4	11

#	Article	IF	Citations
1998	Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World Journal of Gastroenterology, 2016, 22, 3105.	1.4	8
1999	Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation. World Journal of Gastroenterology, 2017, 23, 4311.	1.4	9
2000	Role of radiotherapy for pancreatobiliary neuroendocrine tumors. Radiation Oncology Journal, 2013, 31, 125.	0.7	11
2001	The HSP90 inhibitor onalespib potentiates 177Luâ€'DOTATATE therapy in neuroendocrine tumor cells. International Journal of Oncology, 2019, 55, 1287-1295.	1.4	16
2002	Neuroendocrine tumors of the gallbladder (Review). Oncology Letters, 2020, 19, 3381-3388.	0.8	15
2003	VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review). World Academy of Sciences Journal, 0, , .	0.4	1
2004	A Case of Pancreatic Neuroendocrine Tumor with Tumor Embolus in the Portal Vein Resected Surgically after Neoadjuvant Chemotherapy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 49		
2005	Molecular pathology of pancreatic neuroendocrine tumors. Journal of Gastrointestinal Oncology, 2012, 3, 182-8.	0.6	33
2006	Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. Journal of Gastrointestinal Oncology, 2014, 5, 247-52.	0.6	42
2007	The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 457-62.	0.6	9
2008	Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surgery, 2014, 3, 276-83.	0.5	12
2009	Update on pancreatic neuroendocrine tumors. Gland Surgery, 2014, 3, 258-75.	0.5	77
2010	Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surgery, 2015, 4, 63-8.	0.5	31
2011	Therapy for metastatic pancreatic neuroendocrine tumors. Annals of Translational Medicine, 2014, 2, 8.	0.7	29
2012	mTORC1 signaling in primary central nervous system lymphoma. , 2016, 7, 475.		6
2013	Genomic Landscapes of Pancreatic Neoplasia. Journal of Pathology and Translational Medicine, 2015, 49, 13-22.	0.4	16
2014	Multiple Cardiac Metastases from a Nonfunctioning Pancreatic Neuroendocrine Tumor. Cancer Research and Treatment, 2013, 45, 150-154.	1.3	8
2015	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Cancer Research and Treatment, 2015, 47, 738-746.	1.3	10

#	Article	IF	Citations
2016	Multiple Effects of Molecular Hydrogen and its Distinct Mechanism. Journal of Neurological Disorders, 2014, 02, .	0.1	3
2017	Pancreatic Neuroendocrine Tumors Are Characterized by Loss of <i>Noxa</i> Expression that Can be Recovered by the Proteasome Inhibitor Bortezomib. Journal of Cancer Therapy, 2013, 04, 28-33.	0.1	1
2018	Pancreatic Neuroendocrine Tumors in the 21st Centuryâ€"An Update. Journal of Cancer Therapy, 2017, 08, 1194-1233.	0.1	3
2019	Targeted treatments for metastatic esophageal squamous cell cancer. World Journal of Gastrointestinal Oncology, 2013, 5, 88.	0.8	8
2020	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World Journal of Gastrointestinal Oncology, 2016, 8, 389.	0.8	20
2021	Role of the preoperative usefulness of the pathological diagnosis of pancreatic diseases. World Journal of Gastrointestinal Oncology, 2016, 8, 656.	0.8	13
2022	New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World Journal of Gastrointestinal Oncology, 2017, 9, 4.	0.8	14
2023	Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective. World Journal of Gastrointestinal Oncology, 2017, 9, 341.	0.8	17
2024	The Current Strategy for Managing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Gut and Liver, 2012, 6, 287-294.	1.4	38
2025	Management of patients with hepatic metastases from neuroendocrine tumors. Annals of Saudi Medicine, 2014, 34, 279-290.	0.5	13
2026	Watch and waitpolicy in advanced neuroendocrine tumors: What does it mean?. World Journal of Clinical Oncology, 2017, 8, 96.	0.9	3
2027	Antineoplastic effects of mammalian target of rapamycine inhibitors. World Journal of Transplantation, 2012, 2, 74.	0.6	12
2028	Nowotwory neuroendokrynne trzustki â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w) Tj ETQq0 0 0 rgBT /	0.3	13
2029	Impact of genetic alterations on mTOR-targeted cancer therapy. Chinese Journal of Cancer, 2013, 32, 270-274.	4.9	8
2030	Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1200-1209.	2.3	3
2032	Clinicopathological Features and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors: Analysis from a Single-institution. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5775-5781.	0.5	19
2033	Survival Analysis and Prognostic Factors for Neuroendocrine Tumors in Turkey. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6687-6692.	0.5	20
2034	Combination Therapies with PRRT. Pharmaceuticals, 2021, 14, 1005.	1.7	8

#	Article	IF	Citations
2035	Cardiometabolic consequences of targeted anticancer therapies. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	3
2036	Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers, 2021, 13, 5117.	1.7	31
2038	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Reports, 2021, 37, 109817.	2.9	14
2039	Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncology Practice, 2022, 18, 258-264.	1.4	14
2040	Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support. Diagnostics, 2021, 11, 1850.	1.3	0
2041	Translational challenges in pancreatic neuroendocrine tumor immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188640.	3.3	6
2044	Diagnosis and Treatment of Insulinomas in the Adults. , 0, , .		4
2045	Uncommon Thoracic Tumors. , 2012, , 859-889.		2
2046	Treatment upon Metastatic Pancreatic Nets: Does Chemotherapy Still Play a Role in the Area of Targeting Treatment?. Pancreatic Disorders & Therapy, 2012, 02, .	0.3	0
2047	Tumors of the Liver. , 2012, , 391-397.		0
2048	32 Neuro-endocriene tumoren. , 2012, , 385-395.		0
2049	Molecularly Targeted Therapy: Past, Present and Future. Chemotherapy, 2012, 01, .	0.0	3
2050	A Case of Appendiceal Mixed Adenoneuroendocrine Carcinoma after Appendectomy. Japanese Journal of Gastroenterological Surgery, 2012, 45, 1121-1128.	0.0	2
2051	Profiling of GEPNETs. , 2012, 2012, 1-11.		0
2052	Pancreatic Neuroendocrine Tumors: Emerging Management Paradigm. , 0, , .		0
2053	A Renaissance in Therapeutic Options for Pancreatic Neuroendocrine Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 271-274.	1.8	0
2055	Treating Rare Cancer in Children: The Importance of Evidence. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 586-588.	1.8	0
2056	Endokrine Tumoren des gastroenteropankreatischen Systems. , 2013, , 497-628.		2

#	Article	IF	Citations
2057	A Case of ACTH-producing Pancreatic Neuroendocrine Tumor Presenting with Cushing Syndrome. Soonchunhyang Medical Science, 2012, 18, 159-162.	0.0	0
2058	Neuroendocrine Tumors. Molecular Pathology Library, 2013, , 193-209.	0.1	0
2059	Genomic Alterations in Sporadic Pancreatic Cancer. , 2013, , 1-26.		0
2060	Neuroendocrine Tumors. Korean Journal of Medicine, 2013, 85, 354.	0.1	0
2061	A case of primary endocrine cell carcinoma of the distal bile duct. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2013, 74, 190-195.	0.0	4
2062	Combination Therapy for Liver Metastases: Chemotherapy and Radiologic Interventions. , 2013, , 469-480.		0
2063	Current therapeutic strategy of unresectable pNET in Japan. Suizo, 2013, 28, 707-713.	0.1	0
2064	A Case of Primary Hepatic Neuroendocrine Cell Carcinoma. Nihon Rinsho Geka Gakkai Zasshi (Journal) Tj ETQq1 1 0.784314 rgBT /Overl	0.0	3
2066	Targeted and Other Non-receptor-mediated Therapies. Updates in Surgery Series, 2013, , 135-145.	0.0	0
2067	Surgical treatment of pancreatic neuroendocrine tumors. Suizo, 2013, 28, 699-706.	0.1	1
2068	Role of Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors and Update on Their Treatment. Journal of Postgraduate Medicine Education and Research, 2013, 47, 54-60.	0.1	0
2069	Nonfunctioning pancreatic neuroendocrine tumor with an initial appearance of intra-abdominal hemorrhage. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2013, 74, 522-528.	0.0	1
2070	Molecular targeted therapies and gastroenterological neoplasia. Okayama Igakkai Zasshi, 2013, 125, 145-152.	0.0	0
2071	The Efficacy and Cost of Biological Targeted Agents in Oncology. SSRN Electronic Journal, 0, , .	0.4	0
2072	Onkologische Therapie bei Metastasen endokriner Pankreastumoren. , 2013, , 249-255.		0
2073	New Knowledge in the Diagnosis and Medical Treatment of Pancreatic Neuroendocrine Tumors. , 2013, , 127-141.		0
2074	Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-Nets): A Review. , 2013, 03, .		0
2075	Gastrointestinal Carcinoid Tumors. , 2013, , 1015-1027.		0

#	Article	IF	Citations
2076	Current status of clinical treatment for patients with pancreatic neuroendocine tumors in Japan. Suizo, 2013, 28, 684-690.	0.1	0
2077	A Case of Neuroendocrine Cell Carcinoma in the Hilar Bile Duct: Improved Outcome after Surgery and Chemotherapy. Japanese Journal of Gastroenterological Surgery, 2013, 46, 579-585.	0.0	3
2080	Profiling mTOR Pathway in Neuroendocrine Tumors. , 2014, , 9-27.		0
2081	Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors. , 2014, , 127-140.		0
2082	Clinical Management of Targeted Therapies in Neuroendocrine Tumours. , 2014, , 141-154.		0
2083	Laparoscopic Surgery for an Endometrial Cancer Patient Treated with Everolimus for Insulinoma: A Case Report. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2014, 39, 989-995.	0.0	0
2085	New Anticancer Agents in Neuroendocrine Tumors. , 2014, , 181-198.		0
2086	Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies. , 2014, , 155-165.		0
2087	Intracellular Signaling. , 2014, , 22-39.e8.		1
2088	A Case of Mixed Adenoneuroendocrine Carcinoma of the Ampulla of Vater. Japanese Journal of Gastroenterological Surgery, 2014, 47, 108-115.	0.0	1
2089	Inhibition of mTOR in Neuroendocrine Neoplasms of the Digestive Tract. , 2014, , 115-126.		1
2090	Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors. , 2014, , 43-63.		0
2092	Nonsurgical Strategies in Patients With NET Liver Metastases: A Protocol of Four Systematic Reviews. JMIR Research Protocols, 2014, 3, e9.	0.5	3
2093	Neuroendocrine disorders. , 2014, , 553-574.		0
2094	Neuroendocrine Tumors of the Pancreas: Molecular Pathogenesis and Perspectives on Targeted Therapies. Journal of Cancer Research Updates, 2014, 3, 141-150.	0.3	0
2095	Zollingerâ€“Ellison Syndrome: Diagnosis and Management. , 2015, , 41-62.		0
2096	Genomic Applications in Colorectal and Pancreatic Tumors. , 2015, , 415-434.		0
2098	Inherited and Somatic Genetics of Pancreatic Neuroendocrine Tumors. , 2015, , 9-32.		1

#	Article	IF	Citations
2099	Novel Targets for Future Medical Treatments. , 2015, , 145-162.		0
2100	Glucagonoma. , 2015, , 233-250.		1
2101	Clinical Approaches to the Management of Neuroendocrine Tumours. , 2015, , 719-734.		0
2102	ART for Anti-inflammation. Springer Briefs in Molecular Science, 2015, , 53-77.	0.1	0
2103	Multiple Liver Metastases of a Neuroendocrine Carcinoma of Unknown Origin. Japanese Journal of Gastroenterological Surgery, 2015, 48, 94-101.	0.0	1
2104	Gastrinoma. , 2015, , 287-300.		0
2105	Gastrinoma. , 2015, , 199-221.		0
2106	Insulinoma. , 2015, , 179-197.		0
2107	Management of Hormonal Symptoms. , 2015, , 501-511.		0
2108	Ocena bezpieczeÅ„stwa i efektywnoÅ›Ä‡ jabÅ‚czanu sunitynibu w przerzutowych guzach neuroendokrynnych trzustki (NEN G1/G2) w zależności od liczby i rodzaju wcześniejszych linii terapeutycznych â€" doniesienie wstÄ™pne. Endokrynologia Polska, 2015, 65, 472-478.	0.3	1
2109	Glucagonoma. , 2015, , 317-322.		0
2110	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
2111	Gastroentero-pankreatische neuroendokrine Neoplasien (GEP-NEN). , 2015, , 1-15.		0
2112	DÃ¼nndarmtumoren. , 2015, , 481-486.		0
2113	Advances in the Management of Unresectable or Metastatic Pancreatic Neuroendocrine Tumors: Chemotherapy, Targeted Therapy, Hormonal Treatment, and Future Directions. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2151-2159.	0.5	0
2114	Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor â€" Case Report and Review of the Literature. American Journal of Medical Case Reports, 2015, 3, 205-208.	0.1	0
2115	Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. Hormones, 2016, 15, 118-21.	0.9	1
2118	Effects of everolimus on a rat model of cerulein-induced experimental acute pancreatitis. Turkish Journal of Surgery, 2015, 31, 185-191.	1.0	1

#	Article	IF	Citations
2119	Chemotherapy and Targeted Therapy beyond Adenocarcinoma of the Lung: Neuroendocrine Carcinoma. Korean Journal of Medicine, 2016, 90, 7-14.	0.1	0
2120	Primary Small Cell Carcinoma of the Middle Bile Duct. Japanese Journal of Gastroenterological Surgery, 2016, 49, 418-425.	0.0	2
2121	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
2122	Targeted Therapies for Neuroendocrine Neoplasms. , 2016, , 505-516.		0
2123	Neuroendocrine Tumors (GastroEnteroPancreatic). , 2016, , 207-224.		0
2124	Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. Cancer Drug Discovery and Development, 2016, , 151-180.	0.2	0
2125	The Role of mTOR Inhibitors in Neuroendocrine Tumors. , 2016, , 93-112.		0
2126	Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?. World Journal of Clinical Oncology, 2016, 7, 149.	0.9	1
2127	Management of Pancreatic Gastrinoma. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 655-671.	0.0	0
2128	Management of Perioperative Medications Including Steroids, Growth Factors, and Hormone Receptors. , 2017, , 329-346.		0
2129	Exceptional Therapeutic Outcome of Metastatic Neuroendocrine Tumor with Peptide Receptor Radionuclide Therapy with Brief Review of Literature. Journal of Nuclear Medicine & Radiation Therapy, 2017, 08, .	0.2	1
2130	The Heat Shock Protein Storyâ€"From Taking mTORC1,2 and Heat Shock Protein Inhibitors as Therapeutic Measures for Treating Cancers to Development of Cancer Vaccines. Journal of Cancer Therapy, 2017, 08, 962-1029.	0.1	4
2131	Hepatic metastasis from neuroendocrine cancers. , 2017, , 1355-1367.e4.		0
2132	Seltene Tumoren des Gastrointestinaltraktes beim alten und geriatrischen Patienten (NET, GIST). , 2017, , 1-18.		0
2133	Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing. Anticancer Research, 2017, 37, 705-712.	0.5	3
2134	DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?. Respiratory Disease Series, 2018, , 139-164.	0.1	0
2135	Classification of Neuroendocrine Tumors: Consensus Guidelines for the Management and Treatment. Endocrinology and Disorders, 2017, 1, 01-04.	0.1	0
2137	Therapy for Metastatic Disease: Pancreas. , 2018, , 295-303.		0

#	Article	IF	Citations
2138	Seltene Tumoren des Gastrointestinaltraktes beim alten und geriatrischen Patienten (NET, GIST). , 2018, , 381-398.		0
2139	Neuroendocrine Tumors. , 2018, , .		0
2140	Other Malignant Hepatic Tumors. , 2018, , 708-719.e3.		0
2141	Medical Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumors. , 2018, , 281-287.		0
2142	Management of Pancreatic and Duodenal Neuroendocrine Tumors. Updates in Surgery Series, 2018, , 153-167.	0.0	0
2143	Neuroendocrine Pancreatic Tumors. Cancer Dissemination Pathways, 2018, , 99-109.	0.0	0
2144	Liver Metastases of Neuroendocrine Tumors and CCC. , 2018, , 107-127.		0
2145	A Case of Primary Hepatic Neuroendocrine Tumor with Multiple Intrahepatic Metastases Aiding Long-term Survival. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2018, 79, 858-863.	0.0	2
2147	Prognostic significance of tumor-associated macrophages in pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2018, 36, e16178-e16178.	0.8	0
2148	Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment. Cureus, 2018, 10, e2798.	0.2	1
2149	Three decades of survival in Pancreatic Neuroendocrine Tumor with Unresectable Liver Metastases. , 0, , 002-006.		0
2150	Hepatopancreaticobiliary Surgery. , 2018, , .		0
2151	NEW THERAPIES IN UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS. Journal of Surgical Sciences, 2019, 1, 135-138.	0.0	0
2152	Treatment of Neuroendocrine Tumour Disease. , 2019, , 259-273.		0
2153	Clinical Approaches to the Management of Neuroendocrine Tumours. , 2019, , 851-867.		0
2155	Management of Secondary Hepatic Neoplasms. , 2019, , 1565-1574.		0
2156	Gastroenteropancreatic Neuroendocrine Tumors. , 2019, , 269-287.		0
2157	Ancillary Studies in the Cytologic Diagnosis of Pancreatico-biliary Lesions. Essentials in Cytopathology Series, 2019, , 275-340.	0.1	0

#	Article	IF	Citations
2158	Tumor Growth Prediction Using Convolutional Networks. Advances in Computer Vision and Pattern Recognition, 2019, , 239-260.	0.9	0
2160	Navigating the treatment landscape in gastroenteropancreatic neuroendocrine neoplasms. OnCOReview, 2019, 9, 31-39.	0.1	0
2161	Tumor neuroendocrino pancreÃ¡tico secretor de corticotropina, un reto en el manejo terapÃ©utico. A propÃ³sito de 2 casos. Endocrinologia, Diabetes Y NutriciÃ“n, 2019, 66, 204-206.	0.1	2
2162	Postoperative adjuvant therapy for patients with Pancreatic Neuroendocrine Neoplasms. Suizo, 2019, 34, 92-96.	0.1	1
2163	Traitement des nÃ©oplasmes neuroendocrines digestifs. Oncologie, 2019, 21, 97-103.	0.2	0
2164	æ¶ˆåŒ–å™¨ãŒã,“. Journal of Otolaryngology of Japan, 2019, 122, 717-723.	0.1	0
2166	Liver transplantation in patients with liver metastases from neuroendocrine tumors. Minerva Chirurgica, 2019, 74, 399-406.	0.8	7
2167	Neuroendocrine Tumors (Gastroenteropancreatic). , 2020, , 345-381.		0
2168	Resection of Primary Hepatic Neuroendocrine Tumor. Japanese Journal of Gastroenterological Surgery, 2020, 53, 139-146.	0.0	0
2169	Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs in Context, 2020, 9, 1-13.	1.0	6
2171	Oncological management of advanced neuroendocrine tumours (Review). Molecular and Clinical Oncology, 2020, 13, 8.	0.4	0
2172	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. Oncotarget, 2020, 11, 2172-2181.	0.8	5
2173	Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Network Open, 2021, 4, e2131744.	2.8	4
2174	Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Drug Safety, 2021, 20, 321-334.	1.0	4
2175	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. Protein and Peptide Letters, 2020, 27, 1276-1287.	0.4	2
2176	A Case Report of Resection of Liver Tumor Considerd to Have Developed from Metastases of Pancreatic Gastrinoma 13 Years after Primary Resection. Nihon Rinsho Geka Gakkai Zasshi (Journal of) Tj ETQq1 1 0.784314 rgBT /Ov	0.78	
2177	Gastroenteropancreatic Neuroendocrine Neoplasms. , 2020, , 658-666.		0
2178	Pancreas; Endocrine Tumors. , 2020, , 10-23.		0

#	Article	IF	Citations
2179	Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours. Medical Radiology, 2020, , 475-494.	0.0	0
2180	Radical Operation and Everolimus Therapy for Rectal Neuroendocrine Tumor with Liver Metastases: A Case Report with Review of the Literature. Case Reports in Clinical Medicine, 2020, 09, 275-281.	0.1	0
2181	ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS. , 2020, , H-1-H9-9.		0
2182	Peptide Receptor Radionuclide Therapy. , 2020, , 867-898.		0
2183	Neuroendocrine Neoplasms. , 2020, , 181-195.		0
2184	NephrotoxizitÃt onkologischer Therapien. , 2020, , 205-220.		0
2185	Crosstalks between Yin-Yang 1 (YY1) and autophagy in cancer. , 2020, , 9-27.		0
2186	Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients. Pharmacogenomics Journal, 2020, 20, 647-654.	0.9	1
2187	Indian Council of Medical Research Consensus Document for the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 166-172.	0.1	1
2188	Treatment of neuroendocrine liver metastases: a patent landscape review. Pharmaceutical Patent Analyst, 2020, 9, 29-32.	0.4	0
2189	Primary neuroendocrine liver tumor mimicking hepatocellular carcinoma in a patient with prior hepatitis B virus infection. Acta Hepatologica Japonica, 2020, 61, 116-121.	0.0	0
2190	Targeted therapy for gastrointestinal and pancreatic neuroendocrine tumors. Malignant Tumours, 2020, 9, 49-58.	0.1	1
2192	Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: differences in basic biology and treatment. World Journal of Gastrointestinal Oncology, 2020, 12, 705-718.	0.8	4
2193	Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World Journal of Gastroenterology, 2020, 26, 4036-4054.	1.4	27
2195	A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP: Journal of the Pancreas, 2013, 14, 498-501.	1.5	26
2197	Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series. JOP: Journal of the Pancreas, 2013, 14, 415-22.	1.5	3
2198	Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 501-6.	0.7	3
2199	Mammalian target of rapamycin: a central node of complex signaling cascades. International Journal of Clinical and Experimental Pathology, 2011, 4, 476-95.	0.5	68

#	Article	IF	Citations
2200	Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. International Journal of Clinical and Experimental Pathology, 2012, 5, 187-94.	0.5	73
2201	Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature. Journal of Gastrointestinal Oncology, 2011, 2, 117-21.	0.6	1
2202	Primary ductal adenocarcinoma of the lacrimal sac: the first reported case. International Journal of Clinical and Experimental Pathology, 2013, 6, 1929-34.	0.5	11
2203	Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Gastrointestinal Cancer Research: GCR, 2013, 6, S10-2.	0.8	4
2204	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Molecular Diagnosis and Therapy, 2012, 16, 151-61.	1.6	8
2205	A woman with metastatic pancreatic neuroendocrine tumor. Gastrointestinal Cancer Research: GCR, 2014, 7, 27-32.	0.8	2
2206	Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Annals of Gastroenterology, 2013, 26, 29-36.	0.4	35
2207	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. American Journal of Cancer Research, 2014, 4, 907-15.	1.4	4
2208	Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 46-55.	1.0	15
2210	(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 59-72.	1.0	14
2211	A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Research, 2016, 36, 713-9.	0.5	66
2212	Collaborative Practice in the Management of Neuroendocrine Tumors. Journal of the Advanced Practitioner in Oncology, 2016, 7, 278-281.	0.2	0
2213	Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in 2017. JOP: Journal of the Pancreas, 2017, 18, 444-447.	1.5	0
2214	Gastroentero-pankreatische neuroendokrine Neoplasien (GEP-NEN). , 2022, , 391-404.		0
2215	Progress in the Management of Pancreatic Neuroendocrine Tumors. Annual Review of Medicine, 2022, 73, .	5.0	4
2216	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013700.	1.5	7
2217	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study. European Journal of Cancer, Supplement, 2021, 16, 14-23.	2.2	2
2218	The Quest for an Accurate Functional Tumor Volume with ⁶⁸Ga-DOTATATE PET/CT. Journal of Nuclear Medicine, 2022, 63, 1027-1032.	2.8	11

#	Article	IF	Citations
2219	Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial. BMC Cancer, 2021, 21, 1206.	1.1	1
2220	Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NETÂpatients?. European Journal of Cancer, Supplement, 2021, 16, 1-4.	2.2	0
2221	Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. , 2021, 9, e003195.		3
2222	Neuroendocrine disorders. , 2022, , 627-650.		0
2223	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer, Supplement, 2021, 16, 5-13.	2.2	2
2224	Primary hepatic neuroendocrine tumour with multiple liver metastases: A case report with literature review. International Journal of Surgery Case Reports, 2021, 89, 106590.	0.2	8
2225	Integrated or Independent Actions of Metformin in Target Tissues Underlying Its Current Use and New Possible Applications in the Endocrine and Metabolic Disorder Area. International Journal of Molecular Sciences, 2021, 22, 13068.	1.8	11
2230	Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. Oncologist, 2022, 27, e328-e339.	1.9	3
2231	Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases. Annals of Surgery, 2022, 276, e450-e458.	2.1	17
2232	Non-Functioning Pancreatic Neuroendocrine Tumours. , 2022, , 991-998.		0
2233	Vasointestinal Polypeptide Secreting Tumours. , 2022, , 1023-1028.		0
2234	Multiple Endocrine Neoplasia Type 1. , 2022, , 1046-1052.		0
2235	Gastrinoma. , 2022, , 999-1006.		0
2236	Overview and Pathophysiology of Neuroendocrine Neoplasms. , 2022, , 957-964.		0
2237	Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). Journal of Neuroendocrinology, 2022, 34, e13097.	1.2	5
2238	Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. Journal of Clinical Medicine, 2022, 11, 249.	1.0	3
2239	Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors. Medicine (United States), 2022, 101, e28610.	0.4	2
2240	Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors. Cancers, 2022, 14, 433.	1.7	9

#	Article	IF	Citations
2241	Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response. CKJ: Clinical Kidney Journal, 2022, 15, 1160-1168.	1.4	2
2242	Relationship between marital status and survival in patients with lung adenocarcinoma. Medicine (United States), 2022, 101, e28492.	0.4	5
2243	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. Healthcare (Switzerland), 2022, 10, 218.	1.0	1
2244	Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma. Current Molecular Pharmacology, 2022, 15, .	0.7	0
2245	VIPoma: an unsuspecting culprit of severe secretory diarrhoea in a human immunodeficiency virusâ€infected patient. Internal Medicine Journal, 2022, 52, 125-129.	0.5	0
2246	A rare case of pancreatic neuroendocrine neoplasm causing Cushingâ€™s syndrome. Clinical Journal of Gastroenterology, 2022, 15, 256.	0.4	2
2247	Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs) : The Role of Checkpoint Inhibitors. Current Cancer Drug Targets, 2022, 22, .	0.8	0
2248	Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptidesâ€"Where Are We Now. Cancers, 2022, 14, 761.	1.7	6
2249	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. Oncologist, 2022, 27, 97-103.	1.9	6
2250	Side effects of radiopeptide therapy for neuroendocrine tumors. , 2022, , .		0
2251	Combined medical therapy, nuclear medicine therapy and other therapies in metastatic neuroendocrine tumor. , 2022, , .		0
2252	Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin. Anticancer Research, 2022, 42, 1381-1396.	0.5	0
2253	Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2022, 14, 1119.	1.7	28
2254	Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers, 2022, 14, 1250.	1.7	6
2255	Neuroendocrine Tumor with Metachronous Gastrointestinal Stromal Tumor in a Patient: A Case Report. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2022, 79, 72-76.	0.2	1
2256	Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World Journal of Gastrointestinal Surgery, 2022, 14, 78-106.	0.8	0
2257	Management of bronchopulmonary neuroendocrine tumors. International Journal of Cancer Care and Delivery, 0, , .	0.0	0
2258	A Multinational Pilot Study on Patientsâ€™ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires. Journal of Clinical Medicine, 2022, 11, 1271.	1.0	1

#	Article	IF	Citations
2260	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	2.8	21
2261	Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. Cancers, 2022, 14, 1428.	1.7	6
2262	A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The â€˜PROTORâ€™ Study. Anticancer Research, 2022, 42, 1941-1948.	0.5	1
2263	What Gastroenterologists Should Know about Carcinoid Syndrome. Gastroenterology Insights, 2022, 13, 127-138.	0.7	3
2264	Insulin and cancer: a tangled web. Biochemical Journal, 2022, 479, 583-607.	1.7	22
2265	Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. Drugs and Aging, 2022, 39, 257.	1.3	0
2266	Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumorsâ€”Need for a Conductor. Cancers, 2022, 14, 1478.	1.7	3
2267	METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedicalscience, 0, 16, .	0.6	1
2268	Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms. Cancer Diagnosis & Prognosis, 2022, 2, 150-159.	0.3	3
2269	Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-Related Cancer, 2022, 29, 335-344.	1.6	8
2270	Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist, 2022, 27, 573-578.	1.9	30
2271	Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy. Clinical Nuclear Medicine, 2022, 47, 409-413.	0.7	3
2272	Neuroendocrine Tumors: a Relevant Clinical Update. Current Oncology Reports, 2022, 24, 703-714.	1.8	9
2273	Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation. Journal of Oncology Pharmacy Practice, 2023, 29, 1094-1102.	0.5	4
2274	Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers, 2022, 14, 1795.	1.7	15
2275	Efficacy and safety of 177Luâ€‘DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3529-3537.	3.3	6
2276	Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification. Critical Reviews in Oncology/Hematology, 2022, 172, 103648.	2.0	8
2277	miRâ€144â€3p/miRâ€451a promotes lymphovascular invasion through repression of PTEN/p19 in rectal neuroendocrine tumors. Journal of Gastroenterology and Hepatology (Australia), 2022, , .	1.4	4

#	Article	IF	Citations
2278	Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, Publish Ahead of Print, .	0.6	0
2279	Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2022, 29, 225-239.	1.6	3
2280	Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors. Pancreas, 2021, 50, 1435-1439.	0.5	6
2281	[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2037-2048.	3.3	7
2282	Recent Advances in the Diagnosis and Management of Carcinoid Syndrome. Disease-a-Month, 2021, , 101304.	0.4	4
2283	The 100 most cited articles on pancreatic neuroendocrine tumors from 2000 to 2020: a bibliometric analysis. Japanese Journal of Clinical Oncology, 2022, 52, 251-259.	0.6	5
2284	An Overview of Pancreatic Neuroendocrine Tumors. , 0, , .		0
2285	Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study. Advances in Therapy, 2022, , 1.	1.3	1
2286	Vasoactive intestinal peptide secreting tumour: An overview. World Journal of Gastrointestinal Oncology, 2022, 14, 808-819.	0.8	6
2287	Real-world comparison of healthcare resource utilization and costs of [¹⁷⁷Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the Hospital Episode Statistics dataset. Current Medical Research and Opinion, 2022, , 1-33.	0.9	0
2288	Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers, 2022, 14, 2028.	1.7	6
2289	Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Japanese Journal of Clinical Oncology, 2022, 52, 716-724.	0.6	6
2290	Assessment, triage, and liver-directed therapies for neuroendocrine tumor metastases. , 0, , 165-175.		0
2298	Sunitinib and everolimus in pancreatic neuroendocrine tumors. Tumori, 2012, 98, 394.	0.6	2
2302	Emerging therapies for pancreas neuroendocrine cancers. Chinese Clinical Oncology, 2013, 2, 23.	0.4	8
2303	Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. Chinese Clinical Oncology, 2013, 2, 22.	0.4	2
2304	Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?. JOP: Journal of the Pancreas, 2013, 14, 102-4.	1.5	0
2305	Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP: Journal of the Pancreas, 2013, 14, 152-4.	1.5	6

#	Article	IF	Citations
2306	Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. JOP: Journal of the Pancreas, 2013, 14, 155-7.	1.5	1
2307	Update on novel therapies for pancreatic neuroendocrine tumors: 2013. JOP: Journal of the Pancreas, 2013, 14, 377-80.	1.5	4
2308	Neuroendocrine tumors: treatment updates. JOP: Journal of the Pancreas, 2013, 14, 367-71.	1.5	2
2309	Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas. JOP: Journal of the Pancreas, 2013, 14, 381-3.	1.5	2
2311	The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues. JOP: Journal of the Pancreas, 2014, 15, 295-8.	1.5	0
2312	Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive cancer center. Endocrine Oncology, 2022, , .	0.1	2
2313	Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and metaâ€analysis. Journal of Neuroendocrinology, 2022, 34, .	1.2	1
2314	A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma. Frontiers in Oncology, 2022, 12, 817916.	1.3	9
2315	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-tumor Therapy, 0, , 172-199.	0.5	6
2316	Neuroendocrine hepatic metastatic disease: the surgeonâ€™s perspective. Abdominal Radiology, 2022, , 1.	1.0	3
2317	The Mount Sinai Clinical Pathway for the Diagnosis and Management of Hypercortisolism due to Ectopic ACTH Syndrome. Journal of the Endocrine Society, 2022, 6, .	0.1	8
2319	New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World Journal of Gastroenterology, 2022, 28, 1751-1767.	1.4	8
2320	Pulmonary neuroendocrine tumours and somatostatin receptor status: anÂassessment of unlicensed use of somatostatin analogues in the clinical practice. ESMO Open, 2022, 7, 100478.	2.0	4
2321	Advances in medical treatment for pancreatic neuroendocrine neoplasms. World Journal of Gastroenterology, 2022, 28, 2163-2175.	1.4	1
2322	Novel Effects of Statins on Cancer via Autophagy. Pharmaceuticals, 2022, 15, 648.	1.7	6
2323	Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential. Pathology Research and Practice, 2022, 236, 153956.	1.0	7
2324	Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection. Cancers, 2022, 14, 2662.	1.7	6
2325	New Therapy Options for Neuroendocrine Carcinoma of the Pancreasâ€”The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. Cancers, 2022, 14, 2685.	1.7	3

#	Article	IF	Citations
2326	Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?. Journal of Clinical Oncology, 2022, 40, 2818-2829.	0.8	13
2327	Malignant insulinoma: Can we predict the long-term outcomes?. World Journal of Clinical Cases, 2022, 10, 5124-5132.	0.3	3
2328	Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report. SAGE Open Medical Case Reports, 2022, 10, 2050313X2211069.	0.2	1
2329	Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms. Internal Medicine, 2023, 62, 159-167.	0.3	4
2330	CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors. Radiologia Medica, 2022, 127, 691-701.	4.7	32
2331	Tivozanib: A New Hope for Treating Renal Cell Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 562-570.	0.9	1
2332	Molecular deciphering of primary liver neuroendocrine neoplasms confirms their distinct existence with foregutâ€like profile. Journal of Pathology, 2022, 258, 58-68.	2.1	3
2333	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2022, 176, 103749.	2.0	37
2334	Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients. Therapie, 2022, , .	0.6	0
2335	Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Frontiers in Oncology, 0, 12, .	1.3	7
2337	Advances in Targeted Therapy for Patients with Neuroendocrine Tumours. Touch Reviews in Oncology & Haematology, 2022, 18, 66.	0.1	0
2338	Zollinger Ellison Syndrome Refractory to Medical Therapy in the Setting of Multiple Endocrine Neoplasia Type I. Cureus, 2022, , .	0.2	2
2339	Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients. Journal of Nuclear Medicine, 2023, 64, 40-46.	2.8	5
2340	A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data. Frontiers in Pharmacology, 0, 13, .	1.6	0
2341	Sequencing of Therapies in Progressive Neuroendocrine Tumors. Annals of Surgical Oncology, 0, , .	0.7	0
2342	Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Review of Endocrinology and Metabolism, 2022, 17, 389-403.	1.2	11
2343	Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function. Journal of Clinical Medicine, 2022, 11, 3983.	1.0	3
2344	Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers, 2022, 14, 3317.	1.7	2

#	Article	IF	Citations
2345	Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. European Journal of Cancer, 2022, 172, 340-348.	1.3	12
2346	Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: AÂpopulation-based study. European Journal of Cancer, 2022, 172, 252-263.	1.3	5
2347	Pancreatic Neuroendocrine Tumors. , 2023, , 197-217.		26
2348	Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment. Cancers, 2022, 14, 3481.	1.7	4
2349	Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A singleâ€€enter retrospective analysis. Journal of Neuroendocrinology, 2022, 34, .	1.2	2
2350	Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms. Endocrine, 2022, 78, 159-168.	1.1	4
2351	DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist, 2022, 27, 940-951.	1.9	16
2352	Context matters â€“ Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	7
2353	Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. Frontiers in Molecular Biosciences, 0, 9, .	1.6	5
2354	Targeted Therapies in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2963-2972.	1.8	18
2355	Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surgical Pathology Clinics, 2022, 15, 541-554.	0.7	3
2356	Treatment options of metastatic and nonmetastatic VIPoma: a review. Langenbeck's Archives of Surgery, 2022, 407, 2629-2636.	0.8	2
2357	Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trialÂâ€“ Prodige 31 REMINET: An FFCD study. European Journal of Cancer, 2022, 175, 31-40.	1.3	7
2358	S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial. EClinicalMedicine, 2022, 54, 101667.	3.2	2
2359	Watch and Wait Strategies in NET Patients: More than Expected. Archives of Clinical and Medical Case Reports, 2022, 06, .	0.0	0
2360	Pathology of Pancreatic Neuroendocrine Tumors. , 2022, , 639-681.		0
2361	Epidemiology, Pathogenesis, and Prognosis of Pancreatic Neuroendocrine Tumors. , 2022, , 623-637.		0
2362	Radionuclide Therapy in Neuroendocrine Tumors. , 2022, , 173-186.		0

#	Article	IF	Citations
2363	Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. , 2022, , 761-776.		0
2364	Systemic Therapy for Pancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer, 2023, 22, 34-44.	1.0	1
2365	Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. Journal of Endocrinological Investigation, 2023, 46, 213-234.	1.8	13
2366	Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation. Frontiers in Oncology, 0, 12, .	1.3	4
2367	Genetics of Pancreatic Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 1033-1051.	0.9	3
2368	Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 2022, 14, 4769.	1.7	3
2369	Gastroenteropancreatic Neuroendocrine Tumors. Gastroenterology Clinics of North America, 2022, 51, 625-647.	1.0	6
2370	Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188804.	3.3	2
2371	Longâ€term treatment of cancerâ€prone germline PTEN mutant miceÂwith lowâ€dose rapamycin extends lifespan and delays tumour development. Journal of Pathology, 2022, 258, 382-394.	2.1	7
2372	Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes. Cancers, 2022, 14, 4471.	1.7	5
2373	On-Target Side Effects of Targeted Therapeutics of Cancer. Pathology and Oncology Research, 0, 28, .	0.9	9
2374	Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncology and Therapy, 2022, 10, 463-479.	1.0	2
2375	Targeting senescence as an anticancer therapy. Molecular Oncology, 2022, 16, 3855-3880.	2.1	19
2376	Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm. Surgery, 2023, 173, 365-372.	1.0	3
2377	The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database. Frontiers in Oncology, 0, 12, .	1.3	0
2378	Baicalein activates 5â€™ adenosine monophosphate-activated protein kinase, inhibits the mammalian target of rapamycin, and exhibits antiproliferative effects in pancreatic neuroendocrine tumors inÂvitro and inÂvivo. Surgery, 2022, , .	1.0	1
2379	Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability. Cancers, 2022, 14, 5049.	1.7	1
2380	Influence of marital status on the treatment and survival of middle-aged and elderly patients with primary bone cancer. Frontiers in Medicine, 0, 9, .	1.2	0

#	Article	IF	Citations
2381	The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?. Frontiers in Endocrinology, 0, 13, .	1.5	18
2382	Imaging of Drug-Related Pneumonitis in Oncology. Seminars in Respiratory and Critical Care Medicine, 0, , .	0.8	0
2383	Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology, 2023, 41, 1359-1369.	0.8	53
2384	A case of erythema multiforme-like rashÂinduced by everolimus in a patient with a pancreatic neuroendocrine tumor. Clinical Journal of Gastroenterology, 0, , .	0.4	1
2385	Current standards in the surgical treatment of pancreatic and small intestinal neuroendocrine tumors. Memo - Magazine of European Medical Oncology, 0, , .	0.3	1
2386	Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. Cancers, 2022, 14, 5248.	1.7	3
2387	mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 12470.	1.8	6
2388	Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters. Biomedicines, 2022, 10, 2618.	1.4	1
2389	The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan. Scientific Reports, 2022, 12, .	1.6	2
2390	A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. Investigational New Drugs, 2022, 40, 1306-1314.	1.2	7
2391	Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer, 2022, 128, 4251-4284.	2.0	145
2392	Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. Nature Reviews Clinical Oncology, 2023, 20, 16-32.	12.5	11
2394	Study Protocol for a Trial: A Single-Arm, Open-Labeled Study Evaluating Transcatheter Arterial Embolization Plus Everolimus Combination Therapy for Patients With Liver Metastasis of Gastroenteropancreatic Neuroendocrine Tumors. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211277.	0.6	0
2395	Growth Hormone-Releasing Hormone-Secreting Neuroendocrine Tumors. Contemporary Endocrinology, 2022, , 15-29.	0.3	0
2396	Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives. Metabolites, 2022, 12, 1103.	1.3	2
2397	The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastroâ€“Enteroâ€“Pancreatic (GEP-NEN) System. Cancers, 2022, 14, 5465.	1.7	1
2398	Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects. Cancers, 2022, 14, 5481.	1.7	2
2399	Therapiekonzepte bei fernmetastasierten GEP-NEN â€“ medikamentÃ¶se und interventionelle Therapie. Springer Reference Medizin, 2023, , 577-588.	0.0	0

#	Article	IF	Citations
2401	Chronological improvement of pancreatectomy for resectable but advanced pancreatic neuroendocrine neoplasms. Pancreatology, 2022, , .	0.5	0
2402	Sporadischer organischer Hyperinsulinismus (Insulinom). Springer Reference Medizin, 2023, , 477-487.	0.0	0
2403	Bcl-2, JAK and mTOR Inhibitors. , 2022, , 293-313.		0
2404	Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Cancers, 2022, 14, 5669.	1.7	1
2406	Suffruticosol C-Mediated Autophagy and Cell Cycle Arrest via Inhibition of mTORC1 Signaling. Nutrients, 2022, 14, 5000.	1.7	3
2407	NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2). Cells, 2022, 11, 3719.	1.8	0
2408	Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 2022, 14, 6114.	1.7	2
2410	Cancer-Associated Fibroblasts Induce Proliferation and Therapeutic Resistance to Everolimus in Neuroendocrine Tumors through STAT3 Activation. Neuroendocrinology, 2023, 113, 501-518.	1.2	5
2411	Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis. Cancer Management and Research, 0, Volume 14, 3507-3523.	0.9	4
2412	Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines, 2022, 10, 3102.	1.4	0
2413	Design of new drugs for medullary thyroid carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
2414	Insulinoma as a cause of seizure-like activity and spontaneous hypoglycaemia. BMJ Case Reports, 2023, 16, e250799.	0.2	1
2415	Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges. Endocrine, 2023, 80, 266-282.	1.1	3
2416	Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review. Journal of Clinical Medicine, 2023, 12, 717.	1.0	3
2417	Androgen receptor increases and negative expression of GCDFP-15 in primary ductal adenocarcinoma of the lacrimal gland: a case description. Quantitative Imaging in Medicine and Surgery, 2023, 13, 1200-1205.	1.1	2
2418	The Importance of mTORC1-Autophagy Axis for Skeletal Muscle Diseases. International Journal of Molecular Sciences, 2023, 24, 297.	1.8	10
2419	Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms. Nutrients, 2023, 15, 185.	1.7	3
2420	An Insight on Functioning Pancreatic Neuroendocrine Neoplasms. Biomedicines, 2023, 11, 303.	1.4	2

#	Article	IF	Citations
2421	Neuroendocrine Neoplasms. PET Clinics, 2023, 18, 161-168.	1.5	2
2422	Neuroendocrine Neoplasms. PET Clinics, 2023, 18, 169-187.	1.5	0
2423	Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis. Life Sciences, 2023, 323, 121662.	2.0	6
2424	Evolving landscape of clinical trials in gastroenteropancreatic neuroendocrine neoplasms in the past two decades. Endocrine Connections, 2023, 12, .	0.8	2
2425	Advances in Epidemiology, Diagnostics and Drug Treatment of Pancreatic Neuroendocrine Neoplasm. Advances in Clinical Medicine, 2023, 13, 1849-1859.	0.0	0
2427	Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN). Current Oncology Reports, 2023, 25, 465-478.	1.8	0
2428	Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311568.	1.4	2
2429	Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?. Journal of Pancreatology, 0, Publish Ahead of Print, .	0.3	0
2431	Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease. Cancers, 2023, 15, 1739.	1.7	2
2432	Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. Acta Biochimica Et Biophysica Sinica, 2023, , .	0.9	1
2434	Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2023, 15, 1861.	1.7	4
2435	MEN1 Degradation Induced by Neddylation and the CUL4Bâ€“DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression. Cancer Research, 2023, 83, 2226-2247.	0.4	4
2436	All you need to know about gastrinoma today | Gastrinoma and <scp>Zollingerâ€Ellison</scp> syndrome: A thorough update. Journal of Neuroendocrinology, 2023, 35, .	1.2	2
2437	Molecular Alterations and Therapeutic Targets in Pancreatic Neuroendocrine Tumors. Journal of Pancreatology, 0, Publish Ahead of Print, .	0.3	0
2438	Diagnosis and management of neuroendocrine tumours. Clinical Medicine, 2023, 23, 119-124.	0.8	2
2439	The emerging role of PI3K inhibitors for solid tumour treatment and beyond. British Journal of Cancer, 2023, 128, 2150-2162.	2.9	18
2440	Long-term organoid culture of a small intestinal neuroendocrine tumor. Frontiers in Endocrinology, 0, 14, .	1.5	0
2441	Neuroendocrine Neoplasms of the Gastrointestinal Tract versus Neuroendocrine Neoplasms of the Gynaecological Tractâ€”Comparison of the Risk Factors and Non-Surgical Treatment Efficacy. International Journal of Molecular Sciences, 2023, 24, 6853.	1.8	0

#	Article	IF	Citations
2442	Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease. Cancers, 2023, 15, 2249.	1.7	1
2443	Gallbladder neuroendocrine carcinoma: A report of two cases and literature review. Oncology Letters, 2023, 25, .	0.8	1
2444	The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. Oncologist, 2023, 28, e723-e736.	1.9	3
2447	Pancreatic Neuroendocrine Tumors: Diagnosis, Management, and Intraoperative Techniques. , 2023, , 35-53.		0
2452	In Silico Pharmacology and Drug Repurposing Approaches. , 2023, , 253-281.		0
2470	A case of frequent hypoglycemic attacks successfully controlled with capecitabine plus temozolomide and 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with recurrent pancreatic insulinoma. Clinical Journal of Gastroenterology, 2023, 16, 767-771.	0.4	1
2472	Pancreatic Neuroendocrine Neoplasms. V-2. Staging and Treatment. , 2023, , 465-474.		0
2475	Molecular Imaging and Therapy of Neuroendocrine Tumors. , 0, , .		0
2523	Challenges and opportunities in rare cancer research in China. Science China Life Sciences, 2024, 67, 274-285.	2.3	0
2531	The Evolution of n.c.a. 177Lu to n.c.a. 177Lu-Edotreotide for the Treatment of Neuroendocrine Tumours. Sixteen Years of Collaboration Between Zentralklinik Bad Berka and ITM. , 2024, , 147-153.		0
2532	Somatic mutation: Pharmacogenomics in oncology care. , 2024, , 329-356.		0